Document_And_Entity_Informatio
Document And Entity Information | 9 Months Ended |
Sep. 30, 2014 | |
Document Information [Line Items] | |
Entity Registrant Name | Skyline Medical Inc. |
Entity Central Index Key | 1446159 |
Entity Filer Category | Smaller Reporting Company |
Document Type | S-1 |
Amendment Flag | FALSE |
Document Period End Date | 30-Sep-14 |
CONDENSED_BALANCE_SHEETS
CONDENSED BALANCE SHEETS (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Current Assets: | |||
Cash | $244,044 | $101,953 | $13,139 |
Accounts Receivable | 238,604 | 97,245 | 39,711 |
Inventories | 315,620 | 122,175 | 145,209 |
Prepaid Expense and other assets | 148,950 | 60,588 | 27,409 |
Total Current Assets | 947,218 | 381,961 | 225,468 |
Fixed Assets, net | 216,946 | 158,110 | 3,521 |
Intangibles, net | 72,701 | 53,355 | 140,588 |
Total Assets | 1,236,865 | 593,426 | 369,577 |
Current Liabilities: | |||
Current portion of convertible debt, net of discounts of $0 and $21,138 (See Note 6) | 0 | 1,081,187 | |
Accounts payable | 1,577,818 | 1,062,108 | 733,595 |
Accrued expenses | 2,089,885 | 2,057,957 | 1,599,519 |
Short-term note payable net of discounts of $353,583 and $0(See Note 4) | 1,169,677 | 280,000 | 0 |
Deferred Revenue | 5,000 | 69,000 | 0 |
Total Current Liabilities | 4,842,380 | 3,469,065 | 3,414,301 |
Long-term debt and convertible debt, net of discounts of $0 and $0 (See Note 6) | 0 | 89,300 | |
Accrued Expenses | 229,318 | 331,216 | 0 |
Liability for equity-linked financial instruments (See Note 8) | 0 | 11,599 | 169,179 |
Total Liabilities | 5,071,698 | 3,811,880 | 3,672,780 |
Commitments and Contingencies | |||
Stockholders' Deficit: | |||
Series A Convertible Preferred Stock, $.01 par value, $100 Stated Value, 40,000 authorized, 20,550 outstanding | 206 | 0 | |
Common stock, $.01 par value, 10,666,667 authorized, 2,999,386 and 2,932,501 outstanding | 29,993 | 29,325 | 13,900 |
Additional paid-in capital | 29,380,273 | 25,449,636 | 15,974,008 |
Deficit accumulated during development stage | -33,245,305 | -28,697,415 | -19,291,111 |
Total Stockholders' Deficit | -3,834,833 | -3,218,453 | -3,303,203 |
Total Liabilities and Stockholders’ Deficit | $1,236,865 | $593,426 | $369,577 |
CONDENSED_BALANCE_SHEETS_Paren
CONDENSED BALANCE SHEETS [Parenthetical] (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Allowance for Doubtful Accounts Receivable (in dollars) | $0 | $4,073 | |
Accumulated discounts on current portion of convertible debt (in dollars) | 0 | 21,138 | |
Accumulated discounts on long-term debt and convertible debt (in dollars) | 0 | 0 | |
Discount on short term note payable (in dollars) | $353,583 | $0 | |
Series A convertible preferred stock, par value (in dollars per share) | 0.01 | 0.01 | |
Series A convertible preferred stock, stated value (in dollars per share) | $100 | $100 | |
Series A convertible preferred stock, shares authorized | 40,000 | 40,000 | |
Series A convertible preferred stock, shares outstanding | 20,550 | 20,550 | |
Common stock, par value (in dollars per share) | $0.01 | $0.01 | $0.01 |
Common stock, shares authorized | 10,666,667 | 10,666,667 | 10,666,667 |
Common stock, shares outstanding | 2,999,386 | 2,932,501 | 1,389,964 |
CONDENSED_STATEMNETS_OF_OPERAT
CONDENSED STATEMNETS OF OPERATION (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | 140 Months Ended | |||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Revenue | $397,254 | $107,835 | $785,767 | $386,418 | $468,125 | $188,772 | $769,559 |
Cost of goods sold | 134,726 | 26,181 | 264,174 | 135,120 | 189,707 | 128,540 | 381,467 |
Gross Margin | 262,528 | 81,654 | 521,593 | 251,298 | 278,418 | 60,232 | 388,092 |
General and administrative expense | 737,519 | 3,195,589 | 3,247,024 | 5,906,805 | 7,530,037 | 6,285,905 | 23,280,400 |
Operations expense | 183,154 | 354,027 | 740,012 | 763,422 | 1,096,969 | 761,047 | 3,387,550 |
Sales and marketing expense | 325,141 | 164,712 | 849,364 | 357,274 | 578,793 | 172,970 | 1,640,248 |
Interest expense | 131,935 | 407,516 | 164,962 | 629,722 | 636,503 | 259,349 | 1,562,959 |
Gain on valuation of equity-linked financial instruments | 0 | -65,287 | -11,599 | -153,960 | -157,580 | 3,116 | -785,650 |
Total expense | 1,377,749 | 4,056,557 | 4,989,763 | 7,503,263 | 9,684,722 | 7,482,387 | 29,085,507 |
Net income (loss) available to common shareholders | ($1,115,221) | ($3,974,903) | ($4,468,170) | ($7,251,965) | ($9,406,304) | ($7,422,155) | ($28,697,415) |
Loss per common share - basic and diluted (in dollars per share) | ($0.37) | ($2.18) | ($1.51) | ($4.30) | ($4.64) | ($8) | ($28.80) |
Weighted average shares used in computation - basic and diluted (in shares) | 2,984,335 | 1,821,006 | 2,967,483 | 1,687,625 | 2,026,115 | 927,838 | 996,362 |
STATEMENTS_OF_STOCKHOLDERS_DEF
STATEMENTS OF STOCKHOLDERS' DEFICIT (USD $) | Total | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | |
Balance at Apr. 22, 2002 | ||||||
Issuance of common stock 9/1/02, $1.25 | [1] | $10,000 | $80 | $9,920 | $0 | |
Issuance of common stock 9/1/02, $1.25 (in shares) | [1] | 7,981 | ||||
Issuance of common 10/23/02, $125.25/share | 5,000 | 5,000 | ||||
Issuance of common 10/23/02, $125.25/share (in shares) | 40 | |||||
Net loss | -51,057 | -51,057 | ||||
Balance at Dec. 31, 2002 | -36,057 | 80 | 14,920 | -51,057 | ||
Balance (in shares) at Dec. 31, 2002 | 8,021 | |||||
Issuance of common stock | [2] | 400 | 3 | 397 | ||
Issuance of common stock (in shares) | [2] | 320 | ||||
Issuance of common 6/11 & 12, $125.25 | [3] | 35,000 | 3 | 34,997 | ||
Issuance of common 6/11 & 12, $125.25 (in shares) | [3] | 288 | ||||
Net loss | -90,461 | -90,461 | ||||
Balance at Dec. 31, 2003 | -91,118 | 86 | 50,314 | -141,518 | ||
Balance (in shares) at Dec. 31, 2003 | 8,629 | |||||
Issuance of common 5/25/04, $1.25 | [4] | 110 | 1 | 109 | ||
Issuance of common 5/25/04, $1.25 (in shares) | [4] | 88 | ||||
Net loss | -90,353 | -90,353 | ||||
Balance at Dec. 31, 2004 | -181,361 | 87 | 50,423 | -231,871 | ||
Balance (in shares) at Dec. 31, 2004 | 8,717 | |||||
Issuance of common stock | [5] | 250 | 2 | 248 | ||
Issuance of common stock (in shares) | [5] | 200 | ||||
Vested stock options and warrants | 2,793 | 0 | 2,793 | |||
Net loss | -123,852 | -123,852 | ||||
Balance at Dec. 31, 2005 | -302,170 | 89 | 53,464 | -355,723 | ||
Balance (in shares) at Dec. 31, 2005 | 8,917 | |||||
Issuance of common 5/16 & 8/8, $1.25 | [6] | 1,451 | 12 | 1,439 | ||
Issuance of common 5/16 & 8/8, $1.25 (in shares) | [6] | 1,159 | ||||
Issuance of common 10/19 & 23, $1.25 | [7] | 650 | 5 | 645 | ||
Issuance of common 10/19 & 23, $1.25 (in shares) | [7] | 519 | ||||
Issuance of common 12/01, $125.25 | [8] | 44,810 | 4 | 44,806 | ||
Issuance of common 12/01, $125.25 (in shares) | [8] | 384 | ||||
Vested stock options and warrants | 13,644 | 13,644 | ||||
Net loss | -273,026 | -273,026 | ||||
Balance at Dec. 31, 2006 | -514,641 | 110 | 113,998 | -628,749 | ||
Balance (in shares) at Dec. 31, 2006 | 10,979 | |||||
Issuance of common stock | [9] | 1,000 | 0 | 1,000 | ||
Issuance of common stock (in shares) | [9] | 8 | ||||
Vested stock options and warrants | 73,907 | 0 | 73,907 | |||
Capital contributions resulting from waivers of debt | 346,714 | 0 | 346,714 | |||
Value of equity instruments issued with debt | 132,938 | 0 | 132,938 | |||
Net loss | -752,415 | -752,415 | ||||
Balance at Dec. 31, 2007 | -712,497 | 110 | 668,557 | -1,381,164 | ||
Balance (in shares) at Dec. 31, 2007 | 10,987 | |||||
Issuance of common stock | [10] | 1,593,502 | 607 | 1,592,895 | ||
Issuance of common stock (in shares) | [10] | 60,705 | ||||
Shares issued to finders, agents | 0 | 268 | -268 | |||
Shares issued to finders, agents (in shares) | 26,836 | |||||
Shares issued to pay direct legal fees | 0 | 38 | -38 | |||
Shares issued to pay direct legal fees (in shares) | 3,810 | |||||
Issuance of common due to anti-dilution provisions | 0 | 27 | -27 | |||
Issuance of common due to anti-dilution provisions (in shares) | 2,746 | |||||
Shares issued to pay investor relations services 6/23/08, $26.25 | 87,500 | 33 | 87,467 | |||
Shares issued to pay investor relations services 6/23/08, $26.25 (in shares) | 3,334 | |||||
Vested stock options and warrants | 354,994 | 0 | 354,994 | |||
Capital contributions resulting from waivers of debt | 129,684 | 0 | 129,684 | |||
Net loss | -1,762,628 | -1,762,628 | ||||
Balance at Dec. 31, 2008 | -309,445 | 1,084 | 2,833,264 | -3,143,792 | ||
Balance (in shares) at Dec. 31, 2008 | 108,418 | |||||
Cumulative effect of adoption of EITF 07-5 | -479,910 | 0 | -486,564 | 6,654 | ||
Vested stock options and warrants | 111,835 | 0 | 111,835 | |||
Shares issued 3/20/09 to pay for fund raising | 0 | 17 | -17 | |||
Shares issued 3/20/09 to pay for fund raising (in shares) | 1,667 | |||||
Shares issued under PMM in 2009, $37.50 | 1,073,905 | 286 | 1,073,619 | |||
Shares issued under PMM in 2009, $37.50 (in shares) | 28,638 | |||||
Capital contributions resulting from waivers of debt | 84,600 | 0 | 84,600 | |||
Value of equity-linked financial instruments issued in connection with PPMs | -222,296 | 0 | -222,296 | |||
Shares issued to consultant for fund raising | 0 | 4 | -4 | |||
Shares issued to consultant for fund raising (in shares) | 400 | |||||
Shares issued upon conversion of debt and interest, $20.25 | 256,454 | 125 | 256,329 | |||
Shares issued upon conversion of debt and interest, $20.25 (in shares) | 12,473 | |||||
Value of equity instruments issued with debt | 30,150 | 0 | 30,150 | |||
Shares issued upon conversion of shareholder note, $26.25 | 4,906 | 2 | 4,904 | |||
Shares issued upon conversion of shareholder note, $26.25 (in shares) | 187 | |||||
Net loss | -2,892,230 | -2,892,230 | ||||
Balance at Dec. 31, 2009 | -2,342,031 | 1,518 | 3,685,820 | -6,029,368 | ||
Balance (in shares) at Dec. 31, 2009 | 151,783 | |||||
Vested stock options and warrants | 11,382 | 0 | 11,382 | |||
Shares issued in 2010 under PPM, $37.50 | 177,275 | 47 | 177,228 | |||
Shares issued in 2010 under PPM, $37.50 (in shares) | 4,728 | |||||
Shares issued to consultants for IR and consulting, $37.50 | 187,045 | 50 | 186,995 | |||
Shares issued to consultants for IR and consulting, $37.50 (in shares) | 4,988 | |||||
Value of equity instruments issued for consulting services | 354,602 | 0 | 354,602 | |||
Value of equity-linked financial instruments issued in connection with PPM in first quarter | -25,553 | 0 | -25,553 | |||
Shares issued in May 2010 to consultant, $37.50 | 6,425 | 2 | 6,423 | |||
Shares issued in May 2010 to consultant, $37.50 (in shares) | 172 | |||||
Shares issued in May 2010 to 2008 investors as a penalty for late registration, $37.50 | 355,124 | 95 | 355,029 | |||
Shares issued in May 2010 to 2008 investors as a penalty for late registration, $37.50 (in shares) | 9,470 | |||||
Value of equity instruments issued with debt | 119,474 | 0 | 119,474 | |||
Value of equity-linked financial instruments issued in connection with PPM in second quarter | -31,332 | 0 | -31,332 | |||
Value of equity-linked financial instruments issued in connection with PPM in third quarter | -31,506 | 0 | -31,506 | |||
Shares issued in September 2010 under PPM, $7.50 | 25,000 | 33 | 24,967 | |||
Shares issued in September 2010 under PPM, $7.50 (in shares) | 3,334 | |||||
Shares issued to consultants in third quarter at $16.50 per share | 107,549 | 65 | 107,484 | |||
Shares issued to consultants in third quarter at $16.50 per share (in shares) | 6,519 | |||||
Shares issued in November 2010 upon exercise of warrants at $10.13 per share | 17,357 | 17 | 17,340 | |||
Shares issued in November 2010 upon exercise of warrants at $10.13 per share (in shares) | 1,715 | |||||
Shares issued in November 2010 to directors as compensation at $11.25 per share | 45,000 | 40 | 44,960 | |||
Shares issued in November 2010 to directors as compensation at $11.25 per share (in shares) | 4,000 | |||||
Vested stock options in fourth quarter | 161,107 | 0 | 161,107 | |||
Equity instruments issued to consultants in fourth quarter | 26,234 | 0 | 26,234 | |||
Net loss | -1,352,709 | -1,352,709 | ||||
Balance at Dec. 31, 2010 | -2,189,557 | 1,867 | 5,190,654 | -7,382,077 | ||
Balance (in shares) at Dec. 31, 2010 | 186,709 | |||||
Value of equity instruments issued with debt | 47,908 | 0 | 47,908 | |||
Equity instruments issued to consultants in first quarter | 91,504 | 0 | 91,504 | |||
Shares issued at $5.63 per share under PPM | 400,000 | 711 | 399,289 | |||
Shares issued at $5.63 per share under PPM (in shares) | 71,112 | |||||
Shares issued at $6.38 per share under PPM | 160,000 | 251 | 159,749 | |||
Shares issued at $6.38 per share under PPM (in shares) | 25,099 | |||||
Shares issued at $6.75 per share under PPM | 18,000 | 27 | 17,973 | |||
Shares issued at $6.75 per share under PPM (in shares) | 2,667 | |||||
Shares issued at $7.50 per share under PPM | 15,000 | 20 | 14,980 | |||
Shares issued at $7.50 per share under PPM (in shares) | 2,000 | |||||
Stock issued upon conversion of debt in first quarter | 20,000 | 55 | 19,945 | |||
Stock issued upon conversion of debt in first quarter (in shares) | 5,547 | |||||
Stock issued to pay interest on debt | 22,500 | 21 | 22,479 | |||
Stock issued to pay interest on debt (in shares) | 2,108 | |||||
Shares issued at $5.25 per share under PPM | 75,000 | 143 | 74,857 | |||
Shares issued at $5.25 per share under PPM (in shares) | 14,286 | |||||
Stock issued upon conversion of debt and interest | 32,000 | 125 | 31,875 | |||
Stock issued upon conversion of debt and interest (in shares) | 12,548 | |||||
Equity instruments issued to consultants | 12,256 | 0 | 12,256 | |||
Equity instruments issued to consultants | 147,116 | 0 | 147,116 | |||
Shares issued at $4.50 per share under PPM | 210,000 | 467 | 209,533 | |||
Shares issued at $4.50 per share under PPM (in shares) | 46,667 | |||||
Shares issued at $15.00 per share under PPM | 275,000 | 183 | 274,817 | |||
Shares issued at $15.00 per share under PPM (in shares) | 18,334 | |||||
Restricted stock issued to consultants | 55,000 | 110 | 54,890 | |||
Restricted stock issued to consultants (in shares) | 10,972 | |||||
Shares issued at $26.25 per share IR compensation | 201,250 | 77 | 201,173 | |||
Shares issued at $26.25 per share IR compensation (in shares) | 7,667 | |||||
Equity instruments upon conversion of Accounts Payable | 20,000 | 0 | 20,000 | |||
Shares issued to private investor at $11.25 per share | 232,000 | 206 | 231,794 | |||
Shares issued to private investor at $11.25 per share (in shares) | 20,623 | |||||
Vested stock options and warrants in first quarter | 1,937,638 | 0 | 1,937,638 | |||
Shares issued upon exercise of options at $.75 per share | 1,000 | 13 | 987 | |||
Shares issued upon exercise of options at $.75 per share (in shares) | 1,334 | |||||
Net loss | -4,486,879 | -4,486,879 | ||||
Balance at Dec. 31, 2011 | -2,703,264 | 4,277 | 9,161,417 | -11,868,956 | ||
Balance (in shares) at Dec. 31, 2011 | 427,673 | |||||
Vested stock options and warrants | 830,372 | 0 | 830,372 | |||
Value of equity instruments issued with debt | 33,469 | 0 | 33,469 | |||
Shares issued to institutional investor upon conversion of Note Payable at $10.07 per share | 8,000 | 8 | 7,992 | |||
Shares issued to institutional investor upon conversion of Note Payable at $10.07 per share (in shares) | 795 | |||||
Shares issued to institutional investor upon conversion of Note Payable at $9.75 per share | 14,000 | 14 | 13,986 | |||
Shares issued to institutional investor upon conversion of Note Payable at $9.75 per share (in shares) | 1,436 | |||||
Shares issued to institutional investor upon conversion of Note Payable at $6.60 per share | 15,000 | 23 | 14,977 | |||
Shares issued to institutional investor upon conversion of Note Payable at $6.60 per share (in shares) | 2,273 | |||||
Shares issued to institutional investor upon conversion of Note Payable at $3.35 per share | 16,000 | 46 | 15,954 | |||
Shares issued to institutional investor upon conversion of Note Payable at $3.35 per share (in shares) | 4,578 | |||||
Shares issued to institutional investor upon conversion of Note Payable at $3.35 per share | 12,000 | 36 | 11,964 | |||
Shares issued to institutional investor upon conversion of Note Payable at $3.35 per share (in shares) | 3,588 | |||||
Shares issued to institutional investor upon conversion of Note Payable at $3.35 per share | 10,000 | 36 | 9,964 | |||
Shares issued to institutional investor upon conversion of Note Payable at $3.35 per share (in shares) | 3,583 | |||||
Shares issued to institutional investor upon conversion of Note Payable at $2.98 per share | 8,500 | 57 | 8,443 | |||
Shares issued to institutional investor upon conversion of Note Payable at $2.98 per share (in shares) | 5,709 | |||||
Shares issued to a private investor at $4.88 per share | 600,000 | 1,231 | 598,769 | |||
Shares issued to a private investor at $4.88 per share (in shares) | 123,076 | |||||
Shares issued for consulting to the then interim CEO at $4.88 per share | 19,500 | 40 | 19,460 | |||
Shares issued for consulting to the then interim CEO at $4.88 per share (in shares) | 4,000 | |||||
Shares issued to an institutional investor upon conversion of Note Payable at $2.15 per share | 10,000 | 47 | 9,953 | |||
Shares issued to an institutional investor upon conversion of Note Payable at $2.15 per share (in shares) | 4,661 | |||||
Shares issued to a private investor at $11.25 per share | 39,500 | 35 | 39,465 | |||
Shares issued to a private investor at $11.25 per share (in shares) | 3,511 | |||||
Stock issued upon conversion of debt at $11.25 per share | 493,884 | 439 | 493,445 | |||
Stock issued upon conversion of debt at $11.25 per share (in shares) | 43,900 | |||||
Stock issued upon conversion of debt at $4.88 per share | 185,299 | 380 | 184,919 | |||
Stock issued upon conversion of debt at $4.88 per share (in shares) | 38,010 | |||||
Shares issued to a private investor per a convertible note default at $11.25 per share | 1,125,000 | 1,000 | 1,124,000 | |||
Shares issued to a private investor per a convertible note default at $11.25 per share (in shares) | 100,000 | |||||
Shares issued to private investor upon conversion of Note Payable at $13.50 per share | 57,042 | 42 | 57,000 | |||
Shares issued to private investor upon conversion of Note Payable at $13.50 per share (in shares) | 4,225 | |||||
Shares issued to private investor upon conversion of Note Payable at $3.90 per share | 59,534 | 153 | 59,381 | |||
Shares issued to private investor upon conversion of Note Payable at $3.90 per share (in shares) | 15,293 | |||||
Shares issued to private investor upon conversion of Note Payable at $7.50 per share | 56,584 | 75 | 56,509 | |||
Shares issued to private investor upon conversion of Note Payable at $7.50 per share (in shares) | 7,543 | |||||
Shares issued to an institutional investor upon conversion of Note Payable at $2.33 per share | 12,000 | 52 | 11,948 | |||
Shares issued to an institutional investor upon conversion of Note Payable at $2.33 per share (in shares) | 5,160 | |||||
Stock issued upon conversion of debt at $11.25 per share | 59,590 | 53 | 59,537 | |||
Stock issued upon conversion of debt at $11.25 per share (in shares) | 5,296 | |||||
Shares issued to a Director as compensation at $6.75 per share | 25,000 | 37 | 24,963 | |||
Shares issued to a Director as compensation at $6.75 per share (in shares) | 3,703 | |||||
Shares issued under PPM at $5.25 per share | 690,946 | 1,316 | 689,629 | |||
Shares issued under PPM at $5.25 per share (in shares) | 131,608 | |||||
Shares issued to institutional investor upon conversion of Note Payable at $2.65 per share | 18,000 | 68 | 17,932 | |||
Shares issued to institutional investor upon conversion of Note Payable at $2.65 per share (in shares) | 6,797 | |||||
Shares issued to a private investor upon conversion of Note Payable at $2,40 per share | 9,022 | 38 | 8,984 | |||
Shares issued to a private investor upon conversion of Note Payable at $2,40 per share (in shares) | 3,782 | |||||
Shares issued to an institutional investor upon conversion of Note Payable at $2.23 per share including $11,021 of interest. | 33,021 | 99 | 32,922 | |||
Shares issued to an institutional investor upon conversion of Note Payable at $2.23 per share including $11,021 of interest. (in shares) | 9,876 | |||||
Shares issued at $11.25 per share as Investor Relations compensation | 93,750 | 83 | 93,667 | |||
Shares issued at $11.25 per share as Investor Relations compensation (in shares) | 8,333 | |||||
Shares issued to a private investor upon conversion of Note Payable at $2.40 per share | 50,000 | 210 | 49,790 | |||
Shares issued to a private investor upon conversion of Note Payable at $2.40 per share (in shares) | 20,963 | |||||
Shares issued as settlement to remove anti-dilution agreement at $4.88 per share | 1,722,500 | 3,533 | 1,718,967 | |||
Shares issued as settlement to remove anti-dilution agreement at $4.88 per share (in shares) | 353,333 | |||||
Shares issued in settlement with former COO at $11.25 per share less shares cancelled at $6.75 per share | 142,333 | 107 | 142,226 | |||
Shares issued in settlement with former COO at $11.25 per share less shares cancelled at $6.75 per share (in shares) | 10,715 | |||||
Equity value for options and warrants | 150,189 | 0 | 150,189 | |||
Shares issued at $5.25 per share as Investor Relations compensation | 21,000 | 40 | 20,960 | |||
Shares issued at $5.25 per share as Investor Relations compensation (in shares) | 4,000 | |||||
Shares issued at $11.25 per share as conversion of debt | 23,563 | 21 | 23,542 | |||
Shares issued at $11.25 per share as conversion of debt (in shares) | 2,094 | |||||
Shares issued to a private investor exercising options at $.75 per share | 718 | 10 | 708 | |||
Shares issued to a private investor exercising options at $.75 per share (in shares) | 957 | |||||
Shares issued to debtors as compensation at $7.50 per share | 156,243 | 208 | 156,035 | |||
Shares issued to debtors as compensation at $7.50 per share (in shares) | 20,839 | |||||
Shares issued upon conversion of Note Payable at $5.25 per share | 16,525 | 31 | 16,494 | |||
Shares issued upon conversion of Note Payable at $5.25 per share (in shares) | 3,147 | |||||
Share true-up to certified shareholders list per the stock transfer agency | 2 | 0 | 1 | |||
Share true-up to certified shareholders list per the stock transfer agency (in shares) | 1 | |||||
Shares issued upon exercise of options at $.75 per share | 4,130 | 55 | 4,075 | |||
Shares issued upon exercise of options at $.75 per share (in shares) | 5,506 | |||||
Net loss | -7,422,155 | -7,422,155 | ||||
Balance at Dec. 31, 2012 | -3,303,203 | 13,900 | 15,974,008 | -19,291,111 | ||
Balance (in shares) at Dec. 31, 2012 | 1,389,963 | |||||
Value of equity instruments issued with debt | 392,556 | 392,556 | ||||
Shares issued to debtors as compensation at $11.25 per share | 43,521 | 39 | 43,482 | |||
Shares issued to debtors as compensation at $11.25 per share (in shares) | 3,869 | |||||
Shares issued under PPM to five investors at $5.25 per share | 500,000 | 952 | 499,048 | |||
Shares issued under PPM to five investors at $5.25 per share (in shares) | 95,238 | |||||
Shares issued to an escrow account underlying a debt agreement | [11] | 10,000 | 133 | 9,867 | ||
Shares issued to an escrow account underlying a debt agreement (in shares) | [11] | 13,333 | ||||
Shares issued to debtors as compensation at $11.25 per share | 34,550 | 31 | 34,519 | |||
Shares issued to debtors as compensation at $11.25 per share (in shares) | 3,071 | |||||
Shares issued to an institutional investor at $5.25 per share | 500,000 | 952 | 499,048 | |||
Shares issued to an institutional investor at $5.25 per share (in shares) | 95,238 | |||||
Value of shares per an agreement with a former officer | [12] | 40,480 | 0 | 40,480 | ||
Shares issued to consultant as compensation at $5.03 per share | 16,750 | 33 | 16,717 | |||
Shares issued to consultant as compensation at $5.03 per share (in shares) | 3,333 | |||||
Shares issued to former consultant exercising options at $.75 per share | 2,000 | 27 | 1,973 | |||
Shares issued to former consultant exercising options at $.75 per share (in shares) | 2,667 | |||||
Shares issued to former CEO exercising options at $.75 per share. | 3,333 | 44 | 3,289 | |||
Shares issued to former CEO exercising options at $.75 per share. (in shares) | 4,444 | |||||
Shares issued upon conversion of four notes payable at $11.25 per share | 156,243 | 139 | 156,104 | |||
Shares issued upon conversion of four notes payable at $11.25 per share (in shares) | 13,888 | |||||
Shares issued for interest to the four notes payable at $11.25 per share | 11,170 | 10 | 11,160 | |||
Shares issued for interest to the four notes payable at $11.25 per share (in shares) | 993 | |||||
Shares issued for cashless exercise of warrants at $9.00 per share | 2,778 | 37 | 2,741 | |||
Shares issued for cashless exercise of warrants at $9.00 per share (in shares) | 3,704 | |||||
Shares issued for cashless exercise of warrants at $12.00 per share | 1,633 | 22 | 1,611 | |||
Shares issued for cashless exercise of warrants at $12.00 per share (in shares) | 2,178 | |||||
Shares issued for cashless exercise of warrants at $11.25 per share | 6,327 | 84 | 6,243 | |||
Shares issued for cashless exercise of warrants at $11.25 per share (in shares) | 8,436 | |||||
Shares issued for cashless exercise of warrants at $15.00 per share | 2,618 | 35 | 2,583 | |||
Shares issued for cashless exercise of warrants at $15.00 per share (in shares) | 3,491 | |||||
Shares issued to 24 warrant holders exercised at a reduced price for $7.50 per share | 1,044,490 | 1,393 | 1,043,097 | |||
Shares issued to 24 warrant holders exercised at a reduced price for $7.50 per share (in shares) | 139,265 | |||||
Shares issued to 4 PPM investors converting notes at $9.00 per share | 316,504 | 352 | 316,152 | |||
Shares issued to 4 PPM investors converting notes at $9.00 per share (in shares) | 35,167 | |||||
Shares issued to 10 PPM investors converting notes at $13.50 per share | 1,020,200 | 721 | 1,019,479 | |||
Shares issued to 10 PPM investors converting notes at $13.50 per share (in shares) | 72,072 | |||||
Shares issued to consultant as compensation at $28.50 per share | 57,000 | 20 | 56,980 | |||
Shares issued to consultant as compensation at $28.50 per share (in shares) | 2,000 | |||||
Shares issued for two note conversions at $1.05 per share | 994,928 | 9,476 | 985,452 | |||
Shares issued for two note conversions at $1.05 per share (in shares) | 947,551 | |||||
Shares issued for warrant exercise at $11.25 per share | 160,715 | 143 | 160,572 | |||
Shares issued for warrant exercise at $11.25 per share (in shares) | 14,286 | |||||
Shares issued to an investor for a cashless exercise of warrants at $12.75 per share | 2,044 | 27 | 2,016 | |||
Shares issued to an investor for a cashless exercise of warrants at $12.75 per share (in shares) | 2,724 | |||||
Shares issued to former Board Directors as compensation at $24.38 per share | 100,000 | 13 | 99,987 | |||
Shares issued to former Board Directors as compensation at $24.38 per share (in shares) | 1,333 | |||||
Reduced warrant exercise compensation expense | 2,140,946 | 0 | 2,140,946 | |||
Options issued as part of employee bonus | 147,500 | 0 | 147,500 | |||
Shares issued to one investor for cashless warrant exercised at $9.00 per share | 2,778 | 37 | 2,741 | |||
Shares issued to one investor for cashless warrant exercised at $9.00 per share (in shares) | 3,704 | |||||
Shares issued for a cashless exercise of warrants at $7.50 per share | 30,244 | 403 | 29,841 | |||
Shares issued for a cashless exercise of warrants at $7.50 per share (in shares) | 40,325 | |||||
Shares issued for a cashless exercise of warrants at $5.63 per share | 5,447 | 73 | 5,374 | |||
Shares issued for a cashless exercise of warrants at $5.63 per share (in shares) | 7,263 | |||||
Shares issued for cashless warrant exercise at $9.75 per share | 1,597 | 21 | 1,576 | |||
Shares issued for cashless warrant exercise at $9.75 per share (in shares) | 2,130 | |||||
Shares issued for interest on two note conversions at $13.50 per share | 7,365 | 5 | 7,360 | |||
Shares issued for interest on two note conversions at $13.50 per share (in shares) | 546 | |||||
Shares issued in settlement with a former noteholder at $20.25 per share | 102,060 | 50 | 102,010 | |||
Shares issued in settlement with a former noteholder at $20.25 per share (in shares) | 5,040 | |||||
Shares issued for a stock option exercise at $4.88 per share | 650 | 1 | 649 | |||
Shares issued for a stock option exercise at $4.88 per share (in shares) | 133 | |||||
Shares issued to one warrant holder executed at a reduced price of $9.38 per share | 125,000 | 133 | 124,867 | |||
Shares issued to one warrant holder executed at a reduced price of $9.38 per share (in shares) | 13,333 | |||||
Vesting expense | 1,505,270 | 0 | 1,505,270 | |||
Shares issued for option exercise at $5.25 per share | 1,190 | 2 | 1,188 | |||
Shares issued for option exercise at $5.25 per share (in shares) | 227 | |||||
Shares issued for cashless warrant exercise at $5.63 per share | 1,167 | 16 | 1,151 | |||
Shares issued for cashless warrant exercise at $5.63 per share (in shares) | 1,556 | |||||
Net loss | -9,406,304 | -9,406,304 | ||||
Balance at Dec. 31, 2013 | -3,218,453 | 29,325 | 25,449,636 | -28,697,415 | ||
Balance (in shares) at Dec. 31, 2013 | 2,932,501 | |||||
Value of equity instruments issued with debt | 313,175 | 313,175 | ||||
Shares issued for cashless warrant exercise at $15.00 per share | 1,296 | 17 | 1,279 | |||
Shares issued for cashless warrant exercise at $15.00 per share (in shares) | 1,728 | |||||
Shares issued for option exercise at $1.25 per share | 5,430 | 43 | 5,387 | |||
Shares issued for option exercise at $1.25 per share (in shares) | 4,336 | |||||
Shares issued at $20.63 per share as Investor Relations compensation | 41,250 | 20 | 41,230 | |||
Shares issued at $20.63 per share as Investor Relations compensation (in shares) | 2,000 | |||||
Shares issued for cashless warrant exercise at $12.75 per share | 2,493 | 33 | 2,460 | |||
Shares issued for cashless warrant exercise at $12.75 per share (in shares) | 3,323 | |||||
Shares issued for an option exercise at $5.25 per share | 1,400 | 3 | 1,397 | |||
Shares issued for an option exercise at $5.25 per share (in shares) | 267 | |||||
Shares issued for cashless warrant exercise at $.75 per share | 1,630 | 22 | 1,608 | |||
Shares issued for cashless warrant exercise at $.75 per share (in shares) | 2,174 | |||||
Shares issued for warrant exercise at $13.50 per share | 36,000 | 27 | 35,973 | |||
Shares issued for warrant exercise at $13.50 per share (in shares) | 2,667 | |||||
Shares issued at $18.75 per share as Investor Relations compensation | 25,000 | 13 | 24,987 | |||
Shares issued at $18.75 per share as Investor Relations compensation (in shares) | 1,333 | |||||
Reduction in escrow account per settlement agreement | -3,333 | -44 | -3,289 | |||
Reduction in escrow account per settlement agreement (in shares) | -4,444 | |||||
Shares issued for cashless warrant exercise at $7.50 per share | 3,605 | 48 | 3,557 | |||
Shares issued for cashless warrant exercise at $7.50 per share (in shares) | 4,807 | |||||
Shares issued for cashless warrant exercise at $5.63 per share | 2,333 | 31 | 2,302 | |||
Shares issued for cashless warrant exercise at $5.63 per share (in shares) | 3,112 | |||||
Shares issued for cashless warrant exercise at $12.75 per share | 224 | 3 | 221 | |||
Shares issued for cashless warrant exercise at $12.75 per share (in shares) | 299 | |||||
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share | 0 | 10 | 18,909 | -18,919 | ||
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share (in shares) | 972 | |||||
Vesting expense | 422,184 | 422,184 | ||||
Options issued as part of employee bonus | 694,500 | 694,500 | ||||
Shares issued for combined cashless and cash warrant exercise at $11.25 per share. | 52,500 | 78 | 52,422 | |||
Shares issued for combined cashless and cash warrant exercise at $11.25 per share. (in shares) | 7,778 | |||||
Issuance of Preferred stock | 2,055,001 | 206 | 2,054,795 | |||
Shares issued to Investor Relations consultant exercisable at $11.25 per share | 24,000 | 21 | 23,979 | |||
Shares issued to Investor Relations consultant exercisable at $11.25 per share (in shares) | 2,133 | |||||
Shares issued to Investor Relations consultant exercisable at $18.75 per share | 25,000 | 13 | 24,987 | |||
Shares issued to Investor Relations consultant exercisable at $18.75 per share (in shares) | 1,333 | |||||
Shares issued for cashless warrant exercise at $13.50 per share | 2,794 | 37 | 2,757 | |||
Shares issued for cashless warrant exercise at $13.50 per share (in shares) | 3,725 | |||||
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share | 0 | 16 | 30,384 | -30,400 | ||
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share (in shares) | 1,561 | |||||
Shares issued for cashless warrant exercise at $9.75 per share | 1,058 | 14 | 1,044 | |||
Shares issued for cashless warrant exercise at $9.75 per share (in shares) | 1,410 | |||||
Shares issued for a cash warrant exercise at $5.63 per share | 62,500 | 111 | 62,389 | |||
Shares issued for a cash warrant exercise at $5.63 per share (in shares) | 11,111 | |||||
Shares issued for an option exercise at $5.25 per share | 1,750 | 3 | 1,747 | |||
Shares issued for an option exercise at $5.25 per share (in shares) | 333 | |||||
Shares issued for a note conversion at $6.68 per share | 20,000 | 30 | 19,970 | |||
Shares issued for a note conversion at $6.68 per share (in shares) | 3,018 | |||||
Shares issued for a note conversion at $6.68 per share | 20,000 | 30 | 19,970 | |||
Shares issued for a note conversion at $6.68 per share (in shares) | 3,019 | |||||
Shares issued for a note conversion at $5.85 per share | 20,000 | 34 | 19,966 | |||
Shares issued for a note conversion at $5.85 per share (in shares) | 3,435 | |||||
Shares issued for a note conversion at $5.03 per share | 20,000 | 38 | 19,961 | |||
Shares issued for a note conversion at $5.03 per share (in shares) | 3,894 | |||||
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share | 0 | 16 | 30,386 | -30,401 | ||
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $19.50 per share (in shares) | 1,561 | |||||
Net loss | -4,468,170 | -4,468,170 | ||||
Balance at Sep. 30, 2014 | ($3,834,833) | $206 | $29,993 | $29,380,273 | ($33,245,305) | |
Balance (in shares) at Sep. 30, 2014 | 2,999,386 | |||||
[1] | Founders shares,1,000,000 per split. | |||||
[2] | 23,492 (40,000 pre-split) shares valued at $.0167 per share as compensation for loan guarantees by management | |||||
[3] | Investment including 670 shares issued as a 10% finder’s fee | |||||
[4] | For payment of patent legal fees | |||||
[5] | Compensation for loan guarantees by management | |||||
[6] | For vendor contractual consideration | |||||
[7] | Employment agreements | |||||
[8] | Investment | |||||
[9] | Conversion of convertible notes by management | |||||
[10] | Investment, "October 2008 financing" | |||||
[11] | The shares reduce by 1/3 yearly and are returned to the Company as the debt is paid. | |||||
[12] | The Company purchased shares previously issued to a former officer equal to the cost of withholding taxes advanced by the Company. The value here represents the net pay from the transaction that was retained by the Company. |
STATEMENTS_OF_STOCKHOLDERS_DEF1
STATEMENTS OF STOCKHOLDERS' DEFICIT [Parenthetical] (USD $) | 9 Months Ended | 12 Months Ended | |||||||||||
Dec. 31, 2002 | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2007 | Dec. 31, 2006 | Dec. 31, 2005 | Dec. 31, 2004 | Dec. 31, 2003 | |
Issuance of common stock to Founders , par value | $1.25 | ||||||||||||
Issuance of common stock new issues, par value | $125.25 | $26.25 | |||||||||||
Issuance of common stock, compensation for loan guarantees by management, par value | $1.25 | $1.25 | |||||||||||
Issuance of common stock, investment including finders fee, par value | $125.25 | ||||||||||||
Issuance of common stock, payment of patent legal fees, par value | $1.25 | ||||||||||||
Issuance of common stock, vendor contractual consideration, par value | $1.25 | ||||||||||||
Issuance of common stock, employment agreements, par value | $1.25 | ||||||||||||
Issuance of common stock, investment, par value | $125.25 | ||||||||||||
Issuance of common stock, conversion of convertible securities, par value | $26.25 | $125.25 | |||||||||||
Issuance of common stock, investor relations, par value | $26.25 | ||||||||||||
Issuance of common stock, under PMM in 2009 | $37.50 | ||||||||||||
Issuance of common stock upon conversion of debt and interest, par value | $20.25 | ||||||||||||
Issuance of common stock, under PPM in March 2010, par value | $37.50 | ||||||||||||
Issuance of common stock to consultants for IR and consulting, par value | $37.50 | ||||||||||||
Issuance of common stock to consultants, in May 2010, par value | $37.50 | ||||||||||||
Issuance of common stock, under PPM in April 2010, par value | $37.50 | ||||||||||||
Issuance of common stock, under PPM in September 2010, par value | $7.50 | ||||||||||||
Issuance of common stock to consultants, in third quarter, par value | $16.50 | ||||||||||||
Issuance of common stock, upon exercise of warrants | $10.13 | ||||||||||||
Issuance of common stock, to directors as compensation | $6.75 | $11.25 | |||||||||||
Issuance of common stock, under PPM one in first quarter | $5.63 | ||||||||||||
Issuance of common stock, under PPM two in first quarter | $6.38 | ||||||||||||
Issuance of common stock, under PPM three in first quarter | $6.75 | ||||||||||||
Issuance of common stock, under PPM four in first quarter | $7.50 | ||||||||||||
Issuance of common stock, under PPM two in second quarter | $5.25 | ||||||||||||
Issuance of common stock, under PPM one in third quarter | $4.50 | ||||||||||||
Issuance of common stock, under PPM three in third quarter | $15 | ||||||||||||
Issuance of common stock, under exercise of stock options | $0.75 | $0.75 | |||||||||||
Issuance of common stock, under IR compensation | $11.25 | $26.25 | |||||||||||
Issuance of common stock, to private investor in fourth quarter | $11.25 | ||||||||||||
Issuance of common stock to institutional investor upon conversion of Note Payable one | $10.07 | ||||||||||||
Issuance of common stock to institutional investor upon conversion of Note Payable two | $9.75 | ||||||||||||
Issuance of common stock to institutional investor upon conversion of Note Payable three | $6.60 | ||||||||||||
Issuance of common stock to institutional investor upon conversion of Note Payable four | $3.35 | ||||||||||||
Issuance of common stock to institutional investor upon conversion of Note Payable five | $3.35 | ||||||||||||
Issuance of common stock to institutional investor upon conversion of Note Payable six | $3.35 | ||||||||||||
Issuance of common stock to institutional investor upon conversion of Note Payable seven | $2.98 | ||||||||||||
Issuance of common stock to a private investor in the first quarter | $4.88 | ||||||||||||
Issuance of common stock to the now Interim CEO in the first quarter for consulting | $4.88 | ||||||||||||
Issuance of common stock to institutional investor upon conversion of Note Payable Eight | $2.15 | ||||||||||||
Issuance of common stock to private investor upon conversion of Note Payable one | $11.25 | ||||||||||||
Issuance of common stock to a private investor in the second quarter one | $11.25 | ||||||||||||
Shares issued upon exercise of options | $0.75 | ||||||||||||
Issuance of common stock, conversion of debt, par value one | $11.25 | ||||||||||||
Issuance of common stock, conversion of debt, par value two | $11.25 | ||||||||||||
Issuance of common stock to private investor upon conversion of Note Payable two | $13.50 | ||||||||||||
Issuance of common stock to private investor upon conversion of Note Payable three | $3.90 | ||||||||||||
Issuance of common stock to private investor upon conversion of Note Payable four | $7.50 | ||||||||||||
Issuance of common stock to private investor upon conversion of Note Payable five | $2.40 | ||||||||||||
Issuance of common stock to institutional investor upon conversion of Note Payable Nine | $2.33 | ||||||||||||
Issuance of common stock, conversion of debt, par value three | $11.25 | ||||||||||||
Issuance of common stock, under PPM one in second quarter | $5.25 | ||||||||||||
Issuance of common stock to institutional investor upon conversion of Note Payable Ten | $2.65 | ||||||||||||
Issuance of common stock to private investor upon conversion of Note Payable six | $2.40 | ||||||||||||
Issuance of common stock to institutional investor upon conversion of Note Payable Eleven | $2.23 | ||||||||||||
Shares issued as settlement to remove anti-dilution agreement | $4.88 | ||||||||||||
Shares issued in settlement with former COO | $11.25 | ||||||||||||
Issuance of common stock to debtors compensation | $7.50 | ||||||||||||
Issuance of common stock to conversion of note payable | $5.25 | ||||||||||||
Issuance Of Common Stock To Debtors Compensation One | $11.25 | ||||||||||||
Shares issued under PPM to five investors | $5.25 | ||||||||||||
Issuance Of Common Stock To Debtors Compensation Two | $11.25 | ||||||||||||
Shares issued to an institutional investor at per share | $5.25 | ||||||||||||
Issuance Of Common Stock To Debtors Compensation Three | $5.03 | ||||||||||||
Common stock issued to former consultant exercising option, Par value | $0.75 | ||||||||||||
Common stock issued to former CEO exercising option, par value | $0.75 | ||||||||||||
Shares issued upon conversion of four notes payable, par value | $11.25 | ||||||||||||
Shares issued for interest to the four notes payable, par value | $11.25 | ||||||||||||
Shares Issued For Cashless Exercise Of Warrants Par Value One | $15 | $9 | |||||||||||
Shares Issued For Cashless Exercise Of Warrants Par Value Two | $12.75 | $12 | |||||||||||
Shares Issued For Cashless Exercise Of Warrants Par Value Three | $0.75 | $11.25 | |||||||||||
Shares Issued For Cashless Exercise Of Warrants Par Value Four | $7.50 | $15 | |||||||||||
Shares Issued To Twenty Four Warrant Holders Exercised At Reduced Par Value | $7.50 | ||||||||||||
Shares Issued To Four PPM Investors Converting Notes Par Value | $9 | ||||||||||||
Shares Issued To Ten PPM Investors Converting Notes Par Value | $13.50 | ||||||||||||
Shares Issued To Consultant As Compensation Par Value | $28.50 | ||||||||||||
Shares Issued For Two Note Conversions Par Value | $1.05 | ||||||||||||
Shares Issued For Exercise Of Warrants Par Value | $13.50 | $11.25 | |||||||||||
Shares Issued To Cashless Exercise Of Warrants Par Value | $12.75 | ||||||||||||
Shares Issued To Former Board Directors As Compensation Par Value | $24.38 | ||||||||||||
Shares Issued To One Investor For Cashless Exercise Of Warrants Par Value Two | $9 | ||||||||||||
Shares Issued For Cashless Exercise Of Warrants Par Value Five | $5.63 | $7.50 | |||||||||||
Shares Issued For Interest On Conversion Of Two Note Conversions Par Value | $13.50 | ||||||||||||
Shares Issued For Cashless Exercise Of Warrants Par Value Six | $12.75 | $5.63 | |||||||||||
Shares Issued In Settlement With Former Noteholder Par Value | $20.25 | ||||||||||||
Shares Issued To Option Holder Par Value One | $1.25 | $4.88 | |||||||||||
Shares Issued For Cashless Exercise Of Warrants Par Value Seven | $13.50 | $9.75 | |||||||||||
Shares Issued To One Warrant Holder Exercised At Reduced Par Value | $9.38 | ||||||||||||
Shares Issued For Cashless Exercise Of Warrants Par Value Eight | $9.75 | $5.63 | |||||||||||
Shares Issued To Option Holder Par Value Two | $5.25 | $5.25 | |||||||||||
Par Value Of Cancelled Shares, Issued In settlement With Former COO | $6.75 | ||||||||||||
Par Value Of Common Stock Issued For Investor Relations Compensation One | $20.63 | $5.25 | |||||||||||
Par Value Of Common Stock Issued For Investor Relations Compensation Two | $18.75 | ||||||||||||
Shares Issued To Sixteen Shareholders Of Series A Convertible Preferred Stock Dividends Payable In Common Shares Par Value | $19.50 | ||||||||||||
Shares Issued For Cashless And Cash Exercise Of Warrants Par Value | $11.25 | ||||||||||||
Stock Issued To Investor Relations Consultants Exercise Price One | $11.25 | ||||||||||||
Stock Issued To Investor Relations Consultants Exercise Price Two | $18.75 | ||||||||||||
Shares Issued To Sixteen Shareholders Of Series Convertible Preferred Stock Dividends Payable In Common Shares Par Value One | $19.50 | ||||||||||||
Shares Issued For Cash Exercise Of Warrants Par Value | $5.63 | ||||||||||||
Shares Issued To Option Holder Par Value Three | $5.25 | ||||||||||||
Shares Issued For Note Conversion Par Value One | $6.68 | ||||||||||||
Shares Issued For Note Conversion Par Value Two | $6.68 | ||||||||||||
Shares Issued For Note Conversion Par Value Three | $5.85 | ||||||||||||
Shares Issued For Note Conversion Par Value Four | $5.03 | ||||||||||||
Shares Issued To Sixteen Shareholders Of Series Convertible Preferred Stock Dividends Payable In Common Shares Par Value Two | $19.50 |
CONDENSED_STATEMENTS_OF_CASH_F
CONDENSED STATEMENTS OF CASH FLOWS (USD $) | 9 Months Ended | 12 Months Ended | 140 Months Ended | ||
Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | |
Cash flow from operating activities: | |||||
Net loss | ($4,468,170) | ($7,251,965) | ($9,406,304) | ($7,422,155) | ($28,697,415) |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||
Depreciation and amortization | 44,118 | 156,409 | 148,761 | 1,079 | 159,405 |
Vested stock options and warrants | 440,117 | 3,791,802 | 3,700,070 | 830,372 | 7,197,742 |
Equity instruments issued for management and consulting | 111,917 | 137,230 | 239,290 | 3,919,828 | 6,029,058 |
Stock-based registration payments | 0 | 0 | 355,124 | ||
Capital contributions resulting from waivers of debt | 0 | 0 | 476,398 | ||
Amortization of debt discount | 87,853 | 413,695 | 413,695 | 57,518 | 756,497 |
(Gain) loss on valuation of equity-linked instruments | -11,599 | -153,960 | -157,580 | 3,116 | -785,650 |
Changes in assets and liabilities: | |||||
Accounts receivable | -141,359 | -43,480 | -57,534 | 10,583 | -97,245 |
Inventories | -193,445 | 44,142 | 23,034 | -47,604 | -122,175 |
Prepaid expense and other assets | -88,362 | -7,053 | -33,179 | 2,739 | -60,588 |
Notes payable to shareholders | 0 | 0 | -14,957 | ||
Accounts payable | 515,710 | 3,012 | 429,033 | 421,104 | 2,147,872 |
Accrued expenses | 624,530 | -430,998 | 776,548 | 1,039,255 | 2,494,237 |
Deferred Revenue | -64,000 | 5,000 | 69,000 | 0 | 69,000 |
Net cash used in operating activities: | -3,142,690 | -3,336,166 | -3,855,166 | -1,184,165 | -10,092,697 |
Cash flow from investing activities: | |||||
Purchase of fixed assets | -102,954 | -49,791 | -162,761 | 0 | -175,019 |
Purchase of intangibles | -19,346 | -52,074 | -53,355 | 0 | -195,850 |
Net cash used in investing activities | -122,300 | -101,865 | -216,116 | 0 | -370,869 |
Cash flow from financing activities: | |||||
Proceeds from long-term and convertible debt | 1,500,000 | 1,542,718 | 1,822,718 | 528,525 | 3,935,209 |
Repayment of convertible debt | 0 | 0 | 0 | -150,000 | -250,000 |
Principal payments on debt | -305,000 | 0 | 0 | 0 | -75,667 |
Issuance of preferred stock | 2,055,000 | 0 | |||
Issuance of common stock | 157,081 | 2,210,536 | 2,337,378 | 695,794 | 6,955,977 |
Net cash provided by (used in) financing activities | 3,407,081 | 3,753,254 | 4,160,096 | 1,074,319 | 10,565,519 |
Net increase (decrease) in cash | 142,091 | 315,223 | 88,814 | -109,846 | 101,953 |
Cash at beginning of period | 101,953 | 13,139 | 13,139 | 122,985 | 0 |
Cash at end of period | 244,044 | 328,362 | 101,953 | 13,139 | 101,953 |
Non cash transactions: | |||||
Conversion of debt to accrued liabilities | 0 | 415,775 | 415,775 | 100,000 | 515,775 |
Common stock issued for accrued interest/bonus | 694,500 | 395,304 | 402,669 | 106,310 | 620,839 |
Conversion of accounts payable to convertible debt | 0 | 0 | 546,600 | ||
Common stock issued to satisfy debt | 80,000 | 2,318,568 | 2,318,568 | 817,800 | 3,538,935 |
Stock/warrant issued to satisfy accounts payable/Liabilities | $0 | $100,521 | $100,521 | $418,644 | $539,165 |
SUMMARY_OF_SIGNIFICANT_ACCOUNT
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended | 12 Months Ended | ||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||
Accounting Policies [Abstract] | ||||||||||||||||||
Significant Accounting Policies [Text Block] | NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||||||||||||||||
Nature of Operations and Continuance of Operations | Nature of Operations and Continuance of Operations | |||||||||||||||||
BioDrain Medical, Inc. (the “Company”) was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY FMS products. | Skyline Medical, Inc. (the “Company”) was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY FMS products. | |||||||||||||||||
The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and has a stockholders’ deficit. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. | The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and has a stockholders’ deficit. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. | |||||||||||||||||
Since inception to September 30, 2014, the Company has raised approximately $9,248,000 in equity, inclusive of $2,055,000 from a private placement of Series A Convertible Preferred Stock, and $5,518,000 in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources”. | Since inception to December 31, 2013, the Company raised approximately $6,956,000 in equity and $3,935,000 in debt financing, including $2,337,000 in equity and $1,823,000 in convertible debt in 2013. In 2014, the Company has completed a private offering of units of preferred stock and warrants. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources”. | |||||||||||||||||
Recent Accounting Developments | Recent Accounting Developments | |||||||||||||||||
In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers and created a new topic in the FASB Accounting Standards Codification (“ASC”), Topic 606. The new standard provides a single comprehensive revenue recognition framework for all entities and supersedes nearly all existing U.S. GAAP revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and also requires enhanced disclosures. The amendments are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are currently evaluating the impact this guidance may have on our financial statements and related disclosures. | We reviewed all significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations. | |||||||||||||||||
In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company evaluated and adopted ASU 2014-10 for the reporting period ended September 30, 2014. | Valuation of Intangible Assets | |||||||||||||||||
In June 2014, the FASB issued ASU 2014-12, “Compensation — Stock Compensation” providing explicit guidance on how to account for share-based payments granted to employees in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. We are currently evaluating the impact this guidance may have on our financial statements. | We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles — Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management's best estimate of the related risks and return at the time the impairment assessment is made. | |||||||||||||||||
We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations. | Our accounting estimates and assumptions bear various risks of change, including the length of the current economic downturn facing the United States, the expansion of the slowdown in consumer spending in the U.S. medical markets despite the early expressed opinions of financial experts that the medical market would not be as affected as other markets and failure to gain acceptance in the medical market. | |||||||||||||||||
Valuation of Intangible Assets | Accounting Policies and Estimates | |||||||||||||||||
We review identifiable intangible assets for impairment in accordance with ASC 350- Intangibles — Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management's best estimate of the related risks and return at the time the impairment assessment is made. | The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |||||||||||||||||
Our accounting estimates and assumptions bear various risks of change, including the length of the current economic downturn facing the United States, the expansion of the slowdown in consumer spending in the U.S. medical markets despite the early expressed opinions of financial experts that the medical market would not be as affected as other markets and failure to gain acceptance in the medical market. | Presentation of Taxes Collected from Customers | |||||||||||||||||
Accounting Policies and Estimates | Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. | |||||||||||||||||
The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | Shipping and Handling | |||||||||||||||||
Presentation of Taxes Collected from Customers | Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. | |||||||||||||||||
Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. | Advertising | |||||||||||||||||
Shipping and Handling | Advertising costs are expensed as incurred. There were no advertising expenses for 2013 and 2012. | |||||||||||||||||
Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. | Research and Development | |||||||||||||||||
Advertising | Research and development costs are charged to operations as incurred. Research and development costs were approximately $235,000 and $15,000 for 2013 and 2012, respectively. | |||||||||||||||||
Advertising costs are expensed as incurred. Advertising expenses were $4,201 and $11,994 in the three and nine months ended September 30, 2014 and there were no advertising expenses in the three and nine months ended September 30, 2013. | Revenue Recognition | |||||||||||||||||
Research and Development | The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605 — Revenue Recognition. | |||||||||||||||||
Research and development costs are charged to operations as incurred. Research and development expenses were $72,294 and $321,929 in the three and nine months ended September 30, 2014 and $73,621 and $207,162 for September 30, 2013. | Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution and filters. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution and filters may be returned. Additionally, since the Company buys the STREAMWAY FMS units, cleaning solution and filters from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur. | |||||||||||||||||
Revenue Recognition | Receivables | |||||||||||||||||
The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605 — Revenue Recognition. | Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements. | |||||||||||||||||
Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur. | Inventories | |||||||||||||||||
Receivables | Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: | |||||||||||||||||
Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements. | ||||||||||||||||||
Inventories | ||||||||||||||||||
Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: | December 31, | December 31, | ||||||||||||||||
2013 | 2012 | |||||||||||||||||
Finished goods | $ | 56,818 | $ | 91,008 | ||||||||||||||
September 30, | December 31, | Raw materials | 18,603 | 39,543 | ||||||||||||||
2014 | 2013 | Work-In-Process | 46,754 | 14,658 | ||||||||||||||
Finished goods | $ | 69,331 | $ | 56,818 | Total | $ | 122,175 | $ | 145,209 | |||||||||
Raw materials | 207,928 | 18,603 | Property and Equipment | |||||||||||||||
Work-In-Process | 38,361 | 46,754 | Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: | |||||||||||||||
Total | $ | 315,620 | $ | 122,175 | ||||||||||||||
Property and Equipment | ||||||||||||||||||
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: | Years | |||||||||||||||||
Computers and office equipment | 3 – 7 | |||||||||||||||||
Leasehold improvements | 5 | |||||||||||||||||
Years | Manufacturing Tooling | 3 – 7 | ||||||||||||||||
Computers and office equipment | 3 – 7 | The Company’s investment in Fixed Assets consists of the following: | ||||||||||||||||
Leasehold improvements | 5 | |||||||||||||||||
Manufacturing tooling | 3 – 7 | |||||||||||||||||
Demo Equipment | 3 | December 31, | 31-Dec-12 | |||||||||||||||
The Company’s investment in Fixed Assets consists of the following: | 2013 | |||||||||||||||||
Computers and office equipment | $ | 61,505 | $ | 12,258 | ||||||||||||||
Leasehold Improvements | 23,614 | |||||||||||||||||
September 30, | December 31, | Manufacturing Tooling | 89,900 | |||||||||||||||
2014 | 2013 | Total | 175,019 | 12,258 | ||||||||||||||
Computers and office equipment | $ | 126,234 | $ | 61,505 | Less: Accumulated Depreciation | 16,909 | 8,737 | |||||||||||
Leasehold improvements | 23,874 | 23,614 | Total Fixed Assets, Net | $ | 158,110 | $ | 3,521 | |||||||||||
Manufacturing tooling | 97,288 | 89,900 | Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. | |||||||||||||||
Demo Equipment | 30,577 | — | Intangible Assets | |||||||||||||||
Total | 277,973 | 175,019 | Intangible assets consist of trademarks and patent costs. These assets are not subject to amortization until the property patented is in production. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified. The Company wrote-off the entire original STREAMWAY System patent of $140,588 in 2013. | |||||||||||||||
Less: Accumulated depreciation | 61,027 | 16,909 | Income Taxes | |||||||||||||||
Total Fixed Assets, Net | $ | 216,946 | $ | 158,110 | The Company accounts for income taxes in accordance with ASC 740 — Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. | |||||||||||||
Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. | The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. | |||||||||||||||||
Intangible Assets | Tax years subsequent to 2010 remain open to examination by federal and state tax authorities. | |||||||||||||||||
Intangible assets consist of trademarks and patent costs. These assets are not subject to amortization until the property patented is in production. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified. The Company wrote-off the entire original STREAMWAY System patent of $140,588 in 2013. | Patents and Intellectual Property | |||||||||||||||||
Income Taxes | On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. | |||||||||||||||||
The Company accounts for income taxes in accordance with ASC 740 — Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. | Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. | |||||||||||||||||
The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. | The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and US Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. | |||||||||||||||||
Tax years subsequent to 2010 remain open to examination by federal and state tax authorities. | Subsequent Events | |||||||||||||||||
Patents and Intellectual Property | Sale of Convertible Preferred Stock and Warrants. In February 2014, we raised $2,055,000 less offering expenses from a private place of convertible preferred stock. As of February 4, 2014, Skyline Medical Inc. (the “Company”) entered into a Securities Purchase Agreement with certain investors (the “Purchasers”) pursuant to which the Company agreed to offer and sell 20,550 shares of Series A Convertible Preferred Stock, par value $0.01 (the “Preferred Shares”), and warrants (the “Warrants”) to acquire an aggregate of approximately 21,334 shares of the Company’s common stock, par value $0.01 (“Common Stock”). The Preferred Shares are convertible into shares of Common Stock at an initial conversion price of $19.50 per share of Common Stock. The Warrants are exercisable at an exercise price of $24.38 per share and expire five years from the closing date. The Company received gross proceeds of $2,055,000, before offering expenses. The closing of the sale of the Preferred Shares and Warrants (collectively, the “Securities”) occurred as of February 4, 2014 (the “Closing”). If the Company’s Common Stock is not listed on the NASDAQ Stock Market, the New York Stock Exchange, or the NYSE MKT within 180 days of the Closing, the Company shall issue additional Warrants to purchase additional shares of Common Stock, equal to 30% of the shares of Common Stock which the Preferred Shares purchased by each Purchaser purchased are convertible. | |||||||||||||||||
On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. | The Securities Purchase Agreement requires the Company to register the resale of the shares of Common Stock underlying the Preferred Shares (the “Underlying Shares”) and the Common Stock underlying the Warrants (the “Warrant Shares”). The Company is required to prepare and file a registration statement with the Securities and Exchange Commission within 90 days of the closing of the offering, and to use commercially reasonable efforts to have the registration statement declared effective within 105 days if there is no review by the Securities and Exchange Commission, and within 150 days in the event of such review. | |||||||||||||||||
Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. | The Securities were offered and sold without registration under the Securities Act of 1933, as amended (the “Securities Act”), or state securities laws, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. The Securities may not be offered or sold in the United States without an effective registration statement or pursuant to an exemption from applicable registration requirements. | |||||||||||||||||
The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and US Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. | The Preferred Shares are convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value of the Preferred Shares being converted by the conversion price of $19.50, subject to adjustment for stock splits, reverse stock splits and similar recapitalization events. If the Company issues additional shares of Common Stock, other than certain stock that is excluded under the terms of the Securities Purchase Agreement, in one or more capital raising transactions with an aggregate purchase price of at least $100,000 for a price less than the then existing conversion price for the Preferred Shares (the “New Issuance Price”), then the then existing conversion price shall be reduced to the New Issuance Price, provided, however, that under no circumstances shall the New Issuance Price be less than $9.75 or reduced to a price level that would be in breach of the listing rules of any stock exchange or that would have material adverse effect on the Corporation’s ability to list its Common Stock on a stock exchange, including but not limited to the change of accounting treatment of the Preferred Stock. The Preferred Shares contain certain limitations on conversion so that the holder will not own more than 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of Preferred Shares held by the applicable holder, with the percentage subject to increase in certain circumstances. The Preferred Shares are eligible to vote with the Common Stock on an as-converted basis, but only to the extent that the Preferred Shares are eligible for conversion without exceeding the Beneficial Ownership Limitation. The Preferred Shares are entitled to receive dividends on a pari passu basis with the Common Stock, when, and if declared. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of Common Stock ranking prior to the Preferred Shares upon liquidation, the holders of the Preferred Shares shall receive, prior and in preference to the holders of any junior securities, an amount equal to $2,055,000 times 1.2, plus all declared but unpaid dividends. | |||||||||||||||||
Subsequent Events | The Warrants are exercisable on any day on or after the date of issuance, have an exercise price of $19.50 per share, subject to adjustment, and a term of five years from the date they are first exercisable. However, a holder will be prohibited from exercising a Warrant if, as a result of such exercise, the holder, together with its affiliates, would exceed the Beneficial Ownership Limitation as described above for the Preferred Shares. If any Warrant has not been fully exercised prior to the first anniversary of the Closing and if during such period the Company has not installed or received firm purchase orders (accepted by the Company) for at least 500 STREAMWAY Automated Surgical Fluid Disposal Systems, then, the number of Common Stock for which such Warrant may be exercised shall be increased 2.5 times. | |||||||||||||||||
The Company filed a Certificate of Amendment effecting a 1:75 reverse stock split (the “Reverse Stock Split”) with the Secretary of State of the State of Delaware, which became effective under Delaware law as of October 24, 2014. At the effective time (the “Effective Time”) of the Reverse Stock Split, the issued and outstanding Common Stock of the Company was combined on a 1-for-75 basis such that every seventy-five shares of Common Stock outstanding immediately prior to the Effective Time was combined into one share of Common Stock. This share combination was effected through the exchange and replacement of certificates representing issued and outstanding shares of Common Stock as of the Effective Time, together with immediate book-entry adjustments to the stock register of the Company maintained in accordance with the Delaware General Corporation Law. In the event that the share combination would have resulted in a shareholder being entitled to receive less than a full share of Common Stock, the fractional share that would so result was rounded up to the nearest whole share of Common Stock. The par value of each share of issued and outstanding Common Stock was not affected by the share combination. | Settlement with Group of Warrantholders. In September 2013, the Company received a request to issue 66,585 shares of its common stock to a group of partnerships and individuals in connection with the cashless exercise of stock purchase warrants covering a total of 82,459 shares. In processing the exercise, the Company commenced an internal investigation regarding the warrants and withheld delivery of the certificates for a substantial majority of the shares, pending the outcome of the investigation. | |||||||||||||||||
For purposes of trading of the common stock, the Reverse Stock Split was approved, by FINRA and became effective as of market open on October 28, 2014. | After investigation, the Company disagreed with the group’s position that all of such shares should be delivered in connection with the exercise. Following negotiations, effective March 3, 2014, the Company and the group entered into a settlement agreement that resulted in, among other things, a net reduction of 16,867 shares. This reduction is reflected as outstanding on the balance sheet as of December 31, 2013. | |||||||||||||||||
In the Condensed Financial Statement and Notes thereto, and elsewhere in this Report, all numbers of shares and per share amounts, as appropriate, have been restated to reflect the Reverse Stock Split. | ||||||||||||||||||
In September 2014 we filed a registration statement for the public offering of shares of our common stock and five-year warrants to purchase shares of common stock at an exercise price equal to 125% of the offering price per share of the common stock. We have applied to list our common stock on the NASDAQ Capital Market effective upon the completion of the public offering. | ||||||||||||||||||
Interim Financial Statements | ||||||||||||||||||
The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company’s financial position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10-K filed with the SEC on March 27, 2014. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year. | ||||||||||||||||||
DEVELOPMENT_STAGE_OPERATIONS
DEVELOPMENT STAGE OPERATIONS | 9 Months Ended | 12 Months Ended |
Sep. 30, 2013 | Dec. 31, 2013 | |
Development Stage Enterprises [Abstract] | ||
Development Stage Enterprise General Disclosures [Text Block] | NOTE 2 — DEVELOPMENT STAGE OPERATIONS | NOTE 2 — DEVELOPMENT STAGE OPERATIONS |
The Company was formed April 23, 2002. Since inception to November 3, 2014, 3,021,831 shares of common stock have been issued between par value and $125.00 (post reverse split). Operations since incorporation have been devoted to raising capital, obtaining financing, development of the Company’s product, and administrative services. | The Company was formed April 23, 2002. Since inception through December 31, 2013, 2,932,501 shares of common stock have been issued between par value and $125.25. Operations since incorporation have primarily been devoted to raising capital, obtaining financing, development of the Company’s product, administrative services, customer acceptance and sales and marketing strategies. | |
STOCKHOLDERS_DEFICIT_STOCK_OPT
STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | ||||||||||||||||||||||||||||||||||
Stockholders' Equity Note Disclosure [Text Block] | NOTE 3 — STOCKHOLDERS’ DEFICIT, STOCK OPTIONS AND WARRANTS | NOTE 3 — STOCKHOLDERS’ DEFICIT, STOCK OPTIONS AND WARRANTS | ||||||||||||||||||||||||||||||||
The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options under this plan have terms ranging from three to ten years. | In connection with the financing completed in October 2008, the Company has effected two reverse stock splits, one on June 6, 2008 and another on October 20, 2008. In accordance with SAB Topic 4C, all stock options and warrants and their related exercise prices are stated at their post-reverse stock split values. | |||||||||||||||||||||||||||||||||
On February 4, 2014, (the “Closing Date”) we raised $2,055,000 in gross proceeds from a private placement of Series A Convertible Preferred Stock, par value $0.01 (the “Preferred Shares”) pursuant to a Securities Purchase Agreement with certain investors (the “Purchasers”) purchased 20,550 Preferred Shares, and warrants (the “Warrants”) to acquire an aggregate of approximately 21,334 shares of Common Stock. The Preferred Shares are convertible into shares of Common Stock at an initial conversion price of $19.50 per share of Common Stock. The Warrants are exercisable at an exercise price of $24.38 per share and expire five years from the Closing Date. If the Common Stock is not listed on the NASDAQ Stock Market, the New York Stock Exchange, or the NYSE MKT within 180 days of the Closing, the Company was required to issue additional Warrants to purchase additional shares of Common Stock, equal to 30% of the shares of Common Stock which the Preferred Shares each Purchaser purchased are convertible into. As of August 4, 2014, the Company issued additional warrants to purchase 61,539 shares to the Purchasers in connection with this provision. | The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options under this plan have terms ranging from three to ten years. | |||||||||||||||||||||||||||||||||
The Securities Purchase Agreement requires the Company to register the resale of the shares of Common Stock underlying the Preferred Shares (the “Underlying Shares”) and the Common Stock underlying the Warrants (the “Warrant Shares”). On September 9, 2014, a resale registration statement covering the Underlying Shares, the Warrant Shares and certain other securities (the “Resale Registration Statement”) was declared effective. | Accounting for share-based payment | |||||||||||||||||||||||||||||||||
The Preferred Shares are convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value of the Preferred Shares being converted by the conversion price of $19.50, subject to adjustment for stock splits, reverse stock splits and similar recapitalization events. If the Company issues additional shares of Common Stock, other than certain stock that is excluded under the terms of the Securities Purchase Agreement, in one or more capital raising transactions with an aggregate purchase price of at least $100,000 for a price less than the then existing conversion price for the Preferred Shares (the “New Issuance Price”), then the then existing conversion price shall be reduced to the New Issuance Price, provided, however, that under no circumstances shall the New Issuance Price be less than $9.75 or reduced to a price level that would be in breach of the listing rules of any stock exchange or that would have material adverse effect on the Company’s ability to list its Common Stock on a stock exchange, including but not limited to the change of accounting treatment of the Preferred Stock. In July 2014, in connection with the issuance of certain convertible notes, the conversion price of the Preferred Stock was adjusted to $9.75 per share. Further, the Company has agreed to additional shares of Common Stock to holders of the Preferred Stock in certain circumstances, as described in the following paragraph. The Preferred Shares contain certain limitations on conversion so that the holder will not own more than 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of Preferred Shares held by the applicable holder, with the percentage subject to increase in certain circumstances. The Preferred Shares are eligible to vote with the Common Stock on an as-converted basis, but only to the extent that the Preferred Shares are eligible for conversion without exceeding the Beneficial Ownership Limitation. The Preferred Shares are entitled to receive dividends on a pari passu basis with the Common Stock, when, and if declared. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of Common Stock ranking prior to the Preferred Shares upon liquidation, the holders of the Preferred Shares shall receive, prior and in preference to the holders of any junior securities, an amount equal to $2,055,000 times 1.2, plus all declared but unpaid dividends. | The Company has adopted ASC 718 — Compensation — Stock Compensation (“ASC 718”). Under ASC 718 stock-based employee compensation cost is recognized using the fair value based method for all new awards granted after January 1, 2006 and unvested awards outstanding at January 1, 2006. Compensation costs for unvested stock options and non-vested awards that were outstanding at January 1, 2006, are being recognized over the requisite service period based on the grant-date fair value of those options and awards, using a straight-line method. We elected the modified-prospective method under which prior periods are not retroactively restated. | |||||||||||||||||||||||||||||||||
In July 2014, in connection with the offering of convertible notes and warrants and in connection with the waiver of certain rights, the Company agreed to issue additional shares of Common Stock to the Preferred Stockholders (the “Additional Shares”) (A) automatically upon the closing of a Qualified Public Offering (as defined in the Certificate of Designation), to the extent that (i) the Qualified Public Offering closes within six (6) months of the first closing of the convertible notes offering (“Qualified Public Offering Deadline”) and (ii) 70% of the public offering price per share of the Common Stock in the Qualified Public Offering (the “QPO Discount Price”) is less than the Conversion Price floor contained in Section 7(e)(i) of the Certificate of Designation (the “Conversion Price Floor”), or (B) if a Qualified Public Offering has not been consummated by the Qualified Public Offering Deadline, upon the Preferred Stockholders’ conversion of their shares of Preferred Stock to the extent that 70% of the volume weighted average price of the Common Stock on the principal Trading Market (as defined in the Certificate of Designation) of the Common Stock during the ten Trading Days (as defined in the Certificate of Designation) immediately preceding the Qualified Public Offering Deadline (the “Non-QPO Discount Price”) is less than the Conversion Price Floor. | ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. | |||||||||||||||||||||||||||||||||
The Warrants are exercisable on any day on or after the date of issuance, have an exercise price of $24.38 per share, subject to adjustment, and a term of five years from the date they are first exercisable. However, a holder will be prohibited from exercising a Warrant if, as a result of such exercise, the holder, together with its affiliates, would exceed the Beneficial Ownership Limitation as described above for the Preferred Shares. If any Warrant has not been fully exercised prior to the first anniversary of the Closing and if during such period the Company has not installed or received firm purchase orders (accepted by the Company) for at least 500 STREAMWAY® Automated Surgical Fluid Disposal Systems, then, the number of shares of Common Stock for which such Warrant may be exercised shall be increased 2.5 times. | Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter. | |||||||||||||||||||||||||||||||||
In addition, in July, August and September 2014, the Company issued 71,257 warrants to investors in convertible notes as further described below. | When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. | |||||||||||||||||||||||||||||||||
Accounting for share-based payment | Since the Company has limited trading history in its stock and no first-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future. | |||||||||||||||||||||||||||||||||
The Company has adopted ASC 718- Compensation-Stock Compensation (“ASC 718”). Under ASC 718 stock-based employee compensation cost is recognized using the fair value based method for all new awards granted after January 1, 2006 and unvested awards outstanding at January 1, 2006. Compensation costs for unvested stock options and non-vested awards that were outstanding at January 1, 2006, are being recognized over the requisite service period based on the grant-date fair value of those options and awards, using a straight-line method. We elected the modified-prospective method under which prior periods are not retroactively restated. | Valuation and accounting for options and warrants | |||||||||||||||||||||||||||||||||
ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. | The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. For grants issued during 2008, the Company used a 2.0 to 4.5% risk-free interest rate, 0% dividend rate, 53 – 66% volatility and estimated term of 2.5 to 7.5 years. Values computed using these assumptions ranged from $7.65 per share to $25.20 per share. Warrants or options awarded for services rendered are expensed over the period of service (normally the vesting period) as compensation expense for employees or an appropriate consulting expense category for awards to consultants and directors. Warrants granted in connection with a common equity financing are included in stockholders’ equity, provided that there is no re-pricing provision that requires them to be treated as a liability (See Note 8) and warrants granted in connection with a debt financing are treated as a debt discount and amortized using the interest method as interest expense over the term of the debt. | |||||||||||||||||||||||||||||||||
Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter. | Warrants issued in connection with the $100,000 convertible debt that closed March 1, 2007 created a debt discount of $40,242 that was being amortized as additional interest over its 5-year term. Warrants issued in connection with the $170,000 convertible “bridge” debt that closed in July 2007 created a calculated debt discount of $92,700 that was fully expensed over its loan term that matured April 30, 2008. | |||||||||||||||||||||||||||||||||
When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. | The Company issued $100,000 in convertible debt in October 2009 and issued a warrant, in connection with the debt, for 2,667 shares of common stock at $48.75 per share. The Company determined that the warrant had an initial value of $30,150 that was treated as a debt discount and amortized as additional interest expense over the 24-month term of the note. | |||||||||||||||||||||||||||||||||
Since the Company has limited trading history in its stock and no first-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future. | The Company also issued $200,000 in convertible debt in June 2010 and issued a warrant, in connection with the debt, to purchase 14,815 shares of common stock at $34.50 per share. The Company determined that the value of the June 2010 warrant was $96,613. This value was treated as a debt discount and amortized as additional interest expense over the 22-month term of the note. | |||||||||||||||||||||||||||||||||
Valuation and accounting for options and warrants | The Company also issued $32,000 in convertible debt in September 2010 and issued a warrant to purchase 4,267 shares of common stock at $13.50 per share. The Company determined that this warrant had a value of $15,553 that was treated as a debt discount and amortized as additional interest expense over the 18-month term of the note. | |||||||||||||||||||||||||||||||||
The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. | The Company also issued $16,800 in convertible debt in December 2010 and issued a warrant to purchase 2,667 shares of common stock at $6.30 per share. The Company determined that this warrant had a value of $7,232 that was treated as a debt discount and amortized as additional interest expense over the 24-month term of the note. | |||||||||||||||||||||||||||||||||
In January 2013, in connection with a private placement offering we issued 8% convertible one year promissory notes in an aggregate principal amount of $300,000 convertible into 33,333 shares of common stock assuming a conversion rate of $9.00 per share and five year warrants to purchase up to an aggregate of 33,333 shares of the corporation’s common stock at an exercise price of $11.25 per share. The value of the notes are being treated as a debt discount with an aggregate discount of $77,644, and amortized as an additional interest expense over the twelve month term of the notes. In addition, we issued to the placement agent for these sales five year warrants to purchase an aggregate of 2,667 shares of common stock at an exercise price of $9.00 per share. | In January 2011, the Company issued three convertible notes of $50,000 each and also issued warrants to purchase 21,270 common shares at $15.00 per share. The value of the warrants was determined to be $47,908 and was being treated as a debt discount and amortized as additional interest expense over the 24-month term of the notes. | |||||||||||||||||||||||||||||||||
In January and March 2013, in connection with a separate and new private placement offering we issued 95,238 shares of common stock at $5.25 per share and warrants to purchase 95,238 shares of common stock at $11.25 per share to 5 investors in return for their $500,000 investment in the Company. | For grants of stock options and warrants in 2011 the Company used a 0.34 to 2.44% risk-free interest rate, 0% dividend rate, 54 – 66% volatility and estimated term of 3 to 10 years. Values computed using these assumptions ranged from $0.945 to $25.59 per share. | |||||||||||||||||||||||||||||||||
On March 15, 2013 the Company completed the private sale of 95,239 shares of the Company’s common stock, par value $.01 per share, at $5.25 per share for an aggregate purchase price of $500,000, warrants to purchase 95,239 shares of common stock at an exercise price of $6.00 per share, and warrants to purchase 47,619 shares of common stock at an exercise price of $11.25 per share. | In November 2012, the Company issued four convertible notes of $27,500, $27,500, $51,243 and $50,000, respectively. The note holders were issued shares of our common stock at $7.50 per share value in consideration for the notes. Though short term the value of the notes are being treated as a debt discount with an aggregate discount of $33,469 and amortized as additional interest expense over the six month term of the notes. | |||||||||||||||||||||||||||||||||
In April 2013, the Company issued 2,667 shares of common stock, par value $.01 per share, to a former consultant exercising options; the Company issued 4,444 shares of common stock, par value $.01 per share, at $0.75 per share to the former CEO exercising options. | For grants of stock options and warrants in 2012 the Company used a 0.33% to 1.80% risk-free interest rate, 0% dividend rate, 54%, 59% or 66% volatility and estimated terms of 3, 5 or 10 years. Value computed using these assumptions ranged from $0.83 to $7.20 per share. | |||||||||||||||||||||||||||||||||
In May 2013, the Company converted four (4) notes totaling $156,243, plus $11,169 in interest; issued in November 2012, the noteholders received 14,881 shares of common stock, par value $.01, at $7.50 per share. One of the noteholders was Dr. Samuel Horowitz who received 4,762 shares. | In January 2013, in connection with a private placement offering the Company issued 8% convertible one year promissory notes in an aggregate principal amount of $300,000 convertible into 33,334 shares of common stock assuming a conversion rate of $9.00 per share and five year warrants to purchase up to an aggregate 33,334 shares of the corporation’s common stock at an exercise price of $11.25 per share. The value of the notes were treated as a debt discount with an aggregate discount of $77,644, and amortized as an additional interest expense over the twelve month term of the notes. In addition, we issued to the placement agent for these sales five year warrants to purchase an aggregate of 2,667 shares of common stock at an exercise price of $9.00 per share. | |||||||||||||||||||||||||||||||||
In May and June 2013 in connection with a private placement offering we issued 8% convertible one year promissory notes in an aggregate principal amount of $1,000,000 convertible into 80,000 shares of common stock assuming a conversion rate of $13.50 per share and five year warrants to purchase up to an aggregate of 61,481 shares of the corporation’s common stock at an exercise price of $14.85 per share. The value of the notes net of discount was $275,640 in 2013; due in May and June 2014. In addition, we issued to the placement agent for these sales five year warrants to purchase an aggregate of 5,926 shares of common stock at an exercise price of $13.50 per share. | In January and March 2013, in connection with a separate and new private placement offering we issued 95,239 shares of common stock at $5.25 per share and warrants to purchase 95,239 shares of common stock at $11.25 per share to 5 investors in return for their $500,000 investment in the Company. | |||||||||||||||||||||||||||||||||
In August and September 2013 the Company entered into agreements with holders of certain of its outstanding warrants to purchase the Company’s common stock to amend the exercise price of the warrant to $7.50 per share in connection with the agreement of each such holder to exercise the warrants in full. Prior to the amendments, the exercise prices of such warrants ranged from $11.25 to $34.50 per share. Twenty-four warrants were exercised with a reduced exercise price, and nineteen warrants were exercised pursuant to a net exercise provision. Together such warrant exercises resulted in aggregate cash proceeds of $1,044,490 to the Company, and the issuance of an aggregate 139,265 shares of common stock through the reduced warrant exercise and 87,117 shares which were issued pursuant to a net exercise provision. | On March 15, 2013 the Company completed the private sale of 95,239 shares of the Company’s common stock, par value $.01 per share, at $5.25 per share for an aggregate purchase price of $500,000, warrants to purchase 95,239 shares of common stock at an exercise price of $6.00 per share, and warrants to purchase 47,620 shares of common stock at an exercise price of $11.25 per share. | |||||||||||||||||||||||||||||||||
In October 2013 the Company entered into agreements with a holder of certain of its outstanding warrants to purchase the Company’s common stock to amend the exercise price of the warrant to $9.38 per share in connection with the agreement of the holder to exercise the warrants in full. Prior to the amendments, the exercise price of such warrants was $18.75 per share. Two warrants were exercised with a reduced exercise price. Together the warrant exercises resulted in aggregate cash proceeds of $125,000 to the Company, and the issuance of an aggregate 13,333 shares of common stock. | In April 2013, the Company issued 2,667 shares of common stock, par value $.01 per share, to a former consultant exercising options; the Company issued 4,445 shares of common stock, par value $.01 per share, at $.75 per share to the former CEO exercising options. | |||||||||||||||||||||||||||||||||
For grants of stock options and warrants in 2013 the Company used a 0.78% to 2.04% risk-free interest rate, 0% dividend rate, 59% or 66% volatility and estimated terms of 5 or 10 years. Value computed using these assumptions ranged from $1.43 to $18.34 per share. | In May 2013, the Company converted four (4) notes totaling $156,243, plus $11,169 in interest; issued in November 2012, the noteholders received 14,882 shares of common stock, par value $.01, at $7.50 per share. One of the noteholders was Dr. Samuel Herschkowitz who received 4,763 shares. | |||||||||||||||||||||||||||||||||
In January 2014 the Company issued 4,336 shares of common stock to the former CEO at $1.25 per share upon his exercising options. | In May and June 2013 in connection with a private placement offering we issued 8% convertible one year promissory notes in an aggregate principal amount of $1,000,000 convertible into 80,000 shares of common stock assuming a conversion rate of $13.50 per share and five year warrants to purchase up to an aggregate of 61,482 shares of the corporation’s common stock at an exercise price of $14.85 per share. The value of the notes net of discount was $275,640 in 2013; due in May and June 2014. In addition, we issued to the placement agent for these sales five year warrants to purchase an aggregate of 5,926 shares of common stock at an exercise price of $13.50 per share. | |||||||||||||||||||||||||||||||||
In January through March 2014, 9 warrant holders exercised warrants through a cashless exercise for a total of 15,442 shares of common stock. | In August and September 2013 the Company entered into agreements with holders of certain of its outstanding warrants to purchase the Company’s common stock to amend the exercise price of the warrant to $7.50 per share in connection with the agreement of each such holder to exercise the warrants in full. Prior to the amendments, the exercise prices of such warrants ranged from $11.25 to $34.50 per share. Twenty-four warrants were exercised with a reduced exercise price, and nineteen warrants were exercised pursuant to a net exercise provision. Together such warrant exercises resulted in aggregate cash proceeds of $1,044,490 to the Company, and the issuance of an aggregate 139,266 shares of common stock through the reduced warrant exercise and 87,118 shares which were issued pursuant to a net exercise provision. | |||||||||||||||||||||||||||||||||
In January and February 2014 the Company issued warrants to purchase 21,538 shares pursuant to a February 4, 2014 private placement whereby the Company issued 20,550 shares of Series A Convertible Preferred Stock raising gross proceeds of $2,055,000. The warrants are at an exercise price of $24.38. | In October 2013 the Company entered into agreements with a holder of certain of its outstanding warrants to purchase the Company’s common stock to amend the exercise price of the warrant to $9.38 per share in connection with the agreement of the holder to exercise the warrants in full. Prior to the amendments, the exercise price of such warrants was $18.75 per share. Two warrants were exercised with a reduced exercise price. Together the warrant exercises resulted in aggregate cash proceeds of $125,000 to the Company, and the issuance of an aggregate 13,334 shares of common stock. | |||||||||||||||||||||||||||||||||
In February 2014 the Company issued a warrant to purchase 1,482 shares of common stock at an exercise price of $20.25 to a major shareholder Dr. Samuel Herschkowitz. The warrant is in consideration for a bridge loan extended in December 2013 that has been paid in February 2014. | For grants of stock options and warrants in 2013 the Company used a 0.78% to 2.04% risk-free interest rate, 0% dividend rate, 59% or 66% volatility and estimated terms of 5 or 10 years. Value computed using these assumptions ranged from $8.93 to $18.15 per share. | |||||||||||||||||||||||||||||||||
On March 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $19.50 per share. As a result 970 shares of common stock were issued to 16 holders of Preferred Shares. | The following summarizes transactions for stock options and warrants for the periods indicated: | |||||||||||||||||||||||||||||||||
In March 2014, the Company issued 4,444 shares of common stock to a warrant holder for a partial cash exercise at $11.25 per share; issued 3,333 shares to the holder via the cashless exercise of the remainder of the warrant. | ||||||||||||||||||||||||||||||||||
In June 2014, the Company issued 3,725 shares of common stock to a warrant holder exercising cashless warrants. | ||||||||||||||||||||||||||||||||||
On June 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $19.50 per share. As a result 1,561 shares of common stock were issued to 16 holders of Preferred Shares. | Stock Options(1) | Warrants(1) | ||||||||||||||||||||||||||||||||
On June 30, 2014, the Company issued a warrant to purchase 5,431 shares of common stock at an exercise price of $12.38 to SOK Partners, LLC, in consideration for a bridge loan in the form of convertible notes. On September 9, 2014 the Resale Registration Statement went into effect. The convertible note agreement provided an immediate approximately 11% reduction to the warrant agreement. Therefore, the warrant has been adjusted to purchase 4,831 shares of common stock at an exercise price of $12.38 to SOK Partners, LLC in consideration for a bridge loan. | Number of | Average | Number of | Average | ||||||||||||||||||||||||||||||
In July 2014, the Company issued warrants to purchase 28,986 shares of common stock at an exercise price of $12.38 to two lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect approximately an 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014. | Shares | Exercise Price | Shares | Exercise Price | ||||||||||||||||||||||||||||||
In August 2014, the Company issued warrants to purchase 61,539 of common stock at an exercise price of $24.38 to the Purchasers of the Preferred Shares. The Securities Purchase Agreement with the Preferred Shareholders stipulated that if the Company was not listed on either the NASDAQ Stock Market, the New York Stock Exchange or the NYSE MKT within 180 days of closing the agreement then warrants to purchase the above additional shares would be issued in aggregate to the Preferred Shareholders. | Outstanding at December 31, 2005 | 239 | $ | 125.25 | 279 | $ | 196.5 | |||||||||||||||||||||||||||
In August and September 2014, the Company issued warrants to purchase 37,440 shares of common stock at an exercise price of $12.38 to four lenders in consideration for a bridge loan in the form of convertible notes. The shares above reflect the approximate 11% reduction resulting from the Resale Registration Statement that went effective September 9, 2014. | Issued | 319 | 125.25 | 958 | 63.75 | |||||||||||||||||||||||||||||
On September 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $19.50 per share. As a result 1,561 shares of common stock were issued to 16 holders of Preferred Shares. | Outstanding at December 31, 2006 | 558 | 125.25 | 1,237 | 93.75 | |||||||||||||||||||||||||||||
For grants of stock options and warrants in 2014 the Company used a 1.44% to 2.75% risk-free interest rate, 0% dividend rate, 59% to 66% volatility and estimated terms of 5 to 10 years. Value computed using these assumptions ranged from $3.21 to $13.91 per share. | Issued | 80 | 125.25 | 380 | 26.25 | |||||||||||||||||||||||||||||
The following summarizes transactions for stock options and warrants for the periods indicated: | Outstanding at December 31, 2007 | 638 | 125.25 | 1,617 | 78 | |||||||||||||||||||||||||||||
Issued | 16,577 | 15 | 67,669 | 33.75 | ||||||||||||||||||||||||||||||
Expired | (160 | ) | 282 | |||||||||||||||||||||||||||||||
Stock Options | Warrants | Outstanding at December 31, 2008 | 17,215 | 19.5 | 69,126 | 33.75 | ||||||||||||||||||||||||||||
Number of | Average | Number of | Average | Issued | 2,733 | 27.75 | 29,177 | 48.75 | ||||||||||||||||||||||||||
Shares | Exercise Price | Shares | Exercise Price | Outstanding at December 31, 2009 | 19,948 | 20.25 | 98,303 | 36.75 | ||||||||||||||||||||||||||
Outstanding at December 31, 2012 | 168,856 | $ | 6.75 | 468,431 | $ | 9.75 | Issued | 29,467 | 12.75 | 45,809 | 25.5 | |||||||||||||||||||||||
Issued | 239,816 | 6.75 | 343,196 | 9 | Expired | (2,773 | ) | 32.25 | (120 | ) | 125.25 | |||||||||||||||||||||||
Expired | (15,467 | ) | 18 | (111,025 | ) | 13.5 | Exercised | (1,714 | ) | 34.5 | ||||||||||||||||||||||||
Exercised | (7,472 | ) | 0.75 | (238,682 | ) | 8.25 | Outstanding at December 31, 2010 | 46,642 | 14.25 | 142,278 | 33 | |||||||||||||||||||||||
Outstanding at December 31, 2013 | 385,733 | 6.75 | 461,920 | 10.5 | Issued | 33,111 | 0.75 | 242,963 | 10.5 | |||||||||||||||||||||||||
Issued | 71,838 | 8.11 | 155,818 | 3.74 | Expired | (1,119 | ) | 54.75 | (26,812 | ) | 36 | |||||||||||||||||||||||
Expired | (6,746 | ) | 25.65 | (77,685 | ) | 9.88 | Exercised | (1,333 | ) | 0.75 | ||||||||||||||||||||||||
Exercised | (4,936 | ) | 1.76 | (40,722 | ) | 8.38 | Outstanding at December 31, 2011 | 77,301 | 8.25 | 358,429 | 17.25 | |||||||||||||||||||||||
Outstanding at September 30, 2014 | 445,889 | $ | 7.58 | 499,331 | $ | 8.6 | Issued | 126,866 | 6 | 155,846 | 11.25 | |||||||||||||||||||||||
At September 30, 2014, 427,051 stock options are fully vested and currently exercisable with a weighted average exercise price of $7.26 and a weighted average remaining term of 8.24 years. All warrants are fully vested and exercisable. Stock-based compensation recognized for the nine months ending September 2014 and September 30, 2013 was $440,117 and $3,791,802, respectively. The Company has $262,055 of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over a weighted average period of approximately 18 months. | Expired | (29,805 | ) | 8.25 | (44,886 | ) | 37.5 | |||||||||||||||||||||||||||
The following summarizes the status of options and warrants outstanding at September 30, 2014: | Exercised | (5,506 | ) | 0.75 | (958 | ) | 0.75 | |||||||||||||||||||||||||||
Outstanding at December 31, 2012 | 168,856 | 6.75 | 468,431 | 9.75 | ||||||||||||||||||||||||||||||
Issued | 239,816 | 6.75 | 343,196 | 9 | ||||||||||||||||||||||||||||||
Range of Exercise Prices | Shares | Weighted | Expired | (15,467 | ) | 18 | (111,025 | ) | 13.5 | |||||||||||||||||||||||||
Average | Exercised | (7,472 | ) | 0.75 | (238,682 | ) | 8.25 | |||||||||||||||||||||||||||
Remaining Life | Outstanding at December 31, 2013 | 385,733 | $ | 6.75 | 461,920 | $ | 10.5 | |||||||||||||||||||||||||||
Options: | ||||||||||||||||||||||||||||||||||
$0.75 | 7,333 | 6.77 | -1 | Adjusted for the reverse stock splits in total at June 6, 2008, October 20, 2008, and October 24, 2014. | ||||||||||||||||||||||||||||||
$4.88 | 134 | 8.45 | At December 31, 2013, 368,783 stock options are fully vested and currently exercisable with a weighted average exercise price of $6.38 and a weighted average remaining term of 8.80 years. There are 461,920 warrants that are fully vested and exercisable. Stock-based compensation recognized in 2013 and 2012 was $3,700,070 and $830,372, respectively. The Company has $166,905 of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next 22 months. | |||||||||||||||||||||||||||||||
$5.25 | 2,031 | 7.94 | The following summarizes the status of options and warrants outstanding at December 31, 2013: | |||||||||||||||||||||||||||||||
$5.63 | 192,000 | 8.46 | ||||||||||||||||||||||||||||||||
$5.93 | 23,206 | 8.47 | ||||||||||||||||||||||||||||||||
$6.00 | 123,998 | 7.88 | Range of Exercise Prices | Shares | Weighted | |||||||||||||||||||||||||||||
$6.60 | 5,332 | 7.32 | Average | |||||||||||||||||||||||||||||||
$8.25 | 3,636 | 10 | Remaining | |||||||||||||||||||||||||||||||
$9.94 | 3,019 | 8.79 | Life | |||||||||||||||||||||||||||||||
$10.50 | 3,238 | 8.79 | Options: | |||||||||||||||||||||||||||||||
$11.25 | 14,799 | 7.72 | $0.75 | 7,334 | 7.52 | |||||||||||||||||||||||||||||
$12.75 | 10,069 | 9.54 | $1.28 | 4,336 | 4.43 | |||||||||||||||||||||||||||||
$13.88 | 2,160 | 9.51 | $4.88 | 134 | 9.2 | |||||||||||||||||||||||||||||
$15.00 | 3,334 | 9.47 | $5.25 | 2,631 | 9.44 | |||||||||||||||||||||||||||||
$17.25 | 40,261 | 9.44 | $5.63 | 192,000 | 9.21 | |||||||||||||||||||||||||||||
$18.75 | 3,335 | 9.4 | $5.93 | 23,207 | 9.22 | |||||||||||||||||||||||||||||
$20.25 | 4,940 | 9.26 | $6.00 | 124,000 | 8.63 | |||||||||||||||||||||||||||||
$21.75 | 1,336 | 9.02 | $66.00 | 5,334 | 8.07 | |||||||||||||||||||||||||||||
$23.85 | 1,260 | 9.01 | $9.94 | 3,019 | 9.54 | |||||||||||||||||||||||||||||
$24.75 | 334 | 8.99 | $10.50 | 3,239 | 9.54 | |||||||||||||||||||||||||||||
$25.61 | 134 | 8.99 | $11.25 | 9,023 | 7.16 | |||||||||||||||||||||||||||||
Total | 445,889 | $12.75 | 67 | 9.36 | ||||||||||||||||||||||||||||||
Warrants: | $20.25 | 4,939 | 10 | |||||||||||||||||||||||||||||||
$0.75 | 400 | 1.19 | $21.75 | 1,334 | 9.77 | |||||||||||||||||||||||||||||
$6.00 | 102,857 | 3.45 | $23.85 | 1,258 | 9.75 | |||||||||||||||||||||||||||||
$9.00 | 2,666 | 3.32 | $24.75 | 1,334 | 9.73 | |||||||||||||||||||||||||||||
$11.25 | 204,200 | 3.27 | $25.61 | 267 | 9.75 | |||||||||||||||||||||||||||||
$12.38 | 71,257 | 3.53 | $26.25 | 1,000 | 0.37 | |||||||||||||||||||||||||||||
$13.50 | 4,444 | 3.72 | $43.88 | 1,277 | 0.44 | |||||||||||||||||||||||||||||
$14.85 | 23,612 | 3.66 | Total | 385,733 | ||||||||||||||||||||||||||||||
$15.00 | 1,168 | 0.34 | Warrants: | |||||||||||||||||||||||||||||||
$18.75 | 4,166 | 0.03 | $0.75 | 2,667 | 1.94 | |||||||||||||||||||||||||||||
$20.25 | 1,481 | 3.03 | $5.63 | 35,556 | 0.85 | |||||||||||||||||||||||||||||
$24.38 | 83,080 | 4.86 | $6.00 | 102,857 | 4.2 | |||||||||||||||||||||||||||||
Total | 499,331 | $7.50 | 19,047 | 0.33 | ||||||||||||||||||||||||||||||
Stock options and warrants expire on various dates from October 2014 to September 2024. | $9.00 | 2,667 | 4.9 | |||||||||||||||||||||||||||||||
The shareholders approved an increase in authorized shares to 1,066,667 shares in an annual shareholder meeting held on June 22, 2010 and approved an increase in authorized shares to 2,666,667 shares in a special shareholder meeting held on September 7, 2011. | $11.25 | 221,977 | 3.98 | |||||||||||||||||||||||||||||||
The shareholders approved an increase in authorized shares to 4,000,000 shares in a special shareholder meeting held on January 15, 2013. | $12.00 | 2,000 | 0.38 | |||||||||||||||||||||||||||||||
The shareholders approved an amendment of the Company’s 2012 Stock Incentive Plan to increase the reserve of shares authorized for issuance to 666,667 shares and to increase the threshold of limitation on certain grants to 266,667 shares on April 15, 2013. | $12.75 | 17,255 | 0.27 | |||||||||||||||||||||||||||||||
An increase from 4,000,000 to 10,666,667 authorized shares, and an amendment of the Company’s 2012 Stock Incentive Plan to increase the reserve of shares authorized for issuance to 1,333,334 shares was approved at the September 10, 2013 annual meeting. | $13.50 | 7,112 | 2.83 | |||||||||||||||||||||||||||||||
Stock Options and Warrants Granted by the Company | $14.85 | 23,611 | 4.41 | |||||||||||||||||||||||||||||||
The following table is the listing of stock options and warrants as of September 30, 2014 by year of grant: | $1,500 | 16,500 | 0.18 | |||||||||||||||||||||||||||||||
Stock Options: | $18.75 | 5,000 | 0.77 | |||||||||||||||||||||||||||||||
$34.50 | 1,110 | 0.3 | ||||||||||||||||||||||||||||||||
$57.68 | 4,561 | 0.5 | ||||||||||||||||||||||||||||||||
Year | Shares | Price | Total | 461,920 | ||||||||||||||||||||||||||||||
2010 | 5,466 | $ | 11.25 | Stock options and warrants expire on various dates from January 2014 to December 2023. | ||||||||||||||||||||||||||||||
2011 | 7,333 | 0.75 | Under the terms of the Company's agreement with investors in the October 2008 financing, 25,600 shares of common stock were the maximum number of shares allocated to the Company's existing shareholders at the time of the offering (also referred to as the original shareholders or the “Founders”). Since the total of the Company's fully diluted shares of common stock was greater than 25,600 shares, in order for the Company to proceed with the offering, the Board of Directors approved a reverse stock split of 1-for-1.2545. After this split was approved, additional options and warrants were identified, requiring a second reverse stock split in order to reach the 25,600 shares. The second reverse stock split on the reduced 1-for-1.2545 balance was determined to be 1-for-1.33176963. Taken together, if only one reverse stock split was performed, the number would have been a reverse stock split of 1-for-1.670705. | |||||||||||||||||||||||||||||||
2012 | 126,029 | 5.25 – 6.00 | On June 6, 2008, the Board of Directors approved the first reverse stock split. The authorized number of shares of common stock of 266,667 was proportionately divided by 1.2545 to arrive at 212,569. | |||||||||||||||||||||||||||||||
2013 | 238,556 | 4.88 – 25.61 | On October 20, 2008, the Board of Directors (i) approved the second reverse stock split pursuant to which the authorized number of shares of common stock of 212,569 was proportionately divided by 1.33177 to arrive at 159,614 shares and (ii) approved a resolution to increase the number of authorized shares of the Company's common stock from 159,614 to 533,334, which was approved by the Company’s shareholders holding a majority of the shares entitled to vote thereon at a special meeting of shareholders held on December 3, 2008. | |||||||||||||||||||||||||||||||
2014 | 68,505 | 8.25 – 18.75 | The shareholders approved an increase in authorized shares to 1,066,667 shares in an annual shareholder meeting held on June 22, 2010 and approved an increase in authorized shares to 2,666,667 shares in a special shareholder meeting held on September 7, 2011. | |||||||||||||||||||||||||||||||
Total | 445,889 | $ | .75 – 25.61 | The shareholders approved an increase in authorized shares to 4,000,000 shares in a special shareholder meeting held on January 15, 2013. | ||||||||||||||||||||||||||||||
Warrants: | The shareholders approved an amendment of the Company’s 2012 Stock Incentive Plan to increase the reserve of shares authorized for issuance to 666,667 shares and to increase the threshold of limitation on certain grants to 266,667 shares on April 15, 2013. | |||||||||||||||||||||||||||||||||
An increase from 4,000,000 to 10,666,667 authorized shares, and an amendment of the Company’s 2012 Stock Incentive Plan to increase the reserve of shares authorized for issuance to 1,333,334 shares was approved at the September 10, 2013 annual meeting. | ||||||||||||||||||||||||||||||||||
Stock Options and Warrants Granted by the Company | ||||||||||||||||||||||||||||||||||
Year | Shares | Price | The following table is the listing of stock options and warrants as of December 31, 2013 by year of grant: | |||||||||||||||||||||||||||||||
2010 | 400 | $ | 0.75 | Stock Options: | ||||||||||||||||||||||||||||||
2011 | 4,166 | 18.75 | ||||||||||||||||||||||||||||||||
2012 | 71,368 | 11.25 – 15.00 | ||||||||||||||||||||||||||||||||
2013 | 267,579 | 6.00 – 14.85 | Year | Shares | Price | |||||||||||||||||||||||||||||
2014 | 155,818 | 12.38 – 24.38 | 2008 | 5,613 | $ | 1.28 – 43.88 | ||||||||||||||||||||||||||||
Total | 499,331 | $ | .75 – 24.38 | 2009 | 1,000 | 26.25 | ||||||||||||||||||||||||||||
2010 | 5,467 | 11.25 | ||||||||||||||||||||||||||||||||
2011 | 7,334 | 0.75 | ||||||||||||||||||||||||||||||||
2012 | 126,636 | 5.25 – 6.00 | ||||||||||||||||||||||||||||||||
2013 | 239,683 | 4.88 – 25.61 | ||||||||||||||||||||||||||||||||
Total | 385,733 | $ | .75 – 43.88 | |||||||||||||||||||||||||||||||
Warrants: | ||||||||||||||||||||||||||||||||||
Year | Shares | Price | ||||||||||||||||||||||||||||||||
2008 | 4,561 | $ | 34.50 – 57.68 | |||||||||||||||||||||||||||||||
2009 | 1,110 | 34.5 | ||||||||||||||||||||||||||||||||
2010 | 2,667 | 0.75 | ||||||||||||||||||||||||||||||||
2011 | 114,635 | 5.63 – 18.75 | ||||||||||||||||||||||||||||||||
2012 | 71,367 | 11.25 – 15.00 | ||||||||||||||||||||||||||||||||
2013 | 267,580 | 6.00 – 14.85 | ||||||||||||||||||||||||||||||||
Total | 461,920 | $ | .75 – 57.68 | |||||||||||||||||||||||||||||||
SHORTTERM_NOTES_PAYABLE
SHORT-TERM NOTES PAYABLE | 9 Months Ended |
Sep. 30, 2014 | |
Debt Disclosure [Abstract] | |
Short-term Debt [Text Block] | NOTE 4 — SHORT-TERM NOTES PAYABLE |
On July 23, 2014, the Company entered into a Securities Purchase Agreement (the “SOK Securities Purchase Agreement”) with SOK Partners, LLC, an affiliate of the Company (“SOK”), pursuant to which the Company agreed to issue and sell (i) a senior convertible note, in an original principal amount of $122,196 (the “SOK Note”), which SOK Note shall be convertible into a certain amount of shares (the “SOK Conversion Shares”) of Common Stock, in accordance with the terms of the SOK Note, and (ii) a warrant (the “SOK Warrant”) to initially acquire up to 5,431 additional shares of Common Stock (the “SOK Warrant Shares”, and collectively with the SOK Note, the SOK Warrant and the SOK Conversion Shares, the “SOK Securities”) for an aggregate purchase price of $100,000 (with the reduced principal amount as described below representing an approximately 8.7% original issue discount) (the “SOK Convertible Notes Offering”). Upon effectiveness of the Resale Registration Statement (as defined below) on September 9, 2014, the principal amount of the note was reduced to $108,696 and the number of warrants was reduced to 4,831 shares. | |
Also, on July 23, 2014, the Company entered into a Securities Purchase Agreement with 31 Group, LLC (an affiliate of Aegis Capital Corp., the underwriter for the Company’s pending public offering) pursuant to which the Company agreed to issue and sell (i) a senior convertible note, in an original principal amount of $610,978 (subsequently reduced to $543,478) (the “31 Group Note”), which shall be convertible into a certain amount of shares of Common Stock, in accordance with the terms of the 31 Group Note, (ii) a warrant (the “31 Group Warrant”) to initially acquire up to 27,155 additional shares of Common Stock (subsequently reduced to 24,155 shares) (the “31 Group Conversion Shares”, and collectively with the 31 Group Note, the 31 Group Warrant and the 31 Group Conversion Shares, the “31 Group Securities”) for an aggregate purchase price of $500,000 (representing an approximately 8.7% original issue discount) (the “31 Group Convertible Notes Offering”). | |
Also, on July 23, 2014, the Company entered into a Securities Purchase Agreement with Evan Myrianthopoulos (a managing director of the representative of the underwriters), pursuant to which the Company agreed to issue and sell (i) a senior convertible note, in an original principal amount of $30,548.90 (subsequently reduced to $27,173.90) (the “Myrianthopoulos Note”), which shall be convertible into a certain amount of shares of Common Stock, in accordance with the terms of the Myrianthopoulos Note, (ii) a warrant (the “Myrianthopoulos Warrant”) to initially acquire up to 1,358 additional shares of Common Stock (subsequently reduced to 1,208 shares) (the “Myrianthopoulos Conversion Shares”, and collectively with the Myrianthopoulos Note, the Myrianthopoulos Warrant and the Myrianthopoulos Conversion Shares, the “Myrianthopoulos Securities”) for an aggregate purchase price of $25,000 (representing an approximately 8.7% original issue discount) (the “Myrianthopoulos Convertible Notes Offering”). | |
On July 31, 2014, August 8, 2014, August 12, 2014, September 4, 2014 and September 5, 2014, the Company entered into Securities Purchase Agreements (collectively, the “Affiliate Securities Purchase Agreements”) with certain affiliates of the Company and certain persons with whom the Company was required to have a pre-existing relationship (the “Affiliates”) pursuant to which the Company agreed to issue and sell (i) senior convertible notes, in an original aggregate principal amount of $1,069,222 (subsequently reduced to $951,086) (the “Affiliate Notes”), which Affiliate Notes shall be convertible into a certain amount of shares (the “Affiliate Conversion Shares”) of the Company’s Common Stock in accordance with the terms of the Affiliate Notes, and (ii) warrants (the “Affiliate Warrants”) to initially acquire up to 48,879 additional shares of Common Stock (subsequently reduced to 42,271 shares) (the “Affiliate Warrant Shares”, and collectively with the Affiliate Notes, the Affiliate Warrants and the Affiliate Conversion Shares, the “Affiliate Securities”) for an aggregate purchase price of $875,000 (representing an approximately 8.7% original issue discount) (the “Affiliate Convertible Notes Offering”). | |
The SOK Note, 31 Group Note, the Myrianthopoulos Note and the Affiliate Notes mature on July 23, 2015 (subject to extension as provided in the Notes) and, in addition to the original issue discount, accrue interest at a rate of 12.0% per annum. The Notes are convertible at any time after issuance, in whole or in part, at the Investor’s or SOK’s option, as the case may be, into shares of Common Stock, at a conversion price equal to the lesser of (i) the product of (x) the arithmetic average of the lowest three volume weighted average prices of the Common Stock during the ten consecutive trading days ending and including the trading day immediately preceding the applicable conversion date and (y) 72.5% (or if an event of default has occurred and is continuing, 70%), and (ii) $11.25 (as adjusted for stock splits, stock dividends, recapitalizations or similar events). | |
On September 30, 2014, the SOK Note, 31 Group Note, the Myrianthopoulos Note and the Affiliate Notes had a combined amortization of $250,494. At the same point in time the SOK Note, the 31 Group Note, the Myrianthopoulos Note and the Affiliate Notes had a combined original issue discount of $103,088. Additionally, as of September 30, 2014, the 31 Group, LLC converted $40,000 of their note. One of the affiliate investors also converted $40,000 of their note by September 30, 2014. | |
LOSS_PER_SHARE
LOSS PER SHARE | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | ||||||||||||||||||||||||||||||
Earnings Per Share [Text Block] | NOTE 5 — LOSS PER SHARE | NOTE 4 — LOSS PER SHARE | ||||||||||||||||||||||||||||
The following table presents the shares used in the basic and diluted loss per common share computations: | The following table presents the shares used in the basic and diluted loss per common share computations: | |||||||||||||||||||||||||||||
Three Months Ended | Nine Months Ended | Year Ended December 31, | From | |||||||||||||||||||||||||||
September 30, | September 30, | 2013 | 2012 | April 23, 2002 (Inception) To December 31, 2013 | ||||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | Numerator: | ||||||||||||||||||||||||||
Numerator: | Net loss available in basic and diluted calculation | $ | (9,406,304 | ) | $ | (7,422,155 | ) | $ | (28,697,415 | ) | ||||||||||||||||||||
Net loss available in basic and diluted calculation | $ | (1,115,221 | ) | $ | (3,974,903 | ) | $ | (4,468,170 | ) | $ | (7,251,965 | ) | Denominator: | |||||||||||||||||
Denominator: | Weighted average common shares | 2,026,115 | 927,838 | 996,362 | ||||||||||||||||||||||||||
Weighted average common shares | 259,899 | 1,821,006 | 2,052,709 | 1,687,625 | outstanding-basic | |||||||||||||||||||||||||
outstanding-basic | Effect of dilutive stock options and warrants(1) | — | — | — | ||||||||||||||||||||||||||
Effect of diluted stock options and warrants(1) | — | — | — | — | Weighted average common shares | 2,026,115 | 927,838 | 996,362 | ||||||||||||||||||||||
Weighted average common shares | 2,984,335 | 1,821,006 | 2,967,483 | 1,687,625 | outstanding-diluted | |||||||||||||||||||||||||
outstanding-basic | Loss per common share-basic and diluted | $ | (4.64 | ) | $ | (8.00 | ) | $ | (28.80 | ) | ||||||||||||||||||||
Loss per common share-basic and diluted | $ | (0.37 | ) | $ | (2.18 | ) | $ | (1.51 | ) | $ | (4.30 | ) | ||||||||||||||||||
-1 | The number of shares underlying options and warrants outstanding as of December 31, 2013 and December 31, 2012 are 847,777 and 637,277, respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. | |||||||||||||||||||||||||||||
-1 | The number of shares underlying options and warrants outstanding as of September 30, 2014 and September 30, 2013 are 945,220 and 861,287 respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. | |||||||||||||||||||||||||||||
INCOME_TAXES
INCOME TAXES | 9 Months Ended | 12 Months Ended | ||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||
Income Tax Disclosure [Abstract] | ||||||||||||||||||
Income Tax Disclosure [Text Block] | NOTE 6 — INCOME TAXES | NOTE 5 — INCOME TAXES | ||||||||||||||||
The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. | The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. | |||||||||||||||||
There is no income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a 100% valuation allowance for the deferred tax assets and state income taxes is appropriate. | There is no income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a 100% valuation allowance for the deferred tax assets and state income taxes is appropriate. | |||||||||||||||||
During September 2013, the Company experienced an “ownership change” as defined in Section 382 of the Internal Revenue Code which could potentially limit the ability to utilize the Company’s net operating losses (NOLs). The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change. | Federal and state income tax return operating loss carryovers as of December 31, 2013 were approximately $13,969,000 and will begin to expire in 2017. | |||||||||||||||||
At September 30, 2014, the Company had approximately $16.0 million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2015, subject to the Section 382 limitation described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $17.1 million of gross NOLs to reduce future state taxable income at September 30, 2014, which will expire in years 2022 through 2034 if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At September 30, 2014, the federal and state valuation allowances were $7.1 million and $1.5 million, respectively. | The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change. | |||||||||||||||||
The components of deferred income taxes at September 30, 2014 and December 31, 2013 are as follows: | The components of deferred income taxes at December 31, 2013 and December 31, 2012 are as follows: | |||||||||||||||||
September 30, | December 31, | December 31, | December 31, | |||||||||||||||
2014 | 2013 | 2013 | 2012 | |||||||||||||||
Deferred Tax Asset: | Deferred Tax Asset: | |||||||||||||||||
Net Operating Loss | $ | 7,920,000 | $ | 3,259,000 | Net Operating Loss | $ | 3,259,000 | $ | 2,209,000 | |||||||||
Other | 631,000 | 59,000 | Other | 59,000 | 73,000 | |||||||||||||
Total Deferred Tax Asset | 8,551,000 | 3,318,000 | Total Deferred Tax Asset | 3,318,000 | 2,282,000 | |||||||||||||
Less Valuation Allowance | 8,551,000 | 3,318,000 | Less Valuation Allowance | 3,318,000 | 2,282,000 | |||||||||||||
Net Deferred Income Taxes | $ | — | $ | — | Net Deferred Income Taxes | $ | — | $ | — | |||||||||
LONGTERM_DEBT
LONG-TERM DEBT | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Long-Term Debt, Unclassified [Abstract] | |||||||||
Long-term Debt [Text Block] | NOTE 6 — LONG-TERM DEBT | ||||||||
Long-term debt is as follows: | |||||||||
31-Dec-13 | 31-Dec-12 | ||||||||
Note payable issued on October 26, 2009, net of a discount of $0 and $0 discount, with interest at 8% to March 31, 2012 when the remaining balance was payable and convertible into shares of common stock at $26.25 per share. The note was renegotiated in February 2013. | — | 100,000 | |||||||
Note payable issued on June 12, 2010 with interest at 12% to March 31, 2012 when the remaining balance was payable, and is convertible into shares of common stock at $13.50 per share. The note was renegotiated in February 2013. | — | 200,000 | |||||||
Note payable issued on December 23, 2010, with interest at 10%, matured December 23, 2012 and was convertible into shares of common stock at $6.30 per share. The note was renegotiated in February 2013. | — | 16,800 | |||||||
Note payable issued on September 21, 2010 with interest at 12%, matured March 30, 2012 and was convertible into shares of common stock at $13.50 per share. The note was renegotiated in February 2013. | — | 32,000 | |||||||
Note payable issued January 1, 2011 to a law firm that accepted this note in full payment of their past due legal fees. The note bears interest at 6%, matures January 1, 2015 and is convertible into shares of common stock at $11.25 per share. The note was renegotiated in March 2013, and has been paid in full. | — | 89,300 | |||||||
On November 6, 2012 the Company issued four convertible notes at 20% interest, each, net of an aggregate discount of $21,138, due on April 6, 2013. The four notes were converted into 13,889 shares at $7.50 per share. | — | 122,774 | |||||||
Total | — | 560,874 | |||||||
Less amount due within one year | — | 471,574 | |||||||
Long-Term Debt | $ | — | $ | 89,300 | |||||
Cash payments for interest were $55,198 and $31,008 for 2013 and 2012, respectively. | |||||||||
The four renegotiated notes above, totaling $450,958 in principal and interest, will be paid for the next two (2) years as follows: $120,000 in 2014 and $120,000 in 2015. The remaining balance including attorney’s fees and interest is due on February 1, 2016. The debt is secured by 8,889 shares of common stock held in escrow. The escrow account releases 1/3 or 4,445 shares per year to the Company if there is no default. If a default occurs the entire amount of stock left in escrow at the time of default is released to the former note holders. | |||||||||
RENT_OBLIGATION
RENT OBLIGATION | 9 Months Ended | 12 Months Ended | ||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||
Rent Obligation [Abstract] | ||||||||||
Leases of Lessee Disclosure [Text Block] | NOTE 7 — RENT OBLIGATION | NOTE 7 — RENT OBLIGATION | ||||||||
The Company leases its principal office under a lease that can be cancelled after three years with proper notice per the lease and an amortized schedule of adjustments that will be due to the landlord. The lease extends five years and expires January 2018. In addition to rent, the Company pays real estate taxes and repairs and maintenance on the leased property. Rent expense was $15,719 and $48,775, for the three and nine months ended September 30, 2014 and was $11,162 and $46,321 for the three and nine months ended September 30, 2013 respectively. | The Company leases its principal office under a lease that can be cancelled after three years with proper notice per the lease and an amortized schedule of adjustments that will be due to the landlord. The lease extends five years and expires January 2018. In addition to rent, the Company pays real estate taxes and repairs and maintenance on the leased property. Rent expense was $61,150 and $45,961 for 2013 and 2012, respectively. | |||||||||
The Company’s rent obligation for the next five years is as follows: | The Company’s rent obligation for the next five years are as follows: | |||||||||
2015 | $ | 37,000 | 2014 | $ | 36,000 | |||||
2016 | $ | 38,000 | 2015 | $ | 37,000 | |||||
2017 | $ | 39,000 | 2016 | $ | 38,000 | |||||
2018 | $ | 3,600 | 2017 | $ | 39,000 | |||||
2019 | $ | — | 2018 | $ | 3,000 | |||||
LIABILITY_FOR_EQUITYLINKED_FIN
LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Text Block] | NOTE 8 — LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS | NOTE 8 — LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Company adopted ASC 815- Derivatives and Hedging (“ASC 815”) on January 1, 2009. ASC 815 mandates a two-step process for evaluating whether an equity-linked financial instrument or embedded feature is indexed to the entity's own stock. It was effective for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years, which was the Company's first quarter of 2009. Many of the warrants issued by the Company contain a strike price adjustment feature, which upon adoption of ASC 815, changed the classification (from equity to liability) and the related accounting for warrants with a $479,910 estimated fair value of as of January 1, 2009. An adjustment was made to remove $486,564 from paid-in capital (the cumulative values of the warrants on their grant dates), a positive adjustment of $6,654 was made to accumulated deficit, representing the gain on valuation from the grant date to January 1, 2009, and $479,910 was booked as a liability. The warrants issued in 2011 do not contain a strike price adjustment feature and, therefore, are not treated as a liability. | The Company adopted ASC 815 — Derivatives and Hedging (“ASC 815”) on January 1, 2009. ASC 815 mandates a two-step process for evaluating whether an equity-linked financial instrument or embedded feature is indexed to the entity's own stock. It was effective for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years, which was the Company's first quarter of 2009. Many of the warrants issued by the Company contain a strike price adjustment feature, which upon adoption of ASC 815, changed the classification (from equity to liability) and the related accounting for warrants with a $479,910 estimated fair value of as of January 1, 2009. An adjustment was made to remove $486,564 from paid-in capital (the cumulative values of the warrants on their grant dates), a positive adjustment of $6,654 was made to accumulated deficit, representing the gain on valuation from the grant date to January 1, 2009, and $479,910 was booked as a liability. The warrants issued in 2012 and 2011 do not contain a strike price adjustment feature and, therefore, are not treated as a liability. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The January 1, 2009 valuation was computed using the Black-Scholes valuation model based upon a 2.5-year expected term, an expected volatility of 63%, an exercise price of $34.50 per share, a stock price of $26.25, a zero dividend rate and a 1.37% risk free interest rate. Subsequent to January 1, 2009 these warrants were re-valued at the end of each quarter and a gain or loss was recorded based upon their increase or decrease in value during the quarter. Likewise, new warrants that were issued during 2009 and 2010 were valued, using the Black-Scholes valuation model on their date of grant and an entry was made to reduce paid-in capital and increase the liability for equity-linked financial instruments. These warrants were also re-valued at the end of each quarter based upon their expected life, the stock price, the exercise price, assumed dividend rate, expected volatility and risk free interest rate. A significant reduction in the liability was realized in 2010 primarily due to a reduction from $37.50 to $16.50 per share in the underlying stock price. The Company realized a slight increase in the liability for existing warrants during the first quarter of 2012. In 2013 there was a significant decrease in the liability primarily due to current expirations and the amount of warrants reaching expiration in the near term. In 2014, all warrants expired and the liability was reduced to zero. | The January 1, 2009 valuation was computed using the Black-Scholes valuation model based upon a 2.5-year expected term, an expected volatility of 63%, an exercise price of $34.50 per share, a stock price of $26.25, a zero dividend rate and a 1.37% risk free interest rate. Subsequent to January 1, 2009 these warrants were re-valued at the end of each quarter and a gain or loss was recorded based upon their increase or decrease in value during the quarter. Likewise, new warrants that were issued during 2009 and 2010 were valued, using the Black-Scholes valuation model on their date of grant and an entry was made to reduce paid-in capital and increase the liability for equity-linked financial instruments. These warrants were also re-valued at the end of each quarter based upon their expected life, the stock price, the exercise price, assumed dividend rate, expected volatility and risk free interest rate. A significant reduction in the liability was realized in 2010 primarily due to a reduction from $37.50 to $16.50 per share in the underlying stock price. The Company realized an increase in the liability for existing warrants during 2011 primarily due to a reduction in the spread between the exercise price and the market price of the underlying shares. In 2012, there was a slight increase to the liability due to the extension of warrants. In 2013 there was a significant decrease as a result of the older warrants expiring or getting exercised. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The inputs to the Black-Scholes model during 2009 through 2014 were as follows: | The inputs to the Black-Scholes model during 2009 through 2013 were as follows: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock price | $26.25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock price | $4.50 to $37.50 | Exercise price | $57.68 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | $.75 to $24.38 | Expected life | .50 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected life | 2.0 to 6.5 years | Expected volatility | 54% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 59% | Assumed dividend rate | —% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assumed dividend rate | —% | Risk-free interest rate | .13% to 2.97% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk-free interest rate | .13% to 2.97% | The original valuations, annual gain (loss) and end of year valuations are shown below: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The original valuations, annual gain/(loss) and end of year valuations are shown below: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Initial | Annual Gain (Loss) | Value at | 2010 | Value at | 2011 | Value at | 2012 | Value at | 2013 | Value at | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Initial Value | Annual | Value at | 2010 Gain | Value at | 2011 Gain | Value at | 2012 Gain | Value at | 2013 Gain | Value at | 2014 Gain | Value at | Value | 12/31/09 | Gain (Loss) | 12/31/10 | Gain (Loss) | 12/31/11 | Gain (Loss) | 12/31/12 | Gain (Loss) | 12/31/13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain | 12/31/09 | (Loss) | 12/31/10 | (Loss) | 12/31/11 | (Loss) | 12/31/12 | (Loss) | 12/31/13 | (Loss) | 9/30/14 | January 1 2009 adoption | $ | 479,910 | $ | (390,368 | ) | $ | 870,278 | $ | 868,772 | $ | 1,506 | $ | (88,290 | ) | $ | 89,796 | $ | (21,856 | ) | $ | 111,652 | $ | 100,053 | $ | 11,599 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Loss) | Warrants issued in quarter ended 6/30/2009 | 169,854 | 20,847 | 149,007 | 147,403 | 1,604 | (4,689 | ) | 6,293 | 6,293 | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
January 1, 2009 adoption | $ | 479,910 | $ | (390,368 | ) | $ | 870,278 | $ | 868,772 | $ | 1,506 | $ | (88,290 | ) | $ | 89,796 | $ | (21,856 | ) | $ | 111,652 | $ | 100,053 | $ | 11,599 | $ | 11,599 | $ | — | Warrants issued in quarter ended 9/30/2009 | 39,743 | (738 | ) | 40,481 | 40,419 | 62 | (1,562 | ) | 1,624 | 910 | 714 | 714 | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued in quarter ended 6/30/2009 | 169,854 | 20,847 | 149,007 | 147,403 | 1,604 | (4,689 | ) | 6,293 | 6,293 | — | — | — | — | — | Warrants issued in quarter ended 12/31/2009 | 12,698 | 617 | 12,081 | 12,053 | 28 | (724 | ) | 752 | 415 | 337 | 337 | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued in quarter ended 9/30/2009 | 39,743 | (738 | ) | 40,481 | 40,419 | 62 | (1,562 | ) | 1,624 | 910 | 714 | 714 | — | — | — | Subtotal | 702,205 | 1,071,847 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued in quarter ended 12/31/2009 | 12,698 | 617 | 12,081 | 12,053 | 28 | (724 | ) | 752 | 415 | 337 | 337 | — | — | — | Warrants issued in quarter ended 3/31/2010 | 25,553 | 25,014 | 539 | (5,570 | ) | 6,109 | 3,701 | 2,408 | 2,408 | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subtotal | 702,205 | 1,071,847 | Warrants issued in quarter ended 6/30/2010 | 31,332 | 30,740 | 592 | (6,122 | ) | 6,714 | 6,083 | 631 | 631 | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued in quarter ended 3/31/2010 | 25,553 | 25,014 | 539 | (5,570 | ) | 6,109 | 3,701 | 2,408 | 2,408 | — | — | — | Warrants issued in quarter ended 9/30/2010 | 31,506 | 20,891 | 10,615 | (44,160 | ) | 54,775 | 1,338 | 53,437 | 53,437 | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued in quarter ended 6/30/2010 | 31,332 | 30,740 | 592 | (6,122 | ) | 6,714 | 6,083 | 631 | 631 | — | — | — | Total | $ | 790,596 | $ | (369,642 | ) | $ | 1,071,847 | $ | 1,145,292 | $ | 14,946 | $ | (151,117 | ) | $ | 166,063 | $ | (3,116 | ) | $ | 169,179 | $ | 157,580 | $ | 11,599 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued in quarter ended 9/30/2010 | 31,506 | 20,891 | 10,615 | (44,160 | ) | 54,775 | 1,338 | 53,437 | 53,437 | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 790,596 | $ | (369,642 | ) | $ | 1,071,847 | $ | 1,145,292 | $ | 14,946 | $ | (151,117 | ) | $ | 166,063 | $ | (3,116 | ) | $ | 169,179 | $ | 157,580 | $ | 11,599 | $ | 11,599 | $ | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RELATED_PARTY_TRANSACTIONS
RELATED PARTY TRANSACTIONS | 9 Months Ended | 12 Months Ended |
Sep. 30, 2014 | Dec. 31, 2013 | |
Related Party Transactions [Abstract] | ||
Related Party Transactions Disclosure [Text Block] | NOTE 9 — RELATED PARTY TRANSACTIONS | NOTE 9 — RELATED PARTY TRANSACTIONS |
The Company, entered into agreements, in 2008, with our Chairman of the Board, Lawrence Gadbaw, and in 2009 with a board member, Peter Morawetz, to pay Mr. Gadbaw $25,000 and Dr. Morawetz $30,000 upon the Company raising $3 million in new equity. Mr. Gadbaw received 3,704 shares at $6.75 per share in June 2012 as compensation in lieu of the $25,000 cash for raising $3 million in new equity. Mr. Gadbaw was paid the balance due under his separation agreement from 2008. This amount was $46,000 upon signing the agreement in 2008 payable at $2,000 per month; the payments to Mr. Gadbaw are complete. Mr. Gadbaw also received a warrant for 400 shares at $11.25 per share on June 30, 2012 as compensation for service as Chairman. Mr. Gadbaw and Dr. Morawetz have both resigned from the Board in the third quarter of 2013. Both Mr. Gadbaw and Dr. Morawetz received 667 shares of common stock each at $24.38 per share; 267 of these shares were for compensation from serving as Board members and the remaining 400 shares were issued to satisfy previous contractual agreements. | The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. Rick Koenigsberger, a director, is a holder of membership units in SOK Partners. | |
Convertible Note Issuances to Dr. Samuel Herschkowitz and SOK Partners, LLC | The Company entered into agreements, in 2008, with our Chairman of the Board, Lawrence Gadbaw, and in 2009 with a board member, Peter Morawetz, to pay Mr. Gadbaw $25,000 and Dr. Morawetz $30,000 upon the Company raising $3 million in new equity. Mr. Gadbaw received 3,704 shares at $6.75 per share in June 2012 as compensation in lieu of the $25,000 cash for raising $3 million in new equity. Mr. Gadbaw was paid the balance due under his separation agreement from 2008. This amount was $46,000 upon signing the agreement in 2008 payable at $2,000 per month; the payments to Mr. Gadbaw are complete. Mr. Gadbaw also received a warrant for 400 shares at $11.25 per share on June 30, 2012 as compensation for service as Chairman. Mr. Gadbaw and Dr. Morawetz have both resigned from the Board in the third quarter of 2013. Both Mr. Gadbaw and Dr. Morawetz received 667 shares of common stock each at $24.38 per share; 267 of these shares were for compensation from serving as Board members and the remaining 400 shares were issued to satisfy previous contractual agreements. | |
On September 11, 2013, both the Herschkowitz Note and the SOK Note (each as defined below in this Note 9) were converted in full by the holders thereof at $1.05 per share. The principal and interest balance of the Herschkowitz Note of $314,484 was converted into 299,509 shares of common stock. The principal and interest balance of the SOK Note of $680,444 was converted into 648,050 shares of common stock. The collateral that secured these notes was released back to the Company. | Convertible Note Issuances to Dr. Samuel Herschkowitz and SOK Partners, LLC | |
The remaining disclosure of this Note 9 provides historical information regarding the Herschkowitz Note, the SOK Note and certain other convertible note issuances. | On September 11, 2013, both the Herschkowitz Note and the SOK Note (each as defined below in this Note 9) were converted in full by the holders thereof at $1.05 per share. The principal and interest balance of the Herschkowitz Note of $314,484 was converted into 299,509 shares of common stock. The principal and interest balance of the SOK Note of $680,444 was converted into 648,050 shares of common stock. The collateral that secured these notes was released back to the Company. | |
On March 28, 2012, the Company, entered into a Convertible Note Purchase Agreement, dated as of March 28, 2012 (the “SOK Purchase Agreement”) with SOK Partners, LLC (“SOK Partners”), and an investment partnership. Josh Kornberg, who is a member of the Company’s Board of Directors, and Dr. Samuel Herschkowitz are affiliates of the manager of SOK Partners and Ricardo Koenigsberger, a director, is a holder of membership units of SOK Partners. Pursuant to the SOK Purchase Agreement, the Company issued a 20.0% convertible note due August 2012 in the principal amount of up to $600,000. Principal and accrued interest on the note is due and payable on August 28, 2012. The Company’s obligations under the note are secured by the grant of a security interest in substantially all tangible and intangible assets of the Company. The SOK Purchase Agreement and the note include customary events of default that include, among other things, non-payment defaults, covenant defaults, inaccuracy of representations and warranties, cross-defaults to other indebtedness and bankruptcy and insolvency defaults. The occurrence of an event of default could result in the acceleration of the Company’s obligations under the note, and interest rate of twenty-four (24%) percent per annum accrues if the note is not paid when due. | The remaining disclosure of this Note 9 provides historical information regarding the Herschkowitz Note, the SOK Note and certain other convertible note issuances. | |
On March 28, 2012, the Company received an advance of $84,657 under the note, including a cash advance of $60,000 net of a prepayment of interest on the first $300,000 in advances under the note. The holder of the note is entitled to convert the note into shares of common stock of the Company at an initial conversion price per share of $4.88 per share, subject to adjustment in the event of (1) certain issuances of common stock or convertible securities at a price lower than the conversion price of the note, and (2) recapitalizations, stock splits, reorganizations and similar events. In addition, the Company is required to issue two installments of an equity bonus to SOK Partners in the form of common stock valued at the rate of $4.88 per share. In March 2012, the Company issued the first equity bonus to SOK Partners, consisting of 61,539 shares of common stock, with a second installment due within five business days after SOK Partners has made aggregate advances under the note of at least $300,000. In May 2012 the Company issued the second installment consisting of 61,539 shares of common stock subsequent to SOK Partners surpassing the aggregate advances of $300,000. Until the maturity date of the note, if the Company obtains financing from any other source without the consent of SOK Partners, then the Company is required to issue additional bonus equity in an amount equal to $600,000 less the aggregate advances on the note made prior to the breach. The principal balance of the SOK Note was $357,282 as of December 31, 2012. | On March 28, 2012, the Company, entered into a Convertible Note Purchase Agreement, dated as of March 28, 2012 (the “SOK Purchase Agreement”) with SOK Partners, LLC (“SOK Partners”), and an investment partnership. Josh Kornberg, who is a member of the Company’s Board of Directors, and Dr. Samuel Herschkowitz are affiliates of the manager of SOK Partners and Ricardo Koenigsberger, a director, is a holder of membership units of SOK Partners. Pursuant to the SOK Purchase Agreement, the Company issued a 20.0% convertible note due August 2012 in the principal amount of up to $600,000. Principal and accrued interest on the note is due and payable on August 28, 2012. The Company’s obligations under the note are secured by the grant of a security interest in substantially all tangible and intangible assets of the Company. The SOK Purchase Agreement and the note include customary events of default that include, among other things, non-payment defaults, covenant defaults, inaccuracy of representations and warranties, cross-defaults to other indebtedness and bankruptcy and insolvency defaults. The occurrence of an event of default could result in the acceleration of the Company’s obligations under the note, and interest rate of twenty-four (24%) percent per annum accrues if the note is not paid when due. | |
As long as any amount payable under the SOK Note remains outstanding, SOK Partners or its designee is entitled to appoint a new member to the Company’s Board of Directors, who will be appointed upon request. Mr. Koenigsberger was appointed to the Board by SOK Partners on June 25, 2012. | On March 28, 2012, the Company received an advance of $84,657 under the note, including a cash advance of $60,000 net of a prepayment of interest on the first $300,000 in advances under the note. The holder of the note is entitled to convert the note into shares of common stock of the Company at an initial conversion price per share of $4.88 per share, subject to adjustment in the event of (1) certain issuances of common stock or convertible securities at a price lower than the conversion price of the note, and (2) recapitalizations, stock splits, reorganizations and similar events. In addition, the Company is required to issue two installments of an equity bonus to SOK Partners in the form of common stock valued at the rate of $4.88 per share. In March 2012, the Company issued the first equity bonus to SOK Partners, consisting of 61,539 shares of common stock, with a second installment due within five business days after SOK Partners has made aggregate advances under the note of at least $300,000. In May 2012 the Company issued the second installment consisting of 61,539 shares of common stock subsequent to SOK Partners surpassing the aggregate advances of $300,000. Until the maturity date of the note, if the Company obtains financing from any other source without the consent of SOK Partners, then the Company is required to issue additional bonus equity in an amount equal to $600,000 less the aggregate advances on the note made prior to the breach. The principal balance of the SOK Note was $357,282 as of December 31, 2012. | |
On March 28, 2012, the Company signed an Amended and Restated Note Purchase Agreement, dated as of December 20, 2011, with Dr. Samuel Herschkowitz (as amended, the “Herschkowitz Purchase Agreement”). Pursuant to the Herschkowitz Purchase Agreement, the Company issued a 20.0% convertible note due June 20, 2012 in the principal amount of $240,000 for previous advances under the note. The Company’s obligations under the note are secured by the grant of a security interest in substantially all tangible and intangible assets of the Company. The Company has previously issued to Dr. Herschkowitz an equity bonus consisting of 20,623 shares of common stock. An additional 100,000 shares were transferred to Dr. Herschkowitz effective in April 2012, upon the occurrence of an event of default on the note. On August 13, 2012, the Company entered into a settlement and forbearance agreement described below, relating to the defaults under the Herschkowitz Note and other matters. | As long as any amount payable under the SOK Note remains outstanding, SOK Partners or its designee is entitled to appoint a new member to the Company’s Board of Directors, who will be appointed upon request. Mr. Koenigsberger was appointed to the Board by SOK Partners on June 25, 2012. | |
As long as any amount payable under the Herschkowitz Note remains outstanding, Dr. Herschkowitz or his designee is entitled to appoint a special advisor to the Company’s Board of Directors, to be appointed as a member upon request. Pursuant to this authority, Josh Kornberg was appointed to the Board on March 9, 2012. In addition, pursuant to this authority, Mr. Koenigsberger was appointed to the Board on June 25, 2012. | On March 28, 2012, the Company signed an Amended and Restated Note Purchase Agreement, dated as of December 20, 2011, with Dr. Samuel Herschkowitz (as amended, the “Herschkowitz Purchase Agreement”). Pursuant to the Herschkowitz Purchase Agreement, the Company issued a 20.0% convertible note due June 20, 2012 in the principal amount of $240,000 for previous advances under the note. The Company’s obligations under the note are secured by the grant of a security interest in substantially all tangible and intangible assets of the Company. The Company has previously issued to Dr. Herschkowitz an equity bonus consisting of 20,623 shares of common stock. An additional 100,000 shares were transferred to Dr. Herschkowitz effective in April 2012, upon the occurrence of an event of default on the note. On August 13, 2012, the Company entered into a settlement and forbearance agreement described below, relating to the defaults under the Herschkowitz Note and other matters. | |
Pursuant to a letter dated April 12, 2012, Dr. Herschkowitz advised the Company of the occurrence of numerous events of default under the terms of the Herschkowitz Note and the Herschkowitz Note Purchase Agreement. As a result of such events of default, Dr. Herschkowitz asserted significant rights as a secured creditor of the Company, including his rights as a secured creditor with a security interest in substantially all assets of the Company. Without a settlement relating to the defaults and other matters, Dr. Herschkowitz could have taken action to levy upon the Company’s assets, including patents and other intellectual property. | As long as any amount payable under the Herschkowitz Note remains outstanding, Dr. Herschkowitz or his designee is entitled to appoint a special advisor to the Company’s Board of Directors, to be appointed as a member upon request. Pursuant to this authority, Josh Kornberg was appointed to the Board on March 9, 2012. In addition, pursuant to this authority, Mr. Koenigsberger was appointed to the Board on June 25, 2012. | |
In addition, the Company and Atlantic Partners Alliance LLC (“APA”) were parties to a letter agreement dated March 14, 2012, providing APA and its affiliates (including Dr. Herschkowitz and SOK) with rights to avoid dilution relating to additional issuances of equity securities by the Company through July 14, 2012, evidencing the parties’ intent that APA would be provided with significant protection against dilution. This protection was in recognition of APA’s investments in the Company involving a high degree of risk and the Company’s contemplated need for restructuring its indebtedness, which were anticipated to result, and have resulted, in significant dilution. The parties acknowledged that Dr. Herschkowitz and SOK would not have made their historical cash investments in the Company to the same degree had the dilution protection not been provided, and the investments by these parties have enabled the Company to avoid insolvency. Since the respective dates of the Herschkowitz Note Purchase Agreement and the SOK Note Purchase Agreement, the Company had issued in excess of 213,334 shares of common stock to parties other than APA and its affiliates, resulting in significant dilution. | Pursuant to a letter dated April 12, 2012, Dr. Herschkowitz advised the Company of the occurrence of numerous events of default under the terms of the Herschkowitz Note and the Herschkowitz Note Purchase Agreement. As a result of such events of default, Dr. Herschkowitz asserted significant rights as a secured creditor of the Company, including his rights as a secured creditor with a security interest in substantially all assets of the Company. Without a settlement relating to the defaults and other matters, Dr. Herschkowitz could have taken action to levy upon the Company’s assets, including patents and other intellectual property. | |
Effective August 15, 2012, the Company entered into a letter agreement with Dr. Herschkowitz, APA and SOK (the “Forbearance Agreement”). Under the Forbearance Agreement, among other things, (i) Dr. Herschkowitz agreed to forbear from asserting his rights as a secured creditor to substantially all of the Company’s assets, resulting from the Company’s defaults; (ii) the Company issued an aggregate 353,334 shares of common stock to Dr. Herschkowitz and SOK and adjusted the conversion price of their convertible notes to $1.05 per share from $4.88 per share, to satisfy the Company’s obligations to adjust for dilution; (iii) Dr. Herschkowitz and SOK agreed to extend the maturity of their notes to December 31, 2012; (iv) the Company agreed to pay certain compensation to Dr. Herschkowitz upon the achievement of financial milestones and (v) Dr. Herschkowitz clarified and waived certain of his rights, including the right to interest at a penalty rate upon default. | In addition, the Company and Atlantic Partners Alliance LLC (“APA”) were parties to a letter agreement dated March 14, 2012, providing APA and its affiliates (including Dr. Herschkowitz and SOK) with rights to avoid dilution relating to additional issuances of equity securities by the Company through July 14, 2012, evidencing the parties’ intent that APA would be provided with significant protection against dilution. This protection was in recognition of APA’s investments in the Company involving a high degree of risk and the Company’s contemplated need for restructuring its indebtedness, which were anticipated to result, and have resulted, in significant dilution. The parties acknowledged that Dr. Herschkowitz and SOK would not have made their historical cash investments in the Company to the same degree had the dilution protection not been provided, and the investments by these parties have enabled the Company to avoid insolvency. Since the respective dates of the Herschkowitz Note Purchase Agreement and the SOK Note Purchase Agreement, the Company had issued in excess of 213,334 shares of common stock to parties other than APA and its affiliates, resulting in significant dilution. | |
In the Forbearance Agreement, Dr. Herschkowitz agreed to forbear from exercising any of his rights arising under the Herschkowitz Note or the Herschkowitz Note Purchase Agreement with respect to the existing defaults against the Company, subject to the limitations set forth in the letter agreement and without releasing or waiving any future breach of the letter agreement. He further agreed to forbear from exercising any rights with respect to events of default, security interests in the collateral and other similar remedies against the Company or his interests under the Herschkowitz Note or the Herschkowitz Note Purchase Agreement until the occurrence of an event of default under the Herschkowitz Note: (a) that does not constitute an existing default and (b) occurs and accrues after the date of the letter agreement. | Effective August 15, 2012, the Company entered into a letter agreement with Dr. Herschkowitz, APA and SOK (the “Forbearance Agreement”). Under the Forbearance Agreement, among other things, (i) Dr. Herschkowitz agreed to forbear from asserting his rights as a secured creditor to substantially all of the Company’s assets, resulting from the Company’s defaults; (ii) the Company issued an aggregate 353,334 shares of common stock to Dr. Herschkowitz and SOK and adjusted the conversion price of their convertible notes to $1.05 per share from $4.88 per share, to satisfy the Company’s obligations to adjust for dilution; (iii) Dr. Herschkowitz and SOK agreed to extend the maturity of their notes to December 31, 2012; (iv) the Company agreed to pay certain compensation to Dr. Herschkowitz upon the achievement of financial milestones and (v) Dr. Herschkowitz clarified and waived certain of his rights, including the right to interest at a penalty rate upon default. | |
Dr. Herschkowitz and the Company acknowledged that 100,000 shares of the Company’s common stock, constituting the “penalty shares” under the Herschkowitz Note Purchase Agreement, were delivered to Dr. Herschkowitz in April 2012 as provided in the Herschkowitz Note Purchase Agreement upon an event of default. Notwithstanding a provision that would have increased the rate of interest from 20% to 24% upon an event of default, Dr. Herschkowitz agreed that the Company would not pay the increased rate of interest but would accrue interest at 20% until a subsequent event of default. | In the Forbearance Agreement, Dr. Herschkowitz agreed to forbear from exercising any of his rights arising under the Herschkowitz Note or the Herschkowitz Note Purchase Agreement with respect to the existing defaults against the Company, subject to the limitations set forth in the letter agreement and without releasing or waiving any future breach of the letter agreement. He further agreed to forbear from exercising any rights with respect to events of default, security interests in the collateral and other similar remedies against the Company or his interests under the Herschkowitz Note or the Herschkowitz Note Purchase Agreement until the occurrence of an event of default under the Herschkowitz Note: (a) that does not constitute an existing default and (b) occurs and accrues after the date of the letter agreement. | |
Under the Forbearance Agreement, the Herschkowitz Note and the SOK Note were amended as follows: (i) the due dates of the notes were extended to December 31, 2012 from the previous due dates of June 20, 2012 and August 28, 2012, respectively; (ii) Dr. Herschkowitz will release his security agreement after payment of all currently outstanding promissory notes to parties other than SOK; and (iii) the Herschkowitz Note was amended to add certain events of default relating to judgments against the Company or other creditors taking action with respect to the collateral. In consideration of the extension additional milestone fees were revised as described below. Pursuant to a Forbearance and Settlement Agreement with these parties dated August 15, 2012, as subsequently amended, the due date of these notes were extended to August 31, 2013. | Dr. Herschkowitz and the Company acknowledged that 100,000 shares of the Company’s common stock, constituting the “penalty shares” under the Herschkowitz Note Purchase Agreement, were delivered to Dr. Herschkowitz in April 2012 as provided in the Herschkowitz Note Purchase Agreement upon an event of default. Notwithstanding a provision that would have increased the rate of interest from 20% to 24% upon an event of default, Dr. Herschkowitz agreed that the Company would not pay the increased rate of interest but would accrue interest at 20% until a subsequent event of default. | |
APA and its affiliates agreed to terminate the letter agreement regarding dilution dated March 14, 2012. In consideration of the various provisions of the letter agreement and in recognition of the understanding of the parties regarding dilution and the agreements of APA and its affiliates to forbear and to extend the due dates of the notes, the Company (i) issued 176,667 shares to Dr. Herschkowitz, (ii) issued 176,667 shares to SOK, and (iii) the conversion price of the Herschkowitz Note and the SOK Note, respectively was changed to $1.05 per share from $4.88 per share. | Under the Forbearance Agreement, the Herschkowitz Note and the SOK Note were amended as follows: (i) the due dates of the notes were extended to December 31, 2012 from the previous due dates of June 20, 2012 and August 28, 2012, respectively; (ii) Dr. Herschkowitz will release his security agreement after payment of all currently outstanding promissory notes to parties other than SOK; and (iii) the Herschkowitz Note was amended to add certain events of default relating to judgments against the Company or other creditors taking action with respect to the collateral. In consideration of the extension additional milestone fees were revised as described below. Pursuant to a Forbearance and Settlement Agreement with these parties dated August 15, 2012, as subsequently amended, the due date of these notes were extended to August 31, 2013. | |
In the event that the Company consummated the following series of transactions on or prior to June 30, 2013: (i) a merger or similar transaction with a public shell company, (ii) raising between $2 million and $4 million through an offering of the securities of the public shell company concurrent with or subsequent to the shell merger and (iii) listing the Company’s shares on NASDAQ pursuant to an underwritten offering of the Company’s securities resulting in gross proceeds of between $5 million and $30 million, then the Company would have to be required to deliver to Dr. Herschkowitz the following compensation: (A) $75,000 upon consummating the shell merger, (B) $150,000 upon consummating the qualifying financing round and (C) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $1,000,000. The Company was also required to reimburse Dr. Herschkowitz at his actual out-of-pocket cost for reasonable expenses incurred in connection with the shell transactions, with a maximum limit of $10,000 for such expenses. | APA and its affiliates agreed to terminate the letter agreement regarding dilution dated March 14, 2012. In consideration of the various provisions of the letter agreement and in recognition of the understanding of the parties regarding dilution and the agreements of APA and its affiliates to forbear and to extend the due dates of the notes, the Company (i) issued 176,667 shares to Dr. Herschkowitz, (ii) issued 176,667 shares to SOK, and (iii) the conversion price of the Herschkowitz Note and the SOK Note, respectively was changed to $1.05 per share from $4.88 per share. | |
In connection with the extension of the due date for the Herschkowitz Note and the SOK Note on March 6, 2013, the milestone fees were revised. The following fees were payable to Dr. Herschkowitz in the event that the Company consummates the following series of transactions on or prior to December 31, 2013: (i) financing raising not less than $1 million, compensation of $75,000; (ii) a going private transaction, compensation of $200,000 or greater and (iii) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $3,000,000. In May 2013 Dr. Herschkowitz received $75,000 after the Company surpassed raising $1 million. | In the event that the Company consummated the following series of transactions on or prior to June 30, 2013: (i) a merger or similar transaction with a public shell company, (ii) raising between $2 million and $4 million through an offering of the securities of the public shell company concurrent with or subsequent to the shell merger and (iii) listing the Company’s shares on NASDAQ pursuant to an underwritten offering of the Company’s securities resulting in gross proceeds of between $5 million and $30 million, then the Company would have to be required to deliver to Dr. Herschkowitz the following compensation: (A) $75,000 upon consummating the shell merger, (B) $150,000 upon consummating the qualifying financing round and (C) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $1,000,000. The Company was also required to reimburse Dr. Herschkowitz at his actual out-of-pocket cost for reasonable expenses incurred in connection with the shell transactions, with a maximum limit of $10,000 for such expenses. | |
As a result of the transactions under the Forbearance Agreement and other investments, Dr. Herschkowitz, SOK and their affiliates currently own shares of common stock and securities representing beneficial ownership of more than 57% of the Company’s outstanding common stock, giving such parties significant control over election of the Board of Directors and other matters. | In connection with the extension of the due date for the Herschkowitz Note and the SOK Note on March 6, 2013, the milestone fees were revised. The following fees were payable to Dr. Herschkowitz in the event that the Company consummates the following series of transactions on or prior to December 31, 2013: (i) financing raising not less than $1 million, compensation of $75,000; (ii) a going private transaction, compensation of $200,000 or greater and (iii) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $3,000,000. In May 2013 Dr. Herschkowitz received $75,000 after the Company surpassed raising $1 million. | |
On November 6, 2012, the Company issued and sold convertible promissory notes in the total principal amount of $156,243 to Dr. Herschkowitz and certain of his assignees. The Company issued to these parties an aggregate 20,833 shares of common stock in consideration of placement of the notes. The notes bear interest at a rate of 20% per annum and are secured by a security interest in the Company’s accounts receivable, patents and certain patent rights and are convertible into common stock upon certain mergers or other fundamental transactions at a conversion price based on the trading price prior to the transaction. The proceeds from this transaction were used to pay off approximately $155,000 in principal amount of secured indebtedness. Such notes were converted in April 2013 in to 13,889 shares of common stock at $7.50 per share. | As a result of the transactions under the Forbearance Agreement and other investments, Dr. Herschkowitz, SOK and their affiliates currently own shares of common stock and securities representing beneficial ownership of more than 65% of the Company’s outstanding common stock, giving such parties significant control over election of the Board of Directors and other matters. | |
In December 2013, the Company received an additional $300,000 in debt financing from SOK Partners under a non-convertible grid note due February 28, 2014, with 10% interest based on a 365 day year. Dr. Herschkowitz received 10% of the gross proceeds in advance, and the Company received $250,000 in three tranches in December 2013. In January 2014, the Company received an additional $20,000 from SOK Partners completing the grid note maximum. Should the company default on the note the interest rate will increase to 20% interest based on a 365 day year. In February 2014, the Company paid $305,589.04 to SOK Partners in complete payment of the grid note, including interest. | On November 6, 2012, the Company issued and sold convertible promissory notes in the total principal amount of $156,243 to Dr. Herschkowitz and certain of his assignees. The Company issued to these parties an aggregate 20,833 shares of common stock in consideration of placement of the notes. The notes bear interest at a rate of 20% per annum and are secured by a security interest in the Company’s accounts receivable, patents and certain patent rights and are convertible into common stock upon certain mergers or other fundamental transactions at a conversion price based on the trading price prior to the transaction. The proceeds from this transaction were used to pay off approximately $155,000 in principal amount of secured indebtedness. Such notes were converted in April 2013 in to 13,889 shares of common stock at $7.50 per share. | |
In connection with the sale of the Preferred Shares on February 4, 2014 as described in Note 3, Josh Kornberg, our CEO, was one of the Purchasers. Mr. Kornberg purchased 19,231 Preferred Shares for a purchase price of $25,000 and received warrants to purchase 52 shares of common stock. | In December 2013 the Company received an additional $300,000 in debt financing from SOK Partners under a non-convertible grid note due February 28, 2014, with 10% interest based on a 365 day year. Dr. Herschkowitz received 10% of the gross proceeds in advance, and the Company received $250,000 in three tranches in December 2013. In January 2014, the Company received an additional $20,000 from SOK Partners completing the grid note maximum. Should the company default on the note the interest rate will increase to 20% interest based on a 365 day year. In February 2014, the Company wired $305,589.04 to SOK Partners in complete payment of the grid note, including interest. | |
On July 23, 2014, the Company entered into the SOK Securities Purchase Agreement pursuant to which the Company agreed to issue and sell certain securities to SOK, as described in Note 4 of this Report. | ||
RETIREMENT_SAVINGS_PLANS
RETIREMENT SAVINGS PLANS | 9 Months Ended | 12 Months Ended |
Sep. 30, 2014 | Dec. 31, 2013 | |
Compensation and Retirement Disclosure [Abstract] | ||
Pension and Other Postretirement Benefits Disclosure [Text Block] | NOTE 10 — RETIREMENT SAVINGS PLAN | NOTE 10 — RETIREMENT SAVINGS PLANS |
We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2012, 2013 and again in 2014, we matched 100% of the employee’s contribution up to 4% of their earnings. The employer contribution was $14,102 and $9,231 for the three months ending September 30, 2014 and September 30, 2013, respectively, and was $29,596 and $27,328, for the nine months ending September 30, 2014 and September 30, 2013, respectively. | We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2012, its inception year, and again in 2013, we matched 100%, of the employee’s contribution up to 4.0% of their earnings. The employer contribution was $32,790 and $1,654 in 2013 and 2012. There were no discretionary contributions to the plan in 2013 and 2012. | |
COMMITMENTS_AND_CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 9 Months Ended | 12 Months Ended |
Sep. 30, 2014 | Dec. 31, 2013 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Commitments and Contingencies Disclosure [Text Block] | NOTE 11 — COMMITMENTS AND CONTINGENCIES | NOTE 11 — COMMITMENTS AND CONTINGENCIES |
On July 17, 2014, Skyline Medical Inc. (the “Company”) and a stockholder entered into a settlement agreement and release (the “Settlement Agreement”) with Marshall Ryan (“Ryan”) and a company related to Ryan (together, the “Plaintiffs”). The settlement relates to a previously disclosed lawsuit by the Plaintiffs initiated in March 2014. Ryan is an engineer who previously worked with the Company on design of certain of the Company’s products. The lawsuit alleged among other things, breach of a 2008 consulting agreement, a 2006 manufacturing agreement and a 2006 supply agreement among the Plaintiffs and the Company, various claims of fraud and negligent misrepresentation, and breach of the duty of good faith and fair dealing. | Marshall Ryan & Mid-State Stainless, Inc. v. Skyline Medical Inc. & Dr. Samuel Herschkowitz. On March 5, 2014, plaintiffs filed an action in District Court in Hennepin County, Minnesota against the Company and one of its stockholders, Dr. Samuel Herschkowitz. Marshall Ryan, one of the plaintiffs, is an engineer who worked with the Company on design of certain of its products. The action alleges, among other things, breach of a consulting agreement, a manufacturing agreement and a supply agreement between plaintiffs and the Company, various claims of fraud and negligent misrepresentation and breach of the duty of good faith and fair dealing. The Company believes the claims are without merit and is preparing its response. | |
Under the Settlement Agreement, the parties have agreed that the lawsuit will be dismissed. The Company has agreed to pay Ryan an aggregate of $500,000 in various cash installments through April 25, 2015, which amount includes $200,000 in installments that are payable during the remainder of 2014. The Settlement Agreement, among other things, extinguishes any prior claims of Plaintiffs for royalties or other alleged rights to payments under their prior agreements with the Company. Payment of the outstanding balance under the Settlement Agreement will be accelerated if the Company raises $2 million or more of gross dollars in a single funding round or raises aggregate funding of $4 million of gross dollars on or before April 10, 2015. If the Company defaults on the required cash payments and fails to cure as provided in the Settlement Agreement, then Ryan will have the option to either sue Skyline to enforce the Settlement Agreement or rescind the Settlement Agreement, including returning all payments previously made thereunder. | ||
The Settlement Agreement also contains mutual releases covering claims other than a breach of the Settlement Agreement. In the Settlement Agreement, Ryan fully, unconditionally and irrevocably affirms and ratifies the Company’s rights to Ryan’s prior patent assignments, and disclaims any right, title or interest in the Company’s Streamway product including any claims to royalties both past and future. In addition, the parties confirmed that the patents related to the Streamway product belong exclusively to Skyline and remain in full force and effect. | ||
SUPPLEMENTAL_CASH_FLOW_DATA
SUPPLEMENTAL CASH FLOW DATA | 9 Months Ended |
Sep. 30, 2014 | |
Supplemental Cash Flow Elements [Abstract] | |
Cash Flow, Supplemental Disclosures [Text Block] | NOTE 12 — SUPPLEMENTAL CASH FLOW DATA |
Cash payments for interest were $21,627 and $14,503 for the three months ended September 30, 2014 and September 30, 2013, and $43,233 and $56,433 for the nine months ended September 30, 2014 and September 30, 2013. | |
SUMMARY_OF_SIGNIFICANT_ACCOUNT1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 9 Months Ended | 12 Months Ended | ||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||
Accounting Policies [Abstract] | ||||||||||||||||||
Basis Of Accounting Policy [Policy Text Block] | Nature of Operations and Continuance of Operations | Nature of Operations and Continuance of Operations | ||||||||||||||||
BioDrain Medical, Inc. (the “Company”) was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY FMS products. | Skyline Medical, Inc. (the “Company”) was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY FMS products. | |||||||||||||||||
The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and has a stockholders’ deficit. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. | The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and has a stockholders’ deficit. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. | |||||||||||||||||
Since inception to September 30, 2014, the Company has raised approximately $9,248,000 in equity, inclusive of $2,055,000 from a private placement of Series A Convertible Preferred Stock, and $5,518,000 in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources”. | Since inception to December 31, 2013, the Company raised approximately $6,956,000 in equity and $3,935,000 in debt financing, including $2,337,000 in equity and $1,823,000 in convertible debt in 2013. In 2014, the Company has completed a private offering of units of preferred stock and warrants. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources”. | |||||||||||||||||
New Accounting Pronouncements Policy [Policy Text Block] | Recent Accounting Developments | Recent Accounting Developments | ||||||||||||||||
In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers and created a new topic in the FASB Accounting Standards Codification (“ASC”), Topic 606. The new standard provides a single comprehensive revenue recognition framework for all entities and supersedes nearly all existing U.S. GAAP revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and also requires enhanced disclosures. The amendments are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are currently evaluating the impact this guidance may have on our financial statements and related disclosures. | We reviewed all significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations. | |||||||||||||||||
In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company evaluated and adopted ASU 2014-10 for the reporting period ended September 30, 2014. | ||||||||||||||||||
In June 2014, the FASB issued ASU 2014-12, “Compensation — Stock Compensation” providing explicit guidance on how to account for share-based payments granted to employees in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. We are currently evaluating the impact this guidance may have on our financial statements. | ||||||||||||||||||
We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations. | ||||||||||||||||||
Valuation Of Intangible Assets [Policy Text Block] | Valuation of Intangible Assets | Valuation of Intangible Assets | ||||||||||||||||
We review identifiable intangible assets for impairment in accordance with ASC 350- Intangibles — Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management's best estimate of the related risks and return at the time the impairment assessment is made. | We review identifiable intangible assets for impairment in accordance with ASC 350 — Intangibles — Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management's best estimate of the related risks and return at the time the impairment assessment is made. | |||||||||||||||||
Our accounting estimates and assumptions bear various risks of change, including the length of the current economic downturn facing the United States, the expansion of the slowdown in consumer spending in the U.S. medical markets despite the early expressed opinions of financial experts that the medical market would not be as affected as other markets and failure to gain acceptance in the medical market. | Our accounting estimates and assumptions bear various risks of change, including the length of the current economic downturn facing the United States, the expansion of the slowdown in consumer spending in the U.S. medical markets despite the early expressed opinions of financial experts that the medical market would not be as affected as other markets and failure to gain acceptance in the medical market. | |||||||||||||||||
Use of Estimates, Policy [Policy Text Block] | Accounting Policies and Estimates | Accounting Policies and Estimates | ||||||||||||||||
The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |||||||||||||||||
Presentation Of Taxes Collected From Customers Policy [Policy Text Block] | Presentation of Taxes Collected from Customers | Presentation of Taxes Collected from Customers | ||||||||||||||||
Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. | Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. | |||||||||||||||||
Shipping and Handling Cost, Policy [Policy Text Block] | Shipping and Handling | Shipping and Handling | ||||||||||||||||
Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. | Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. | |||||||||||||||||
Advertising Costs, Policy [Policy Text Block] | Advertising | Advertising | ||||||||||||||||
Advertising costs are expensed as incurred. Advertising expenses were $4,201 and $11,994 in the three and nine months ended September 30, 2014 and there were no advertising expenses in the three and nine months ended September 30, 2013. | Advertising costs are expensed as incurred. There were no advertising expenses for 2013 and 2012. | |||||||||||||||||
Research and Development Expense, Policy [Policy Text Block] | Research and Development | Research and Development | ||||||||||||||||
Research and development costs are charged to operations as incurred. Research and development expenses were $72,294 and $321,929 in the three and nine months ended September 30, 2014 and $73,621 and $207,162 for September 30, 2013. | Research and development costs are charged to operations as incurred. Research and development costs were approximately $235,000 and $15,000 for 2013 and 2012, respectively. | |||||||||||||||||
Revenue Recognition, Policy [Policy Text Block] | Revenue Recognition | Revenue Recognition | ||||||||||||||||
The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605 — Revenue Recognition. | The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605 — Revenue Recognition. | |||||||||||||||||
Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur. | Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution and filters. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution and filters may be returned. Additionally, since the Company buys the STREAMWAY FMS units, cleaning solution and filters from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur. | |||||||||||||||||
Receivables, Policy [Policy Text Block] | Receivables | Receivables | ||||||||||||||||
Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements. | Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements. | |||||||||||||||||
Inventory, Policy [Policy Text Block] | Inventories | Inventories | ||||||||||||||||
Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: | Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: | |||||||||||||||||
September 30, | December 31, | December 31, | December 31, | |||||||||||||||
2014 | 2013 | 2013 | 2012 | |||||||||||||||
Finished goods | $ | 69,331 | $ | 56,818 | Finished goods | $ | 56,818 | $ | 91,008 | |||||||||
Raw materials | 207,928 | 18,603 | Raw materials | 18,603 | 39,543 | |||||||||||||
Work-In-Process | 38,361 | 46,754 | Work-In-Process | 46,754 | 14,658 | |||||||||||||
Total | $ | 315,620 | $ | 122,175 | Total | $ | 122,175 | $ | 145,209 | |||||||||
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment | Property and Equipment | ||||||||||||||||
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: | Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: | |||||||||||||||||
Years | Years | |||||||||||||||||
Computers and office equipment | 3 – 7 | Computers and office equipment | 3 – 7 | |||||||||||||||
Leasehold improvements | 5 | Leasehold improvements | 5 | |||||||||||||||
Manufacturing tooling | 3 – 7 | Manufacturing Tooling | 3 – 7 | |||||||||||||||
Demo Equipment | 3 | The Company’s investment in Fixed Assets consists of the following: | ||||||||||||||||
The Company’s investment in Fixed Assets consists of the following: | ||||||||||||||||||
December 31, | 31-Dec-12 | |||||||||||||||||
September 30, | December 31, | 2013 | ||||||||||||||||
2014 | 2013 | Computers and office equipment | $ | 61,505 | $ | 12,258 | ||||||||||||
Computers and office equipment | $ | 126,234 | $ | 61,505 | Leasehold Improvements | 23,614 | ||||||||||||
Leasehold improvements | 23,874 | 23,614 | Manufacturing Tooling | 89,900 | ||||||||||||||
Manufacturing tooling | 97,288 | 89,900 | Total | 175,019 | 12,258 | |||||||||||||
Demo Equipment | 30,577 | — | Less: Accumulated Depreciation | 16,909 | 8,737 | |||||||||||||
Total | 277,973 | 175,019 | Total Fixed Assets, Net | $ | 158,110 | $ | 3,521 | |||||||||||
Less: Accumulated depreciation | 61,027 | 16,909 | Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. | |||||||||||||||
Total Fixed Assets, Net | $ | 216,946 | $ | 158,110 | ||||||||||||||
Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. | ||||||||||||||||||
Intangible Assets Policy [Policy Text Block] | Intangible Assets | Intangible Assets | ||||||||||||||||
Intangible assets consist of trademarks and patent costs. These assets are not subject to amortization until the property patented is in production. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified. The Company wrote-off the entire original STREAMWAY System patent of $140,588 in 2013. | Intangible assets consist of trademarks and patent costs. These assets are not subject to amortization until the property patented is in production. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified. The Company wrote-off the entire original STREAMWAY System patent of $140,588 in 2013. | |||||||||||||||||
Income Tax, Policy [Policy Text Block] | Income Taxes | Income Taxes | ||||||||||||||||
The Company accounts for income taxes in accordance with ASC 740 — Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. | The Company accounts for income taxes in accordance with ASC 740 — Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. | |||||||||||||||||
The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. | The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. | |||||||||||||||||
Tax years subsequent to 2010 remain open to examination by federal and state tax authorities. | Tax years subsequent to 2010 remain open to examination by federal and state tax authorities. | |||||||||||||||||
Patents and Intellectual Property Policy [Policy Text Block] | Patents and Intellectual Property | Patents and Intellectual Property | ||||||||||||||||
On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. | On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013. The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148 countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired. | |||||||||||||||||
Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. | Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. | |||||||||||||||||
The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and US Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. | The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 and US Publication No. US20090216205 (collectively, the “Patents”). These Patents will begin to expire on August 8, 2023. | |||||||||||||||||
Subsequent Events, Policy [Policy Text Block] | Subsequent Events | Subsequent Events | ||||||||||||||||
The Company filed a Certificate of Amendment effecting a 1:75 reverse stock split (the “Reverse Stock Split”) with the Secretary of State of the State of Delaware, which became effective under Delaware law as of October 24, 2014. At the effective time (the “Effective Time”) of the Reverse Stock Split, the issued and outstanding Common Stock of the Company was combined on a 1-for-75 basis such that every seventy-five shares of Common Stock outstanding immediately prior to the Effective Time was combined into one share of Common Stock. This share combination was effected through the exchange and replacement of certificates representing issued and outstanding shares of Common Stock as of the Effective Time, together with immediate book-entry adjustments to the stock register of the Company maintained in accordance with the Delaware General Corporation Law. In the event that the share combination would have resulted in a shareholder being entitled to receive less than a full share of Common Stock, the fractional share that would so result was rounded up to the nearest whole share of Common Stock. The par value of each share of issued and outstanding Common Stock was not affected by the share combination. | Sale of Convertible Preferred Stock and Warrants. In February 2014, we raised $2,055,000 less offering expenses from a private place of convertible preferred stock. As of February 4, 2014, Skyline Medical Inc. (the “Company”) entered into a Securities Purchase Agreement with certain investors (the “Purchasers”) pursuant to which the Company agreed to offer and sell 20,550 shares of Series A Convertible Preferred Stock, par value $0.01 (the “Preferred Shares”), and warrants (the “Warrants”) to acquire an aggregate of approximately 21,334 shares of the Company’s common stock, par value $0.01 (“Common Stock”). The Preferred Shares are convertible into shares of Common Stock at an initial conversion price of $19.50 per share of Common Stock. The Warrants are exercisable at an exercise price of $24.38 per share and expire five years from the closing date. The Company received gross proceeds of $2,055,000, before offering expenses. The closing of the sale of the Preferred Shares and Warrants (collectively, the “Securities”) occurred as of February 4, 2014 (the “Closing”). If the Company’s Common Stock is not listed on the NASDAQ Stock Market, the New York Stock Exchange, or the NYSE MKT within 180 days of the Closing, the Company shall issue additional Warrants to purchase additional shares of Common Stock, equal to 30% of the shares of Common Stock which the Preferred Shares purchased by each Purchaser purchased are convertible. | |||||||||||||||||
For purposes of trading of the common stock, the Reverse Stock Split was approved, by FINRA and became effective as of market open on October 28, 2014. | The Securities Purchase Agreement requires the Company to register the resale of the shares of Common Stock underlying the Preferred Shares (the “Underlying Shares”) and the Common Stock underlying the Warrants (the “Warrant Shares”). The Company is required to prepare and file a registration statement with the Securities and Exchange Commission within 90 days of the closing of the offering, and to use commercially reasonable efforts to have the registration statement declared effective within 105 days if there is no review by the Securities and Exchange Commission, and within 150 days in the event of such review. | |||||||||||||||||
In the Condensed Financial Statement and Notes thereto, and elsewhere in this Report, all numbers of shares and per share amounts, as appropriate, have been restated to reflect the Reverse Stock Split. | The Securities were offered and sold without registration under the Securities Act of 1933, as amended (the “Securities Act”), or state securities laws, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. The Securities may not be offered or sold in the United States without an effective registration statement or pursuant to an exemption from applicable registration requirements. | |||||||||||||||||
In September 2014 we filed a registration statement for the public offering of shares of our common stock and five-year warrants to purchase shares of common stock at an exercise price equal to 125% of the offering price per share of the common stock. We have applied to list our common stock on the NASDAQ Capital Market effective upon the completion of the public offering. | The Preferred Shares are convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value of the Preferred Shares being converted by the conversion price of $19.50, subject to adjustment for stock splits, reverse stock splits and similar recapitalization events. If the Company issues additional shares of Common Stock, other than certain stock that is excluded under the terms of the Securities Purchase Agreement, in one or more capital raising transactions with an aggregate purchase price of at least $100,000 for a price less than the then existing conversion price for the Preferred Shares (the “New Issuance Price”), then the then existing conversion price shall be reduced to the New Issuance Price, provided, however, that under no circumstances shall the New Issuance Price be less than $9.75 or reduced to a price level that would be in breach of the listing rules of any stock exchange or that would have material adverse effect on the Corporation’s ability to list its Common Stock on a stock exchange, including but not limited to the change of accounting treatment of the Preferred Stock. The Preferred Shares contain certain limitations on conversion so that the holder will not own more than 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of Preferred Shares held by the applicable holder, with the percentage subject to increase in certain circumstances. The Preferred Shares are eligible to vote with the Common Stock on an as-converted basis, but only to the extent that the Preferred Shares are eligible for conversion without exceeding the Beneficial Ownership Limitation. The Preferred Shares are entitled to receive dividends on a pari passu basis with the Common Stock, when, and if declared. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of Common Stock ranking prior to the Preferred Shares upon liquidation, the holders of the Preferred Shares shall receive, prior and in preference to the holders of any junior securities, an amount equal to $2,055,000 times 1.2, plus all declared but unpaid dividends. | |||||||||||||||||
The Warrants are exercisable on any day on or after the date of issuance, have an exercise price of $19.50 per share, subject to adjustment, and a term of five years from the date they are first exercisable. However, a holder will be prohibited from exercising a Warrant if, as a result of such exercise, the holder, together with its affiliates, would exceed the Beneficial Ownership Limitation as described above for the Preferred Shares. If any Warrant has not been fully exercised prior to the first anniversary of the Closing and if during such period the Company has not installed or received firm purchase orders (accepted by the Company) for at least 500 STREAMWAY Automated Surgical Fluid Disposal Systems, then, the number of Common Stock for which such Warrant may be exercised shall be increased 2.5 times. | ||||||||||||||||||
Settlement with Group of Warrantholders. In September 2013, the Company received a request to issue 66,585 shares of its common stock to a group of partnerships and individuals in connection with the cashless exercise of stock purchase warrants covering a total of 82,459 shares. In processing the exercise, the Company commenced an internal investigation regarding the warrants and withheld delivery of the certificates for a substantial majority of the shares, pending the outcome of the investigation. | ||||||||||||||||||
After investigation, the Company disagreed with the group’s position that all of such shares should be delivered in connection with the exercise. Following negotiations, effective March 3, 2014, the Company and the group entered into a settlement agreement that resulted in, among other things, a net reduction of 16,867 shares. This reduction is reflected as outstanding on the balance sheet as of December 31, 2013. | ||||||||||||||||||
Interim Financial Statements Policy [Policy Text Block] | Interim Financial Statements | |||||||||||||||||
The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company’s financial position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10-K filed with the SEC on March 27, 2014. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year. | ||||||||||||||||||
SUMMARY_OF_SIGNIFICANT_ACCOUNT2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 9 Months Ended | 12 Months Ended | ||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||
Accounting Policies [Abstract] | ||||||||||||||||||
Schedule of Inventory, Current [Table Text Block] | Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: | Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows: | ||||||||||||||||
September 30, | December 31, | December 31, | December 31, | |||||||||||||||
2014 | 2013 | 2013 | 2012 | |||||||||||||||
Finished goods | $ | 69,331 | $ | 56,818 | Finished goods | $ | 56,818 | $ | 91,008 | |||||||||
Raw materials | 207,928 | 18,603 | Raw materials | 18,603 | 39,543 | |||||||||||||
Work-In-Process | 38,361 | 46,754 | Work-In-Process | 46,754 | 14,658 | |||||||||||||
Total | $ | 315,620 | $ | 122,175 | Total | $ | 122,175 | $ | 145,209 | |||||||||
Property, Plant and Equipment [Table Text Block] | Estimated useful asset life by classification is as follows: | Estimated useful asset life by classification is as follows: | ||||||||||||||||
Years | Years | |||||||||||||||||
Computers and office equipment | 3 – 7 | Computers and office equipment | 3 – 7 | |||||||||||||||
Leasehold improvements | 5 | Leasehold improvements | 5 | |||||||||||||||
Manufacturing tooling | 3 – 7 | Manufacturing Tooling | 3 – 7 | |||||||||||||||
Demo Equipment | 3 | The Company’s investment in Fixed Assets consists of the following: | ||||||||||||||||
The Company’s investment in Fixed Assets consists of the following: | ||||||||||||||||||
December 31, | 31-Dec-12 | |||||||||||||||||
September 30, | December 31, | 2013 | ||||||||||||||||
2014 | 2013 | Computers and office equipment | $ | 61,505 | $ | 12,258 | ||||||||||||
Computers and office equipment | $ | 126,234 | $ | 61,505 | Leasehold Improvements | 23,614 | ||||||||||||
Leasehold improvements | 23,874 | 23,614 | Manufacturing Tooling | 89,900 | ||||||||||||||
Manufacturing tooling | 97,288 | 89,900 | Total | 175,019 | 12,258 | |||||||||||||
Demo Equipment | 30,577 | — | Less: Accumulated Depreciation | 16,909 | 8,737 | |||||||||||||
Total | 277,973 | 175,019 | Total Fixed Assets, Net | $ | 158,110 | $ | 3,521 | |||||||||||
Less: Accumulated depreciation | 61,027 | 16,909 | ||||||||||||||||
Total Fixed Assets, Net | $ | 216,946 | $ | 158,110 | ||||||||||||||
STOCKHOLDERS_DEFICIT_STOCK_OPT1
STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Tables) | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | ||||||||||||||||||||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | The following summarizes transactions for stock options and warrants for the periods indicated: | The following summarizes transactions for stock options and warrants for the periods indicated: | ||||||||||||||||||||||||||||||||
Stock Options | Warrants | Stock Options(1) | Warrants(1) | |||||||||||||||||||||||||||||||
Number of | Average | Number of | Average | Number of | Average | Number of | Average | |||||||||||||||||||||||||||
Shares | Exercise Price | Shares | Exercise Price | Shares | Exercise Price | Shares | Exercise Price | |||||||||||||||||||||||||||
Outstanding at December 31, 2012 | 168,856 | $ | 6.75 | 468,431 | $ | 9.75 | Outstanding at December 31, 2005 | 239 | $ | 125.25 | 279 | $ | 196.5 | |||||||||||||||||||||
Issued | 239,816 | 6.75 | 343,196 | 9 | Issued | 319 | 125.25 | 958 | 63.75 | |||||||||||||||||||||||||
Expired | (15,467 | ) | 18 | (111,025 | ) | 13.5 | Outstanding at December 31, 2006 | 558 | 125.25 | 1,237 | 93.75 | |||||||||||||||||||||||
Exercised | (7,472 | ) | 0.75 | (238,682 | ) | 8.25 | Issued | 80 | 125.25 | 380 | 26.25 | |||||||||||||||||||||||
Outstanding at December 31, 2013 | 385,733 | 6.75 | 461,920 | 10.5 | Outstanding at December 31, 2007 | 638 | 125.25 | 1,617 | 78 | |||||||||||||||||||||||||
Issued | 71,838 | 8.11 | 155,818 | 3.74 | Issued | 16,577 | 15 | 67,669 | 33.75 | |||||||||||||||||||||||||
Expired | (6,746 | ) | 25.65 | (77,685 | ) | 9.88 | Expired | (160 | ) | 282 | ||||||||||||||||||||||||
Exercised | (4,936 | ) | 1.76 | (40,722 | ) | 8.38 | Outstanding at December 31, 2008 | 17,215 | 19.5 | 69,126 | 33.75 | |||||||||||||||||||||||
Outstanding at September 30, 2014 | 445,889 | $ | 7.58 | 499,331 | $ | 8.6 | Issued | 2,733 | 27.75 | 29,177 | 48.75 | |||||||||||||||||||||||
Outstanding at December 31, 2009 | 19,948 | 20.25 | 98,303 | 36.75 | ||||||||||||||||||||||||||||||
Issued | 29,467 | 12.75 | 45,809 | 25.5 | ||||||||||||||||||||||||||||||
Expired | (2,773 | ) | 32.25 | (120 | ) | 125.25 | ||||||||||||||||||||||||||||
Exercised | (1,714 | ) | 34.5 | |||||||||||||||||||||||||||||||
Outstanding at December 31, 2010 | 46,642 | 14.25 | 142,278 | 33 | ||||||||||||||||||||||||||||||
Issued | 33,111 | 0.75 | 242,963 | 10.5 | ||||||||||||||||||||||||||||||
Expired | (1,119 | ) | 54.75 | (26,812 | ) | 36 | ||||||||||||||||||||||||||||
Exercised | (1,333 | ) | 0.75 | |||||||||||||||||||||||||||||||
Outstanding at December 31, 2011 | 77,301 | 8.25 | 358,429 | 17.25 | ||||||||||||||||||||||||||||||
Issued | 126,866 | 6 | 155,846 | 11.25 | ||||||||||||||||||||||||||||||
Expired | (29,805 | ) | 8.25 | (44,886 | ) | 37.5 | ||||||||||||||||||||||||||||
Exercised | (5,506 | ) | 0.75 | (958 | ) | 0.75 | ||||||||||||||||||||||||||||
Outstanding at December 31, 2012 | 168,856 | 6.75 | 468,431 | 9.75 | ||||||||||||||||||||||||||||||
Issued | 239,816 | 6.75 | 343,196 | 9 | ||||||||||||||||||||||||||||||
Expired | (15,467 | ) | 18 | (111,025 | ) | 13.5 | ||||||||||||||||||||||||||||
Exercised | (7,472 | ) | 0.75 | (238,682 | ) | 8.25 | ||||||||||||||||||||||||||||
Outstanding at December 31, 2013 | 385,733 | $ | 6.75 | 461,920 | $ | 10.5 | ||||||||||||||||||||||||||||
-1 | Adjusted for the reverse stock splits in total at June 6, 2008, October 20, 2008, and October 24, 2014. | |||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block] | The following summarizes the status of options and warrants outstanding at September 30, 2014: | The following summarizes the status of options and warrants outstanding at December 31, 2013: | ||||||||||||||||||||||||||||||||
Range of Exercise Prices | Shares | Weighted | Range of Exercise Prices | Shares | Weighted | |||||||||||||||||||||||||||||
Average | Average | |||||||||||||||||||||||||||||||||
Remaining Life | Remaining | |||||||||||||||||||||||||||||||||
Options: | Life | |||||||||||||||||||||||||||||||||
$0.75 | 7,333 | 6.77 | Options: | |||||||||||||||||||||||||||||||
$4.88 | 134 | 8.45 | $0.75 | 7,334 | 7.52 | |||||||||||||||||||||||||||||
$5.25 | 2,031 | 7.94 | $1.28 | 4,336 | 4.43 | |||||||||||||||||||||||||||||
$5.63 | 192,000 | 8.46 | $4.88 | 134 | 9.2 | |||||||||||||||||||||||||||||
$5.93 | 23,206 | 8.47 | $5.25 | 2,631 | 9.44 | |||||||||||||||||||||||||||||
$6.00 | 123,998 | 7.88 | $5.63 | 192,000 | 9.21 | |||||||||||||||||||||||||||||
$6.60 | 5,332 | 7.32 | $5.93 | 23,207 | 9.22 | |||||||||||||||||||||||||||||
$8.25 | 3,636 | 10 | $6.00 | 124,000 | 8.63 | |||||||||||||||||||||||||||||
$9.94 | 3,019 | 8.79 | $66.00 | 5,334 | 8.07 | |||||||||||||||||||||||||||||
$10.50 | 3,238 | 8.79 | $9.94 | 3,019 | 9.54 | |||||||||||||||||||||||||||||
$11.25 | 14,799 | 7.72 | $10.50 | 3,239 | 9.54 | |||||||||||||||||||||||||||||
$12.75 | 10,069 | 9.54 | $11.25 | 9,023 | 7.16 | |||||||||||||||||||||||||||||
$13.88 | 2,160 | 9.51 | $12.75 | 67 | 9.36 | |||||||||||||||||||||||||||||
$15.00 | 3,334 | 9.47 | $20.25 | 4,939 | 10 | |||||||||||||||||||||||||||||
$17.25 | 40,261 | 9.44 | $21.75 | 1,334 | 9.77 | |||||||||||||||||||||||||||||
$18.75 | 3,335 | 9.4 | $23.85 | 1,258 | 9.75 | |||||||||||||||||||||||||||||
$20.25 | 4,940 | 9.26 | $24.75 | 1,334 | 9.73 | |||||||||||||||||||||||||||||
$21.75 | 1,336 | 9.02 | $25.61 | 267 | 9.75 | |||||||||||||||||||||||||||||
$23.85 | 1,260 | 9.01 | $26.25 | 1,000 | 0.37 | |||||||||||||||||||||||||||||
$24.75 | 334 | 8.99 | $43.88 | 1,277 | 0.44 | |||||||||||||||||||||||||||||
$25.61 | 134 | 8.99 | Total | 385,733 | ||||||||||||||||||||||||||||||
Total | 445,889 | Warrants: | ||||||||||||||||||||||||||||||||
Warrants: | $0.75 | 2,667 | 1.94 | |||||||||||||||||||||||||||||||
$0.75 | 400 | 1.19 | $5.63 | 35,556 | 0.85 | |||||||||||||||||||||||||||||
$6.00 | 102,857 | 3.45 | $6.00 | 102,857 | 4.2 | |||||||||||||||||||||||||||||
$9.00 | 2,666 | 3.32 | $7.50 | 19,047 | 0.33 | |||||||||||||||||||||||||||||
$11.25 | 204,200 | 3.27 | $9.00 | 2,667 | 4.9 | |||||||||||||||||||||||||||||
$12.38 | 71,257 | 3.53 | $11.25 | 221,977 | 3.98 | |||||||||||||||||||||||||||||
$13.50 | 4,444 | 3.72 | $12.00 | 2,000 | 0.38 | |||||||||||||||||||||||||||||
$14.85 | 23,612 | 3.66 | $12.75 | 17,255 | 0.27 | |||||||||||||||||||||||||||||
$15.00 | 1,168 | 0.34 | $13.50 | 7,112 | 2.83 | |||||||||||||||||||||||||||||
$18.75 | 4,166 | 0.03 | $14.85 | 23,611 | 4.41 | |||||||||||||||||||||||||||||
$20.25 | 1,481 | 3.03 | $1,500 | 16,500 | 0.18 | |||||||||||||||||||||||||||||
$24.38 | 83,080 | 4.86 | $18.75 | 5,000 | 0.77 | |||||||||||||||||||||||||||||
Total | 499,331 | $34.50 | 1,110 | 0.3 | ||||||||||||||||||||||||||||||
$57.68 | 4,561 | 0.5 | ||||||||||||||||||||||||||||||||
Total | 461,920 | |||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] | The following table is the listing of stock options and warrants as of September 30, 2014 by year of grant: | The following table is the listing of stock options and warrants as of December 31, 2013 by year of grant: | ||||||||||||||||||||||||||||||||
Stock Options: | Stock Options: | |||||||||||||||||||||||||||||||||
Year | Shares | Price | Year | Shares | Price | |||||||||||||||||||||||||||||
2010 | 5,466 | $ | 11.25 | 2008 | 5,613 | $ | 1.28 – 43.88 | |||||||||||||||||||||||||||
2011 | 7,333 | 0.75 | 2009 | 1,000 | 26.25 | |||||||||||||||||||||||||||||
2012 | 126,029 | 5.25 – 6.00 | 2010 | 5,467 | 11.25 | |||||||||||||||||||||||||||||
2013 | 238,556 | 4.88 – 25.61 | 2011 | 7,334 | 0.75 | |||||||||||||||||||||||||||||
2014 | 68,505 | 8.25 – 18.75 | 2012 | 126,636 | 5.25 – 6.00 | |||||||||||||||||||||||||||||
Total | 445,889 | $ | .75 – 25.61 | 2013 | 239,683 | 4.88 – 25.61 | ||||||||||||||||||||||||||||
Warrants: | Total | 385,733 | $ | .75 – 43.88 | ||||||||||||||||||||||||||||||
Warrants: | ||||||||||||||||||||||||||||||||||
Year | Shares | Price | ||||||||||||||||||||||||||||||||
2010 | 400 | $ | 0.75 | Year | Shares | Price | ||||||||||||||||||||||||||||
2011 | 4,166 | 18.75 | 2008 | 4,561 | $ | 34.50 – 57.68 | ||||||||||||||||||||||||||||
2012 | 71,368 | 11.25 – 15.00 | 2009 | 1,110 | 34.5 | |||||||||||||||||||||||||||||
2013 | 267,579 | 6.00 – 14.85 | 2010 | 2,667 | 0.75 | |||||||||||||||||||||||||||||
2014 | 155,818 | 12.38 – 24.38 | 2011 | 114,635 | 5.63 – 18.75 | |||||||||||||||||||||||||||||
Total | 499,331 | $ | .75 – 24.38 | 2012 | 71,367 | 11.25 – 15.00 | ||||||||||||||||||||||||||||
2013 | 267,580 | 6.00 – 14.85 | ||||||||||||||||||||||||||||||||
Total | 461,920 | $ | .75 – 57.68 | |||||||||||||||||||||||||||||||
LOSS_PER_SHARE_Tables
LOSS PER SHARE (Tables) | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | ||||||||||||||||||||||||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | The following table presents the shares used in the basic and diluted loss per common share computations: | The following table presents the shares used in the basic and diluted loss per common share computations: | ||||||||||||||||||||||||||||
Three Months Ended | Nine Months Ended | Year Ended December 31, | From | |||||||||||||||||||||||||||
September 30, | September 30, | 2013 | 2012 | April 23, 2002 (Inception) To December 31, 2013 | ||||||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | Numerator: | ||||||||||||||||||||||||||
Numerator: | Net loss available in basic and diluted calculation | $ | (9,406,304 | ) | $ | (7,422,155 | ) | $ | (28,697,415 | ) | ||||||||||||||||||||
Net loss available in basic and diluted calculation | $ | (1,115,221 | ) | $ | (3,974,903 | ) | $ | (4,468,170 | ) | $ | (7,251,965 | ) | Denominator: | |||||||||||||||||
Denominator: | Weighted average common shares | 2,026,115 | 927,838 | 996,362 | ||||||||||||||||||||||||||
Weighted average common shares | 259,899 | 1,821,006 | 2,052,709 | 1,687,625 | outstanding-basic | |||||||||||||||||||||||||
outstanding-basic | Effect of dilutive stock options and warrants(1) | — | — | — | ||||||||||||||||||||||||||
Effect of diluted stock options and warrants(1) | — | — | — | — | Weighted average common shares | 2,026,115 | 927,838 | 996,362 | ||||||||||||||||||||||
Weighted average common shares | 2,984,335 | 1,821,006 | 2,967,483 | 1,687,625 | outstanding-diluted | |||||||||||||||||||||||||
outstanding-basic | Loss per common share-basic and diluted | $ | (4.64 | ) | $ | (8.00 | ) | $ | (28.80 | ) | ||||||||||||||||||||
Loss per common share-basic and diluted | $ | (0.37 | ) | $ | (2.18 | ) | $ | (1.51 | ) | $ | (4.30 | ) | ||||||||||||||||||
-1 | The number of shares underlying options and warrants outstanding as of December 31, 2013 and December 31, 2012 are 847,777 and 637,277, respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. | |||||||||||||||||||||||||||||
-1 | The number of shares underlying options and warrants outstanding as of September 30, 2014 and September 30, 2013 are 945,220 and 861,287 respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. | |||||||||||||||||||||||||||||
INCOME_TAXES_Tables
INCOME TAXES (Tables) | 9 Months Ended | 12 Months Ended | ||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||
Income Tax Disclosure [Abstract] | ||||||||||||||||||
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | The components of deferred income taxes at September 30, 2014 and December 31, 2013 are as follows: | The components of deferred income taxes at December 31, 2013 and December 31, 2012 are as follows: | ||||||||||||||||
September 30, | December 31, | December 31, | December 31, | |||||||||||||||
2014 | 2013 | 2013 | 2012 | |||||||||||||||
Deferred Tax Asset: | Deferred Tax Asset: | |||||||||||||||||
Net Operating Loss | $ | 7,920,000 | $ | 3,259,000 | Net Operating Loss | $ | 3,259,000 | $ | 2,209,000 | |||||||||
Other | 631,000 | 59,000 | Other | 59,000 | 73,000 | |||||||||||||
Total Deferred Tax Asset | 8,551,000 | 3,318,000 | Total Deferred Tax Asset | 3,318,000 | 2,282,000 | |||||||||||||
Less Valuation Allowance | 8,551,000 | 3,318,000 | Less Valuation Allowance | 3,318,000 | 2,282,000 | |||||||||||||
Net Deferred Income Taxes | $ | — | $ | — | Net Deferred Income Taxes | $ | — | $ | — | |||||||||
LONGTERM_DEBT_Tables
LONG-TERM DEBT (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Long-Term Debt, Unclassified [Abstract] | |||||||||
Schedule of Long-term Debt Instruments [Table Text Block] | Long-term debt is as follows: | ||||||||
31-Dec-13 | 31-Dec-12 | ||||||||
Note payable issued on October 26, 2009, net of a discount of $0 and $0 discount, with interest at 8% to March 31, 2012 when the remaining balance was payable and convertible into shares of common stock at $26.25 per share. The note was renegotiated in February 2013. | — | 100,000 | |||||||
Note payable issued on June 12, 2010 with interest at 12% to March 31, 2012 when the remaining balance was payable, and is convertible into shares of common stock at $13.50 per share. The note was renegotiated in February 2013. | — | 200,000 | |||||||
Note payable issued on December 23, 2010, with interest at 10%, matured December 23, 2012 and was convertible into shares of common stock at $6.30 per share. The note was renegotiated in February 2013. | — | 16,800 | |||||||
Note payable issued on September 21, 2010 with interest at 12%, matured March 30, 2012 and was convertible into shares of common stock at $13.50 per share. The note was renegotiated in February 2013. | — | 32,000 | |||||||
Note payable issued January 1, 2011 to a law firm that accepted this note in full payment of their past due legal fees. The note bears interest at 6%, matures January 1, 2015 and is convertible into shares of common stock at $11.25 per share. The note was renegotiated in March 2013, and has been paid in full. | — | 89,300 | |||||||
On November 6, 2012 the Company issued four convertible notes at 20% interest, each, net of an aggregate discount of $21,138, due on April 6, 2013. The four notes were converted into 13,889 shares at $7.50 per share. | — | 122,774 | |||||||
Total | — | 560,874 | |||||||
Less amount due within one year | — | 471,574 | |||||||
Long-Term Debt | $ | — | $ | 89,300 | |||||
RENT_OBLIGATION_Tables
RENT OBLIGATION (Tables) | 9 Months Ended | 12 Months Ended | ||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||
Rent Obligation [Abstract] | ||||||||||
Schedule of Rent Expense [Table Text Block] | The Company’s rent obligation for the next five years is as follows: | The Company’s rent obligation for the next five years are as follows: | ||||||||
2015 | $ | 37,000 | 2014 | $ | 36,000 | |||||
2016 | $ | 38,000 | 2015 | $ | 37,000 | |||||
2017 | $ | 39,000 | 2016 | $ | 38,000 | |||||
2018 | $ | 3,600 | 2017 | $ | 39,000 | |||||
2019 | $ | — | 2018 | $ | 3,000 | |||||
LIABILITY_FOR_EQUITYLINKED_FIN1
LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Tables) | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sep. 30, 2014 | Dec. 31, 2013 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] | The inputs to the Black-Scholes model during 2009 through 2014 were as follows: | The inputs to the Black-Scholes model during 2009 through 2013 were as follows: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock price | $26.25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock price | $4.50 to $37.50 | Exercise price | $57.68 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise price | $.75 to $24.38 | Expected life | .50 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected life | 2.0 to 6.5 years | Expected volatility | 54% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expected volatility | 59% | Assumed dividend rate | —% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assumed dividend rate | —% | Risk-free interest rate | .13% to 2.97% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risk-free interest rate | .13% to 2.97% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | The original valuations, annual gain/(loss) and end of year valuations are shown below: | The original valuations, annual gain (loss) and end of year valuations are shown below: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Initial Value | Annual | Value at | 2010 Gain | Value at | 2011 Gain | Value at | 2012 Gain | Value at | 2013 Gain | Value at | 2014 Gain | Value at | Initial | Annual Gain (Loss) | Value at | 2010 | Value at | 2011 | Value at | 2012 | Value at | 2013 | Value at | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain | 12/31/09 | (Loss) | 12/31/10 | (Loss) | 12/31/11 | (Loss) | 12/31/12 | (Loss) | 12/31/13 | (Loss) | 9/30/14 | Value | 12/31/09 | Gain (Loss) | 12/31/10 | Gain (Loss) | 12/31/11 | Gain (Loss) | 12/31/12 | Gain (Loss) | 12/31/13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Loss) | January 1 2009 adoption | $ | 479,910 | $ | (390,368 | ) | $ | 870,278 | $ | 868,772 | $ | 1,506 | $ | (88,290 | ) | $ | 89,796 | $ | (21,856 | ) | $ | 111,652 | $ | 100,053 | $ | 11,599 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
January 1, 2009 adoption | $ | 479,910 | $ | (390,368 | ) | $ | 870,278 | $ | 868,772 | $ | 1,506 | $ | (88,290 | ) | $ | 89,796 | $ | (21,856 | ) | $ | 111,652 | $ | 100,053 | $ | 11,599 | $ | 11,599 | $ | — | Warrants issued in quarter ended 6/30/2009 | 169,854 | 20,847 | 149,007 | 147,403 | 1,604 | (4,689 | ) | 6,293 | 6,293 | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued in quarter ended 6/30/2009 | 169,854 | 20,847 | 149,007 | 147,403 | 1,604 | (4,689 | ) | 6,293 | 6,293 | — | — | — | — | — | Warrants issued in quarter ended 9/30/2009 | 39,743 | (738 | ) | 40,481 | 40,419 | 62 | (1,562 | ) | 1,624 | 910 | 714 | 714 | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued in quarter ended 9/30/2009 | 39,743 | (738 | ) | 40,481 | 40,419 | 62 | (1,562 | ) | 1,624 | 910 | 714 | 714 | — | — | — | Warrants issued in quarter ended 12/31/2009 | 12,698 | 617 | 12,081 | 12,053 | 28 | (724 | ) | 752 | 415 | 337 | 337 | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued in quarter ended 12/31/2009 | 12,698 | 617 | 12,081 | 12,053 | 28 | (724 | ) | 752 | 415 | 337 | 337 | — | — | — | Subtotal | 702,205 | 1,071,847 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subtotal | 702,205 | 1,071,847 | Warrants issued in quarter ended 3/31/2010 | 25,553 | 25,014 | 539 | (5,570 | ) | 6,109 | 3,701 | 2,408 | 2,408 | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued in quarter ended 3/31/2010 | 25,553 | 25,014 | 539 | (5,570 | ) | 6,109 | 3,701 | 2,408 | 2,408 | — | — | — | Warrants issued in quarter ended 6/30/2010 | 31,332 | 30,740 | 592 | (6,122 | ) | 6,714 | 6,083 | 631 | 631 | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued in quarter ended 6/30/2010 | 31,332 | 30,740 | 592 | (6,122 | ) | 6,714 | 6,083 | 631 | 631 | — | — | — | Warrants issued in quarter ended 9/30/2010 | 31,506 | 20,891 | 10,615 | (44,160 | ) | 54,775 | 1,338 | 53,437 | 53,437 | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued in quarter ended 9/30/2010 | 31,506 | 20,891 | 10,615 | (44,160 | ) | 54,775 | 1,338 | 53,437 | 53,437 | — | — | — | Total | $ | 790,596 | $ | (369,642 | ) | $ | 1,071,847 | $ | 1,145,292 | $ | 14,946 | $ | (151,117 | ) | $ | 166,063 | $ | (3,116 | ) | $ | 169,179 | $ | 157,580 | $ | 11,599 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 790,596 | $ | (369,642 | ) | $ | 1,071,847 | $ | 1,145,292 | $ | 14,946 | $ | (151,117 | ) | $ | 166,063 | $ | (3,116 | ) | $ | 169,179 | $ | 157,580 | $ | 11,599 | $ | 11,599 | $ | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SUMMARY_OF_SIGNIFICANT_ACCOUNT3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Summary Of Significant Accounting Policy [Line Items] | |||
Finished goods | $69,331 | $56,818 | $91,008 |
Raw materials | 207,928 | 18,603 | 39,543 |
Work-In-Process | 38,361 | 46,754 | 14,658 |
Total | $315,620 | $122,175 | $145,209 |
SUMMARY_OF_SIGNIFICANT_ACCOUNT4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2014 | Dec. 31, 2013 | |
Leasehold Improvements [Member] | ||
Summary Of Significant Accounting Policy [Line Items] | ||
Property, Plant and Equipment, Useful Life | 5 years | 5 years |
Computers And Office Equipment [Member] | Maximum [Member] | ||
Summary Of Significant Accounting Policy [Line Items] | ||
Property, Plant and Equipment, Useful Life | 7 years | 7 years |
Computers And Office Equipment [Member] | Minimum [Member] | ||
Summary Of Significant Accounting Policy [Line Items] | ||
Property, Plant and Equipment, Useful Life | 3 years | 3 years |
Manufacturing Tooling [Member] | Maximum [Member] | ||
Summary Of Significant Accounting Policy [Line Items] | ||
Property, Plant and Equipment, Useful Life | 7 years | 7 years |
Manufacturing Tooling [Member] | Minimum [Member] | ||
Summary Of Significant Accounting Policy [Line Items] | ||
Property, Plant and Equipment, Useful Life | 3 years | 3 years |
Demo Equipment [Member] | ||
Summary Of Significant Accounting Policy [Line Items] | ||
Property, Plant and Equipment, Useful Life | 3 years |
SUMMARY_OF_SIGNIFICANT_ACCOUNT5
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Summary Of Significant Accounting Policy [Line Items] | |||
Total | $277,973 | $175,019 | $12,258 |
Less: Accumulated depreciation | 61,027 | 16,909 | 8,737 |
Total Fixed Assets, Net | 216,946 | 158,110 | 3,521 |
Computers and office equipment [Member] | |||
Summary Of Significant Accounting Policy [Line Items] | |||
Total | 126,234 | 61,505 | 12,258 |
Leasehold Improvements [Member] | |||
Summary Of Significant Accounting Policy [Line Items] | |||
Total | 23,874 | 23,614 | |
Manufacturing Tooling [Member] | |||
Summary Of Significant Accounting Policy [Line Items] | |||
Total | 97,288 | 89,900 | |
Demo Equipment [Member] | |||
Summary Of Significant Accounting Policy [Line Items] | |||
Total | $30,577 | $0 |
SUMMARY_OF_SIGNIFICANT_ACCOUNT6
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $) | 1 Months Ended | 0 Months Ended | 2 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | 140 Months Ended | 1 Months Ended | ||||||||||
Feb. 28, 2014 | Oct. 31, 2013 | Sep. 30, 2013 | 31-May-13 | Apr. 30, 2013 | Mar. 15, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Jun. 30, 2013 | Dec. 31, 2002 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2008 | Dec. 31, 2013 | Apr. 30, 2012 | |
Summary Of Significant Accounting Policy [Line Items] | |||||||||||||||||||
Stockholders' Equity, Period Increase (Decrease) | $9,248,000 | $2,337,000 | $6,956,000 | ||||||||||||||||
Debt Instrument, Increase (Decrease) for Period, Net | 5,518,000 | 1,823,000 | 3,935,000 | ||||||||||||||||
Research and Development Expense | 72,294 | 73,621 | 321,929 | 207,162 | 235,000 | 15,000 | |||||||||||||
Amortization of Intangible Assets | 140,588 | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | 5,000 | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 4,763 | 13,889 | |||||||||||||||||
Warrants Issued To Purchase Common Stock | 5,926 | ||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | ||||||||||||
Preferred Stock Conversion Price, Per Share | $19.50 | ||||||||||||||||||
Warrants Expiration | five years | ||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | 3,000,000 | ||||||||||||||||||
Percentage Of Additional Warrants Issued To Purchase Common Stock | 30.00% | ||||||||||||||||||
Convertible Preferred Stock, Terms of Conversion | Preferred Shares are convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value of the Preferred Shares being converted by the conversion price of $19.50, subject to adjustment for stock splits, reverse stock splits and similar recapitalization events. If the Company issues additional shares of Common Stock, other than certain stock that is excluded under the terms of the Securities Purchase Agreement, in one or more capital raising transactions with an aggregate purchase price of at least $100,000 for a price less than the then existing conversion price for the Preferred Shares (the New Issuance Price), then the then existing conversion price shall be reduced to the New Issuance Price, provided, however, that under no circumstances shall the New Issuance Price be less than $9.75 or reduced to a price level that would be in breach of the listing rules of any stock exchange | ||||||||||||||||||
Beneficial Ownership Limitation, Percentage | 4.99% | ||||||||||||||||||
Preferred Shareholders, Receivable, Upon Any Liquidation, Description | an amount equal to $2,055,000 times 1.2, plus all declared but unpaid dividends | ||||||||||||||||||
Warrants Exercise Price | $18.75 | $7.50 | $6 | $7.50 | $13.50 | ||||||||||||||
Request To Issue Common Stock, Shares, To Group Of Partnership And Individuals During Period | 66,585 | ||||||||||||||||||
Cashless Exercise Of Stock Purchase Warrants, Total | 82,459 | ||||||||||||||||||
Common Stock, Shares, Outstanding, Requested To Issue To Group Of Partnership And Individuals | 16,867 | 16,867 | |||||||||||||||||
Advertising Expense | 4,201 | 0 | 11,994 | 0 | |||||||||||||||
Stockholders' Equity, Reverse Stock Split | Under theterms of the Company's agreement with investors in the October 2008 financing, 25,600 shares of common stock were the maximum number of shares allocated to the Company's existing shareholders at the time of the offering (also referred to as the original shareholders or the Founders). Since the total of the Company's fully diluted shares of common stock was greater than 25,600 shares, in order for the Company to proceed with the offering, the Board of Directors approved a reverse stock split of 1-for-1.2545. After this split was approved, additional options and warrants were identified, requiring a second reverse stock split in order to reach the 25,600 shares. The second reverse stock split on the reduced 1-for-1.2545 balance was determined to be 1-for-1.33176963. Taken together, if only one reverse stock split was performed, the number would have been a reverse stock split of 1-for-1.670705. On June 6, 2008, the Board of Directors approved the first reverse stock split. The authorized number of shares of common stock of 266,667 was proportionately divided by 1.2545 to arrive at 212,569. On October 20, 2008, the Board of Directors (i) approved the second reverse stock split pursuant to which the authorized number of shares of common stock of 212,569 was proportionately divided by 1.33177 to arrive at 159,614 shares and (ii) approved a resolution to increase the number of authorized shares of the Company's common stock from 159,614 to 533,334, which was approved by the Companys shareholders holding a majority of the shares entitled to vote thereon at a special meeting of shareholders held on December 3, 2008. | ||||||||||||||||||
Minimum [Member] | |||||||||||||||||||
Summary Of Significant Accounting Policy [Line Items] | |||||||||||||||||||
Warrants Exercise Price | $11.25 | ||||||||||||||||||
Maximum [Member] | |||||||||||||||||||
Summary Of Significant Accounting Policy [Line Items] | |||||||||||||||||||
Warrants Exercise Price | $34.50 | ||||||||||||||||||
Computers and office equipment [Member] | Minimum [Member] | |||||||||||||||||||
Summary Of Significant Accounting Policy [Line Items] | |||||||||||||||||||
Property, Plant and Equipment, Useful Life | 3 years | 3 years | |||||||||||||||||
Computers and office equipment [Member] | Maximum [Member] | |||||||||||||||||||
Summary Of Significant Accounting Policy [Line Items] | |||||||||||||||||||
Property, Plant and Equipment, Useful Life | 7 years | 7 years | |||||||||||||||||
Leasehold Improvements [Member] | |||||||||||||||||||
Summary Of Significant Accounting Policy [Line Items] | |||||||||||||||||||
Property, Plant and Equipment, Useful Life | 5 years | 5 years | |||||||||||||||||
Manufacturing Tooling [Member] | Minimum [Member] | |||||||||||||||||||
Summary Of Significant Accounting Policy [Line Items] | |||||||||||||||||||
Property, Plant and Equipment, Useful Life | 3 years | 3 years | |||||||||||||||||
Manufacturing Tooling [Member] | Maximum [Member] | |||||||||||||||||||
Summary Of Significant Accounting Policy [Line Items] | |||||||||||||||||||
Property, Plant and Equipment, Useful Life | 7 years | 7 years | |||||||||||||||||
Samuel Herschkowitz [Member] | |||||||||||||||||||
Summary Of Significant Accounting Policy [Line Items] | |||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 100,000 | ||||||||||||||||||
Series A Convertible Preferred Stock [Member] | |||||||||||||||||||
Summary Of Significant Accounting Policy [Line Items] | |||||||||||||||||||
Stock Issued During Period, Value, New Issues | 2,055,000 | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 20,550 | ||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $0.01 | ||||||||||||||||||
Subsequent Event [Member] | |||||||||||||||||||
Summary Of Significant Accounting Policy [Line Items] | |||||||||||||||||||
Warrants Issued To Purchase Common Stock | 21,334 | ||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $0.01 | $0.01 | |||||||||||||||||
Exercisable Price Of Warrants | $24.38 | ||||||||||||||||||
Warrants Expiration | five years | ||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | 2,055,000 | ||||||||||||||||||
Percentage Of Additional Warrants Issued To Purchase Common Stock | 30.00% | ||||||||||||||||||
Convertible Preferred Stock, Terms of Conversion | Preferred Shares are convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value of the Preferred Shares being converted by the conversion price of $19.50, subject to adjustment for stock splits, reverse stock splits and similar recapitalization events. If the Company issues additional shares of Common Stock, other than certain stock that is excluded under the terms of the Securities Purchase Agreement, in one or more capital raising transactions with an aggregate purchase price of at least $100,000 for a price less than the then existing conversion price for the Preferred Shares (the New Issuance Price), then the then existing conversion price shall be reduced to the New Issuance Price, provided, however, that under no circumstances shall the New Issuance Price be less than $9.75 or reduced to a price level that would be in breach of the listing rules of any stock exchange | ||||||||||||||||||
Beneficial Ownership Limitation, Percentage | 4.99% | ||||||||||||||||||
Preferred Shareholders, Receivable, Upon Any Liquidation, Description | an amount equal to $2,055,000 times 1.2, plus all declared but unpaid dividends | ||||||||||||||||||
Warrants Exercise Price | $19.50 | ||||||||||||||||||
Exercise Price Of Warrants To Purchase Shares Of Common Stock Equal To Offering Price Per Share Percentage | 125.00% | ||||||||||||||||||
Stockholders' Equity, Reverse Stock Split | The Company filed a Certificate of Amendment effecting a 1:75 reverse stock split (the “Reverse Stock Split”) with the Secretary of State of the State of Delaware, which became effective under Delaware law as of October 24, 2014. At the effective time (the “Effective Time”) of the Reverse Stock Split, the issued and outstanding Common Stock of the Company was combined on a 1-for-75 basis such that every seventy-five shares of Common Stock outstanding immediately prior to the Effective Time was combined into one share of Common Stock. | ||||||||||||||||||
Subsequent Event [Member] | Series A Convertible Preferred Stock [Member] | |||||||||||||||||||
Summary Of Significant Accounting Policy [Line Items] | |||||||||||||||||||
Stock Issued During Period, Value, New Issues | $2,055,000 | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 20,550 | ||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $0.01 | $0.01 | |||||||||||||||||
Preferred Stock Conversion Price, Per Share | $19.50 |
DEVELOPMENT_STAGE_OPERATIONS_D
DEVELOPMENT STAGE OPERATIONS (Details Textual) (USD $) | 1 Months Ended | 140 Months Ended | 150 Months Ended | |||||
Nov. 30, 2012 | Jan. 31, 2011 | Dec. 31, 2010 | Sep. 30, 2010 | Jun. 30, 2010 | Oct. 31, 2009 | Dec. 31, 2013 | Nov. 03, 2014 | |
Development stage operation [Line Items] | ||||||||
Common Stock, Shares, Issued | 2,932,501 | 3,021,831 | ||||||
Equity Issuance Per Share Amount | $7.50 | $15 | $6.30 | $13.50 | $34.50 | $48.75 | $125.25 | |
Post Reverse Stock Split [Member] | ||||||||
Development stage operation [Line Items] | ||||||||
Equity Issuance Per Share Amount | $125 |
STOCKHOLDERS_DEFICIT_STOCK_OPT2
STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Details) (USD $) | 1 Months Ended | 9 Months Ended | 12 Months Ended | |||||||
Mar. 31, 2014 | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2007 | Dec. 31, 2006 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Exercised - Number of shares | -4,444 | |||||||||
Exercised - Average Exercise Price | $11.25 | |||||||||
Equity Option [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Outstanding Number Of Shares | 385,733 | 168,856 | 77,301 | 46,642 | 19,948 | 17,215 | 638 | 558 | 239 | |
Issued - Number of Shares | 71,838 | 239,816 | 126,866 | 33,111 | 29,467 | 2,733 | 16,577 | 80 | 319 | |
Expired - Number of Shares | -6,746 | -15,467 | -29,805 | -1,119 | -2,773 | |||||
Exercised - Number of shares | -4,936 | -7,472 | -5,506 | -1,333 | ||||||
Outstanding Number Of Shares | 445,889 | 385,733 | 168,856 | 77,301 | 46,642 | 19,948 | 17,215 | 638 | 558 | |
Outstanding - Average Exercise Price | $6.75 | $6.75 | $8.25 | $14.25 | $20.25 | $19.50 | $125.25 | $125.25 | $125.25 | |
Issued - Average Exercise Price | $8.11 | $6.75 | $6 | $0.75 | $12.75 | $27.75 | $15 | $125.25 | $125.25 | |
Expired - Average Exercise Price | $25.65 | $18 | $8.25 | $54.75 | $32.25 | |||||
Exercised - Average Exercise Price | $1.76 | $0.75 | $0.75 | $0.75 | ||||||
Outstanding - Average Exercise Price | $7.58 | $6.75 | $6.75 | $8.25 | $14.25 | $20.25 | $19.50 | $125.25 | $125.25 | |
Warrant [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Outstanding Number Of Shares | 461,920 | 468,431 | 358,429 | 142,278 | 98,303 | 69,126 | 1,617 | 1,237 | 279 | |
Issued - Number of Shares | 155,818 | 343,196 | 155,846 | 242,963 | 45,809 | 29,177 | 67,669 | 380 | 958 | |
Expired - Number of Shares | -77,685 | -111,025 | -44,886 | -26,812 | -120 | -160 | ||||
Exercised - Number of shares | -40,722 | -238,682 | -958 | -1,714 | ||||||
Outstanding Number Of Shares | 499,331 | 461,920 | 468,431 | 358,429 | 142,278 | 98,303 | 69,126 | 1,617 | 1,237 | |
Outstanding - Average Exercise Price | $10.50 | $9.75 | $17.25 | $33 | $36.75 | $33.75 | $78 | $93.75 | $196.50 | |
Issued - Average Exercise Price | $3.74 | $9 | $11.25 | $10.50 | $25.50 | $48.75 | $33.75 | $26.25 | $63.75 | |
Expired - Average Exercise Price | $9.88 | $13.50 | $37.50 | $36 | $125.25 | $282 | ||||
Exercised - Average Exercise Price | $8.38 | $8.25 | $0.75 | $34.50 | ||||||
Outstanding - Average Exercise Price | $8.60 | $10.50 | $9.75 | $17.25 | $33 | $36.75 | $33.75 | $78 | $93.75 |
STOCKHOLDERS_DEFICIT_STOCK_OPT3
STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Details 1) (USD $) | 12 Months Ended | 9 Months Ended | ||||||||
Dec. 31, 2013 | Dec. 31, 2009 | Sep. 30, 2014 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2008 | Dec. 31, 2007 | Dec. 31, 2006 | Dec. 31, 2005 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Weighted Average Remaining Life | 6 months | 2 years 6 months | ||||||||
Stock Options One [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 0.75 | $0.75 | ||||||||
Shares | 7,334 | 7,333 | ||||||||
Weighted Average Remaining Life | 7 years 6 months 7 days | 6 years 9 months 7 days | ||||||||
Stock Options Two [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 1.28 | $4.88 | ||||||||
Shares | 4,336 | 134 | ||||||||
Weighted Average Remaining Life | 4 years 5 months 5 days | 8 years 5 months 12 days | ||||||||
Stock Options Three [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 4.88 | $5.25 | ||||||||
Shares | 134 | 2,031 | ||||||||
Weighted Average Remaining Life | 9 years 2 months 12 days | 7 years 11 months 8 days | ||||||||
Stock Options Four [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 5.25 | $5.63 | ||||||||
Shares | 2,631 | 192,000 | ||||||||
Weighted Average Remaining Life | 9 years 5 months 8 days | 8 years 5 months 16 days | ||||||||
Stock Options Five [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 5.63 | $5.93 | ||||||||
Shares | 192,000 | 23,206 | ||||||||
Weighted Average Remaining Life | 9 years 2 months 16 days | 8 years 5 months 19 days | ||||||||
Stock Options Six [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 5.93 | $6 | ||||||||
Shares | 23,207 | 123,998 | ||||||||
Weighted Average Remaining Life | 9 years 2 months 19 days | 7 years 10 months 17 days | ||||||||
Stock Options Seven [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 6 | $6.60 | ||||||||
Shares | 124,000 | 5,332 | ||||||||
Weighted Average Remaining Life | 8 years 7 months 17 days | 7 years 3 months 25 days | ||||||||
Stock Options Eight [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 66 | $8.25 | ||||||||
Shares | 5,334 | 3,636 | ||||||||
Weighted Average Remaining Life | 8 years 25 days | 10 years | ||||||||
Stock Options Nine [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 9.94 | $9.94 | ||||||||
Shares | 3,019 | 3,019 | ||||||||
Weighted Average Remaining Life | 9 years 6 months 14 days | 8 years 9 months 14 days | ||||||||
Stock Option Ten [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 10.5 | $10.50 | ||||||||
Shares | 3,239 | 3,238 | ||||||||
Weighted Average Remaining Life | 9 years 6 months 14 days | 8 years 9 months 14 days | ||||||||
Stock Option Eleven [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 11.25 | $11.25 | ||||||||
Shares | 9,023 | 14,799 | ||||||||
Weighted Average Remaining Life | 7 years 1 month 28 days | 7 years 8 months 19 days | ||||||||
Stock Option Twelve [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 12.75 | $12.75 | ||||||||
Shares | 67 | 10,069 | ||||||||
Weighted Average Remaining Life | 9 years 4 months 10 days | 9 years 6 months 14 days | ||||||||
Stock Options Thirteen [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 20.25 | $13.88 | ||||||||
Shares | 4,939 | 2,160 | ||||||||
Weighted Average Remaining Life | 10 years | 9 years 6 months 4 days | ||||||||
Stock Options Fourteen [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 21.75 | $15 | ||||||||
Shares | 1,334 | 3,334 | ||||||||
Weighted Average Remaining Life | 9 years 9 months 7 days | 9 years 5 months 19 days | ||||||||
Stock Options Fifteen [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 23.85 | $17.25 | ||||||||
Shares | 1,258 | 40,261 | ||||||||
Weighted Average Remaining Life | 9 years 9 months | 9 years 5 months 8 days | ||||||||
Stock Options Sixteen [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 24.75 | $18.75 | ||||||||
Shares | 1,334 | 3,335 | ||||||||
Weighted Average Remaining Life | 9 years 8 months 23 days | 9 years 4 months 24 days | ||||||||
Stock Options Seventeen [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 25.61 | $20.25 | ||||||||
Shares | 267 | 4,940 | ||||||||
Weighted Average Remaining Life | 9 years 9 months | 9 years 3 months 4 days | ||||||||
Stock Options Eighteen [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 26.25 | $21.75 | ||||||||
Shares | 1,000 | 1,336 | ||||||||
Weighted Average Remaining Life | 4 months 13 days | 9 years 7 days | ||||||||
Stock Options Nineteen [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 43.88 | $23.85 | ||||||||
Shares | 1,277 | 1,260 | ||||||||
Weighted Average Remaining Life | 5 months 8 days | 9 years 4 days | ||||||||
Equity Option [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 6.75 | 20.25 | $7.58 | $6.75 | $8.25 | $14.25 | $19.50 | $125.25 | $125.25 | $125.25 |
Shares | 385,733 | 19,948 | 445,889 | 168,856 | 77,301 | 46,642 | 17,215 | 638 | 558 | 239 |
Stock Options Twenty [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | $24.75 | |||||||||
Shares | 334 | |||||||||
Weighted Average Remaining Life | 8 years 11 months 26 days | |||||||||
Stock Option Twenty One [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | $25.61 | |||||||||
Shares | 134 | |||||||||
Weighted Average Remaining Life | 8 years 11 months 26 days | |||||||||
Warrant One [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 0.75 | $0.75 | ||||||||
Shares | 2,667 | 400 | ||||||||
Weighted Average Remaining Life | 1 year 11 months 8 days | 1 year 2 months 8 days | ||||||||
Warrant Two [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 5.63 | $6 | ||||||||
Shares | 35,556 | 102,857 | ||||||||
Weighted Average Remaining Life | 10 months 6 days | 3 years 5 months 12 days | ||||||||
Warrant Three [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 6 | $9 | ||||||||
Shares | 102,857 | 2,666 | ||||||||
Weighted Average Remaining Life | 4 years 2 months 12 days | 3 years 3 months 25 days | ||||||||
Warrant Four [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 7.5 | $11.25 | ||||||||
Shares | 19,047 | 204,200 | ||||||||
Weighted Average Remaining Life | 3 months 29 days | 3 years 3 months 7 days | ||||||||
Warrant Five [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 9 | $12.38 | ||||||||
Shares | 2,667 | 71,257 | ||||||||
Weighted Average Remaining Life | 4 years 10 months 24 days | 3 years 6 months 11 days | ||||||||
Warrant Six [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 11.25 | $13.50 | ||||||||
Shares | 221,977 | 4,444 | ||||||||
Weighted Average Remaining Life | 3 years 11 months 23 days | 3 years 8 months 19 days | ||||||||
Warrant Seven [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 12 | $14.85 | ||||||||
Shares | 2,000 | 23,612 | ||||||||
Weighted Average Remaining Life | 4 months 17 days | 3 years 7 months 28 days | ||||||||
Warrant Eight [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 12.75 | $15 | ||||||||
Shares | 17,255 | 1,168 | ||||||||
Weighted Average Remaining Life | 3 months 7 days | 4 months 2 days | ||||||||
Warrant Nine [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 13.5 | $18.75 | ||||||||
Shares | 7,112 | 4,166 | ||||||||
Weighted Average Remaining Life | 2 years 9 months 29 days | 11 days | ||||||||
Warrant Ten [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 14.85 | $20.25 | ||||||||
Shares | 23,611 | 1,481 | ||||||||
Weighted Average Remaining Life | 4 years 4 months 28 days | 3 years 11 days | ||||||||
Warrant Eleven [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 1,500 | $24.38 | ||||||||
Shares | 16,500 | 83,080 | ||||||||
Weighted Average Remaining Life | 2 months 5 days | 4 years 10 months 10 days | ||||||||
Warrant Twelve [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 18.75 | |||||||||
Shares | 5,000 | |||||||||
Weighted Average Remaining Life | 9 months 7 days | |||||||||
Warrant Thirteen [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 34.5 | |||||||||
Shares | 1,110 | |||||||||
Weighted Average Remaining Life | 3 months 18 days | |||||||||
Warrant Fourteen [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 57.68 | |||||||||
Shares | 4,561 | |||||||||
Weighted Average Remaining Life | 6 months | |||||||||
Warrant [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Range of Exercise Prices | 10.5 | 36.75 | $8.60 | $9.75 | $17.25 | $33 | $33.75 | $78 | $93.75 | $196.50 |
Shares | 461,920 | 98,303 | 499,331 | 468,431 | 358,429 | 142,278 | 69,126 | 1,617 | 1,237 | 279 |
STOCKHOLDERS_DEFICIT_STOCK_OPT4
STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Details 2) (USD $) | 9 Months Ended | 12 Months Ended | ||||||||
Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2007 | Dec. 31, 2006 | Dec. 31, 2005 | |
Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $3.21 | $8.93 | $7.65 | |||||||
Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $13.91 | $18.15 | $25.20 | |||||||
Warrant One [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 400 | 4,561 | ||||||||
Shares | 400 | 2,667 | ||||||||
Issued - Average Exercise Price | $0.75 | |||||||||
Warrant One [Member] | Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $34.50 | |||||||||
Warrant One [Member] | Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $57.68 | |||||||||
Warrant Two [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 4,166 | 1,110 | ||||||||
Shares | 102,857 | 35,556 | ||||||||
Issued - Average Exercise Price | $18.75 | $34.50 | ||||||||
Warrant Three [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 71,368 | 2,667 | ||||||||
Shares | 2,666 | 102,857 | ||||||||
Issued - Average Exercise Price | $0.75 | |||||||||
Warrant Three [Member] | Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $11.25 | |||||||||
Warrant Three [Member] | Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $15 | |||||||||
Warrant Four [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 267,579 | 114,635 | ||||||||
Shares | 204,200 | 19,047 | ||||||||
Warrant Four [Member] | Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $6 | $5.63 | ||||||||
Warrant Four [Member] | Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $14.85 | $18.75 | ||||||||
Warrant Five [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 155,818 | 71,367 | ||||||||
Shares | 71,257 | 2,667 | ||||||||
Warrant Five [Member] | Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $12.38 | $11.25 | ||||||||
Warrant Five [Member] | Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $24.38 | $15 | ||||||||
Warrant Six [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 267,580 | |||||||||
Shares | 4,444 | 221,977 | ||||||||
Warrant Six [Member] | Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $0.75 | $6 | ||||||||
Warrant Six [Member] | Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $24.38 | $14.85 | ||||||||
Warrant Seven [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Shares | 23,612 | 2,000 | ||||||||
Warrant [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 155,818 | 343,196 | 155,846 | 242,963 | 45,809 | 29,177 | 67,669 | 380 | 958 | |
Shares | 499,331 | 461,920 | 468,431 | 358,429 | 142,278 | 98,303 | 69,126 | 1,617 | 1,237 | 279 |
Issued - Average Exercise Price | $3.74 | $9 | $11.25 | $10.50 | $25.50 | $48.75 | $33.75 | $26.25 | $63.75 | |
Warrant [Member] | Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $0.75 | |||||||||
Warrant [Member] | Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $57.68 | |||||||||
Stock Options One [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 5,466 | 5,613 | ||||||||
Shares | 7,333 | 7,334 | ||||||||
Issued - Average Exercise Price | $11.25 | |||||||||
Stock Options One [Member] | Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $1.28 | |||||||||
Stock Options One [Member] | Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $43.88 | |||||||||
Stock Options Two [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 7,333 | 1,000 | ||||||||
Shares | 134 | 4,336 | ||||||||
Issued - Average Exercise Price | $0.75 | $26.25 | ||||||||
Stock Options Three [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 126,029 | 5,467 | ||||||||
Shares | 2,031 | 134 | ||||||||
Issued - Average Exercise Price | $11.25 | |||||||||
Stock Options Three [Member] | Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $5.25 | |||||||||
Stock Options Three [Member] | Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $6 | |||||||||
Stock Options Four [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 238,556 | 7,334 | ||||||||
Shares | 192,000 | 2,631 | ||||||||
Issued - Average Exercise Price | $0.75 | |||||||||
Stock Options Four [Member] | Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $4.88 | |||||||||
Stock Options Four [Member] | Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $25.61 | |||||||||
Stock Options Five [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 68,505 | 126,636 | ||||||||
Shares | 23,206 | 192,000 | ||||||||
Stock Options Five [Member] | Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $8.25 | $5.25 | ||||||||
Stock Options Five [Member] | Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $18.75 | $6 | ||||||||
Stock Options Six [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 239,683 | |||||||||
Shares | 123,998 | 23,207 | ||||||||
Stock Options Six [Member] | Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $0.75 | $4.88 | ||||||||
Stock Options Six [Member] | Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $25.61 | $25.61 | ||||||||
Stock Options Seven [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Shares | 5,332 | 124,000 | ||||||||
Equity Option [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Number of Shares | 71,838 | 239,816 | 126,866 | 33,111 | 29,467 | 2,733 | 16,577 | 80 | 319 | |
Shares | 445,889 | 385,733 | 168,856 | 77,301 | 46,642 | 19,948 | 17,215 | 638 | 558 | 239 |
Issued - Average Exercise Price | $8.11 | $6.75 | $6 | $0.75 | $12.75 | $27.75 | $15 | $125.25 | $125.25 | |
Equity Option [Member] | Minimum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $0.75 | |||||||||
Equity Option [Member] | Maximum [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||
Issued - Average Exercise Price | $43.88 |
STOCKHOLDERS_DEFICIT_STOCK_OPT5
STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Details Textual) (USD $) | 1 Months Ended | 0 Months Ended | 1 Months Ended | 2 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | 140 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||||||
Jul. 23, 2014 | Jun. 30, 2014 | Feb. 28, 2014 | Mar. 15, 2013 | Mar. 31, 2014 | Oct. 31, 2013 | 31-May-13 | Apr. 30, 2013 | Jan. 31, 2013 | Nov. 30, 2012 | Mar. 31, 2012 | Jan. 31, 2011 | Dec. 31, 2010 | Sep. 30, 2010 | Jun. 30, 2010 | Oct. 31, 2009 | Jul. 31, 2007 | Mar. 31, 2007 | Sep. 30, 2014 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Jun. 30, 2013 | Dec. 31, 2002 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2009 | Dec. 31, 2008 | Dec. 31, 2013 | Jul. 31, 2014 | Jan. 31, 2014 | Sep. 30, 2014 | Dec. 31, 2011 | Dec. 31, 2010 | Dec. 31, 2007 | Dec. 31, 2006 | Aug. 31, 2014 | Aug. 04, 2014 | Feb. 04, 2014 | Sep. 11, 2013 | Jan. 15, 2013 | Mar. 28, 2012 | Sep. 07, 2011 | Jun. 22, 2010 | Sep. 10, 2013 | Apr. 15, 2013 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Weighted Average Remaining Life | 6 months | 2 years 6 months | |||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | 0.13% | 0.13% | 2.00% | ||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | 2.97% | 2.97% | 4.50% | ||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | 59.00% | 53.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | 66.00% | 66.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Issuance Of Warrants | $100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Volatility Description | The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. | ||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt discount | 33,469 | 47,908 | 7,232 | 15,553 | 96,613 | 30,150 | 92,700 | 40,242 | 275,640 | 87,853 | 413,695 | 413,695 | 57,518 | 756,497 | |||||||||||||||||||||||||||||||||||
Debt Instrument Convertible Remaining Discount Amortization Period 1 | 24 months | 24 months | 18 months | 22 months | 24 months | 5 years | |||||||||||||||||||||||||||||||||||||||||||
Convertible Bridge Debt, Issuance Of Warrants | 170,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | 30-Apr-08 | ||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Debt | 50,000 | 16,800 | 32,000 | 200,000 | 100,000 | ||||||||||||||||||||||||||||||||||||||||||||
Warrants Issued During Period, Shares, In Connection With Convertible Debt | 21,270 | 2,667 | 4,267 | 14,815 | 2,667 | ||||||||||||||||||||||||||||||||||||||||||||
Equity Issuance Per Share Amount | $7.50 | $15 | $6.30 | $13.50 | $34.50 | $48.75 | $125.25 | ||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 59.00% | 54.00% | 63.00% | ||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 427,051 | 427,051 | 368,783 | 368,783 | 427,051 | ||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $7.26 | $7.26 | $6.38 | $6.38 | 7.26 | ||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Remaining Contractual Term 1 | 8 years 2 months 26 days | 8 years 9 months 18 days | |||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Expense | 440,117 | 3,791,802 | 3,700,070 | 830,372 | |||||||||||||||||||||||||||||||||||||||||||||
Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Stock Options | 262,055 | 262,055 | 166,905 | 166,905 | 262,055 | ||||||||||||||||||||||||||||||||||||||||||||
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1 | 18 months | 22 months | |||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity, Reverse Stock Split | Under theterms of the Company's agreement with investors in the October 2008 financing, 25,600 shares of common stock were the maximum number of shares allocated to the Company's existing shareholders at the time of the offering (also referred to as the original shareholders or the Founders). Since the total of the Company's fully diluted shares of common stock was greater than 25,600 shares, in order for the Company to proceed with the offering, the Board of Directors approved a reverse stock split of 1-for-1.2545. After this split was approved, additional options and warrants were identified, requiring a second reverse stock split in order to reach the 25,600 shares. The second reverse stock split on the reduced 1-for-1.2545 balance was determined to be 1-for-1.33176963. Taken together, if only one reverse stock split was performed, the number would have been a reverse stock split of 1-for-1.670705. On June 6, 2008, the Board of Directors approved the first reverse stock split. The authorized number of shares of common stock of 266,667 was proportionately divided by 1.2545 to arrive at 212,569. On October 20, 2008, the Board of Directors (i) approved the second reverse stock split pursuant to which the authorized number of shares of common stock of 212,569 was proportionately divided by 1.33177 to arrive at 159,614 shares and (ii) approved a resolution to increase the number of authorized shares of the Company's common stock from 159,614 to 533,334, which was approved by the Companys shareholders holding a majority of the shares entitled to vote thereon at a special meeting of shareholders held on December 3, 2008. | ||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares authorized | 10,666,667 | 10,666,667 | 10,666,667 | 10,666,667 | 10,666,667 | 10,666,667 | 4,000,000 | 2,666,667 | 1,066,667 | ||||||||||||||||||||||||||||||||||||||||
Convertible Note Conversion Price | $9 | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 156,243 | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Converted Into Common Stock | 14,882 | 33,334 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $7.50 | $9 | $1.05 | $4.88 | |||||||||||||||||||||||||||||||||||||||||||||
Accumulated discounts on current portion of convertible debt (in dollars) | 77,644 | 0 | 21,138 | 0 | |||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Effective Interest Rate | 24.00% | 24.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Shares issued under PPM to five investors at $.07 per share (in shares) | 95,239 | 95,239 | |||||||||||||||||||||||||||||||||||||||||||||||
Shares issued under PPM to five investors | $5.25 | $5.25 | $5.25 | ||||||||||||||||||||||||||||||||||||||||||||||
Common stock, par value (in dollars per share) | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0.01 | |||||||||||||||||||||||||||||||||||||||||
Warrants Exercise Price | $6 | $18.75 | $7.50 | $7.50 | $13.50 | ||||||||||||||||||||||||||||||||||||||||||||
Shares issued under PPM to five investors at $.07 per share | 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants Issued To Purchase Common Stock | 5,926 | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument Interest | 11,169 | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 4,763 | 13,889 | |||||||||||||||||||||||||||||||||||||||||||||||
CommonStocksharesIssuedToConsultantExercisingOptions | 2,667 | 2,667 | |||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued to former CEO exercising option, par value | $0.75 | $0.75 | |||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued to former consultant exercising option, Par value | $0.01 | $0.75 | |||||||||||||||||||||||||||||||||||||||||||||||
Common stock shares issued to CEO exercising options. | 4,445 | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Issued To Twenty Four Warrant Holders | 1,044,490 | 1,044,490 | |||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Issued To Twenty Four Warrant Holders | 139,266 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of net exercise provision shares | 87,118 | ||||||||||||||||||||||||||||||||||||||||||||||||
Share Based Compensation Arrangement By Share Based Payment Award Warrant Vested And Expected To Vest Exercisable Number | 461,920 | 461,920 | |||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued To One Warrant Holder Exercised At Reduced Par Value | $9.38 | $9.38 | |||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period Value Issued To One Warrant Holders | 125,000 | 125,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period Shares Issued To One Warrant Holders | 13,334 | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 4,831 | 1,482 | 37,440 | 37,440 | 28,986 | 37,440 | 61,539 | 61,539 | 21,538 | ||||||||||||||||||||||||||||||||||||||||
Preferred Stock Conversion Price, Per Share | $19.50 | ||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $12.38 | $24.38 | $24.38 | $24.38 | $12.38 | 24.38 | $24.38 | ||||||||||||||||||||||||||||||||||||||||||
Percentage Of Additional Warrants Issued To Purchase Common Stock | 30.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Preferred Stock, Terms of Conversion | Preferred Shares are convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value of the Preferred Shares being converted by the conversion price of $19.50, subject to adjustment for stock splits, reverse stock splits and similar recapitalization events. If the Company issues additional shares of Common Stock, other than certain stock that is excluded under the terms of the Securities Purchase Agreement, in one or more capital raising transactions with an aggregate purchase price of at least $100,000 for a price less than the then existing conversion price for the Preferred Shares (the New Issuance Price), then the then existing conversion price shall be reduced to the New Issuance Price, provided, however, that under no circumstances shall the New Issuance Price be less than $9.75 or reduced to a price level that would be in breach of the listing rules of any stock exchange | ||||||||||||||||||||||||||||||||||||||||||||||||
Beneficial Ownership Limitation, Percentage | 4.99% | ||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Shareholders, Receivable, Upon Any Liquidation, Description | an amount equal to $2,055,000 times 1.2, plus all declared but unpaid dividends | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants Expiration | five years | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 20,623 | ||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period | 4,444 | ||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $11.25 | ||||||||||||||||||||||||||||||||||||||||||||||||
Cashless Exercise Of Common Stock Warrants Total | 15,442 | ||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 6.00% | 6.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Conversion Of Stock Price Per Share | $19.50 | $19.50 | |||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion Of Convertible Securities | 1,561 | 970 | |||||||||||||||||||||||||||||||||||||||||||||||
Cashless Exercise Of Common Stock Shares Issued | $3,725 | $3,333 | |||||||||||||||||||||||||||||||||||||||||||||||
Percentage Of Reduction To Warrant Agreement | 11.00% | 11.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 1.37% | ||||||||||||||||||||||||||||||||||||||||||||||||
SOK Partners, LLC, [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 5,431 | ||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $12.38 | ||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement Terms | (i) a senior convertible note, in an original principal amount of $122,196 (the SOK Note), which SOK Note shall be convertible into a certain amount of shares (the SOK Conversion Shares) of Common Stock, in accordance with the terms of the SOK Note, and (ii) a warrant (the SOK Warrant) to initially acquire up to 5,431 additional shares of Common Stock (the SOK Warrant Shares, and collectively with the SOK Note, the SOK Warrant and the SOK Conversion Shares, the SOK Securities) for an aggregate purchase price of $100,000 (with the reduced principal amount as described below representing an approximately 8.7% original issue discount) (the SOK Convertible Notes Offering). | ||||||||||||||||||||||||||||||||||||||||||||||||
Percentage Of Reduction To Warrant Agreement | 11.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
CEO [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 52 | ||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period | 4,336 | ||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $1.25 | ||||||||||||||||||||||||||||||||||||||||||||||||
Dr Samuel Herschowitz [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $20.25 | ||||||||||||||||||||||||||||||||||||||||||||||||
Purchasers [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,561 | 1,561 | 1,561 | ||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 6.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Converted Into Common Stock | 33,334 | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $11.25 | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Effective Interest Rate | 8.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement 2 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Conversion Price | $13.50 | ||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 1,000,000 | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Converted Into Common Stock | 80,000 | 61,482 | |||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Effective Interest Rate | 8.00% | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants Exercise Price | $14.85 | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Issued - Average Exercise Price | $3.74 | $9 | $11.25 | 48.75 | 33.75 | $10.50 | $25.50 | $26.25 | $63.75 | ||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 21,334 | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 71,257 | ||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period | 40,722 | 238,682 | 958 | 1,714 | |||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $8.38 | $8.25 | $0.75 | $34.50 | |||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Private Placement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued under PPM to five investors at $.07 per share (in shares) | 95,239 | 95,239 | |||||||||||||||||||||||||||||||||||||||||||||||
Warrants Exercise Price | $11.25 | $11.25 | |||||||||||||||||||||||||||||||||||||||||||||||
Shares issued under PPM to five investors at $.07 per share | 500,000 | 500,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Series A Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 20,550 | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | 2,055,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||
Securities Purchase Agreement Terms | (i) the Qualified Public Offering closes within six (6) months of the first closing of the convertible notes offering (Qualified Public Offering Deadline) and (ii) 70% of the public offering price per share of the Common Stock in the Qualified Public Offering (the QPO Discount Price) is less than the Conversion Price floor contained in Section 7(e)(i) of the Certificate of Designation (the Conversion Price Floor), or (B) if a Qualified Public Offering has not been consummated by the Qualified Public Offering Deadline, upon the Preferred Stockholders conversion of their shares of Preferred Stock to the extent that 70% of the volume weighted average price of the Common Stock on the principal Trading Market (as defined in the Certificate of Designation) of the Common Stock during the ten Trading Days (as defined in the Certificate of Designation) immediately preceding the Qualified Public Offering Deadline (the Non-QPO Discount Price) is less than the Conversion Price Floor | ||||||||||||||||||||||||||||||||||||||||||||||||
Sale of Stock, Price Per Share | $9.75 | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock Incentive Plan 2012 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares authorized | 1,333,334 | 666,667 | |||||||||||||||||||||||||||||||||||||||||||||||
Shares Grants Increase For Threshold | 266,667 | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Debt | 27,500 | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Debt | 27,500 | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Three [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Debt | 51,243 | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Note Four [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Debt | $50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock Options and Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Weighted Average Remaining Life | 5 years | 3 years | |||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | 0.78% | 0.33% | 0.34% | ||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | 2.04% | 1.80% | 2.44% | ||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% | ||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | 54.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | 66.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 54.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 2.75% | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock Options and Warrants One [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Weighted Average Remaining Life | 5 years | 10 years | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 59.00% | 59.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Stock Options and Warrants Two [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Weighted Average Remaining Life | 10 years | 10 years | |||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 66.00% | 66.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Weighted Average Remaining Life | 2 years | 2 years 6 months | |||||||||||||||||||||||||||||||||||||||||||||||
Issued - Average Exercise Price | $3.21 | $8.93 | 7.65 | ||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares authorized | 4,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants Exercise Price | $11.25 | ||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Issued - Average Exercise Price | $0.75 | ||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | Stock Options and Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Weighted Average Remaining Life | 3 years | ||||||||||||||||||||||||||||||||||||||||||||||||
Issued - Average Exercise Price | $0.83 | $0.95 | |||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 1.44% | ||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Weighted Average Remaining Life | 6 years 6 months | 7 years 6 months | |||||||||||||||||||||||||||||||||||||||||||||||
Issued - Average Exercise Price | $13.91 | $18.15 | 25.2 | ||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares authorized | 10,666,667 | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants Exercise Price | $34.50 | ||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Warrant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Issued - Average Exercise Price | $57.68 | ||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | Stock Options and Warrants [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Weighted Average Remaining Life | 10 years | ||||||||||||||||||||||||||||||||||||||||||||||||
Issued - Average Exercise Price | $7.20 | $25.59 |
SHORTTERM_NOTES_PAYABLE_Detail
SHORT-TERM NOTES PAYABLE (Details Textual) (USD $) | 1 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | 140 Months Ended | 1 Months Ended | |||||||||||
Nov. 30, 2012 | Jan. 31, 2011 | Dec. 31, 2010 | Sep. 30, 2010 | Jun. 30, 2010 | Oct. 31, 2009 | Jul. 31, 2007 | Mar. 31, 2007 | Jun. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Jul. 23, 2014 | Jul. 31, 2014 | Sep. 09, 2014 | |
Short-term Debt [Line Items] | |||||||||||||||||
Amortization Of Debt Discount (Premium) | $33,469 | $47,908 | $7,232 | $15,553 | $96,613 | $30,150 | $92,700 | $40,242 | $275,640 | $87,853 | $413,695 | $413,695 | $57,518 | $756,497 | |||
Debt Conversion, Converted Instrument, Amount | 0 | 415,775 | 415,775 | 100,000 | 515,775 | ||||||||||||
Debt Instrument, Maturity Date | 30-Apr-08 | ||||||||||||||||
SOK Partners, LLC, [Member] | |||||||||||||||||
Short-term Debt [Line Items] | |||||||||||||||||
Securities Purchase Agreement Terms | (i) a senior convertible note, in an original principal amount of $122,196 (the SOK Note), which SOK Note shall be convertible into a certain amount of shares (the SOK Conversion Shares) of Common Stock, in accordance with the terms of the SOK Note, and (ii) a warrant (the SOK Warrant) to initially acquire up to 5,431 additional shares of Common Stock (the SOK Warrant Shares, and collectively with the SOK Note, the SOK Warrant and the SOK Conversion Shares, the SOK Securities) for an aggregate purchase price of $100,000 (with the reduced principal amount as described below representing an approximately 8.7% original issue discount) (the SOK Convertible Notes Offering). | ||||||||||||||||
Notes Payable, Current | 108,696 | ||||||||||||||||
Class of Warrant or Right, Outstanding | 4,831 | ||||||||||||||||
Group, LLC [Member] | |||||||||||||||||
Short-term Debt [Line Items] | |||||||||||||||||
Securities Purchase Agreement Terms | (i) a senior convertible note, in an original principal amount of $610,978 (subsequently reduced to $543,478) (the 31 Group Note), which shall be convertible into a certain amount of shares of Common Stock, in accordance with the terms of the 31 Group Note, (ii) a warrant (the 31 Group Warrant) to initially acquire up to 27,155 additional shares of Common Stock (subsequently reduced to 24,155 shares) (the 31 Group Conversion Shares, and collectively with the 31 Group Note, the 31 Group Warrant and the 31 Group Conversion Shares, the 31 Group Securities) for an aggregate purchase price of $500,000 (representing an approximately 8.7% original issue discount) (the 31 Group Convertible Notes Offering). | ||||||||||||||||
Group, LLC [Member] | Convertible Notes Payable [Member] | |||||||||||||||||
Short-term Debt [Line Items] | |||||||||||||||||
Amortization Of Debt Discount (Premium) | 250,494 | ||||||||||||||||
Debt Conversion, Converted Instrument, Amount | 40,000 | ||||||||||||||||
SOK Note, 31 Group Note And Affiliate Notes [Member] | |||||||||||||||||
Short-term Debt [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate During Period | 12.00% | ||||||||||||||||
Debt Instrument, Maturity Date | 23-Jul-15 | ||||||||||||||||
Affiliates [Member] | |||||||||||||||||
Short-term Debt [Line Items] | |||||||||||||||||
Securities Purchase Agreement Terms | (i) senior convertible notes, in an original aggregate principal amount of $1,069,222 (subsequently reduced to $951,086) (the Affiliate Notes), which Affiliate Notes shall be convertible into a certain amount of shares (the Affiliate Conversion Shares) of the Companys Common Stock in accordance with the terms of the Affiliate Notes, and (ii) warrants (the Affiliate Warrants) to initially acquire up to 48,879 additional shares of Common Stock (subsequently reduced to 42,271 shares) (the Affiliate Warrant Shares, and collectively with the Affiliate Notes, the Affiliate Warrants and the Affiliate Conversion Shares, the Affiliate Securities) for an aggregate purchase price of $875,000 (representing an approximately 8.7% original issue discount) (the Affiliate Convertible Notes Offering). | ||||||||||||||||
Affiliates [Member] | Convertible Notes Payable [Member] | |||||||||||||||||
Short-term Debt [Line Items] | |||||||||||||||||
Amortization Of Debt Discount (Premium) | 103,088 | ||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $40,000 | ||||||||||||||||
Evan Myrianthopoulos [Member] | |||||||||||||||||
Short-term Debt [Line Items] | |||||||||||||||||
Securities Purchase Agreement Terms | (i) a senior convertible note, in an original principal amount of $30,548.90 (subsequently reduced to $27,173.90) (the “Myrianthopoulos Note”), which shall be convertible into a certain amount of shares of Common Stock, in accordance with the terms of the Myrianthopoulos Note, (ii) a warrant (the “Myrianthopoulos Warrant”) to initially acquire up to 1,358 additional shares of Common Stock (subsequently reduced to 1,208 shares) (the “Myrianthopoulos Conversion Shares”, and collectively with the Myrianthopoulos Note, the Myrianthopoulos Warrant and the Myrianthopoulos Conversion Shares, the “Myrianthopoulos Securities”) for an aggregate purchase price of $25,000 (representing an approximately 8.7% original issue discount) (the “Myrianthopoulos Convertible Notes Offering”) |
LOSS_PER_SHARE_Details
LOSS PER SHARE (Details) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | 140 Months Ended | ||||||||||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | ||||||||
Numerator: | ||||||||||||||
Net loss available in basic and diluted calculation | ($1,115,221) | ($3,974,903) | ($4,468,170) | ($7,251,965) | ($9,406,304) | ($7,422,155) | ($28,697,415) | |||||||
Denominator: | ||||||||||||||
Weighted average common shares outstanding-basic (in shares) | 259,899 | 1,821,006 | 2,052,709 | 1,687,625 | 2,026,115 | 927,838 | 996,362 | |||||||
Effect of dilutive stock options and warrants (in shares) | 0 | [1] | 0 | [1] | 0 | [1] | 0 | [1] | 0 | [2] | 0 | [2] | 0 | [2] |
Weighted average common shares outstanding-diluted (in shares) | 2,984,335 | 1,821,006 | 2,967,483 | 1,687,625 | 2,026,115 | 927,838 | 996,362 | |||||||
Loss per common share-basic and diluted (in dollars per share) | ($0.37) | ($2.18) | ($1.51) | ($4.30) | ($4.64) | ($8) | ($28.80) | |||||||
[1] | The number of shares underlying options and warrants outstanding as of September 30, 2014 and September 30, 2013 are 945,220 and 861,287 respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. | |||||||||||||
[2] | The number of shares underlying options and warrants outstanding as of December 31, 2013 and December 31, 2012 are 847,777 and 637,277, respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. |
LOSS_PER_SHARE_Details_Textual
LOSS PER SHARE (Details Textual) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Sep. 30, 2013 | Dec. 31, 2012 |
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] | ||||
Options and Warrants Outstanding | $945,220 | $847,777 | $861,287 | $637,277 |
INCOME_TAXES_Details
INCOME TAXES (Details) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Deferred Tax Asset: | |||
Net Operating Loss | $7,920,000 | $3,259,000 | $2,209,000 |
Other | 631,000 | 59,000 | 73,000 |
Total Deferred Tax Asset | 8,551,000 | 3,318,000 | 2,282,000 |
Less Valuation Allowance | 8,551,000 | 3,318,000 | 2,282,000 |
Net Deferred Income Taxes | $0 | $0 | $0 |
INCOME_TAXES_Details_Textual
INCOME TAXES (Details Textual) (USD $) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2014 | Dec. 31, 2013 | |
Tax Credit Carryforward [Line Items] | ||
Valuation Allowance Percentage | 100.00% | 100.00% |
Operating Loss Carryforwards | $13,969,000 | |
Operating Loss Carryforwards, Expiration Date | 31-Dec-22 | 31-Dec-17 |
Domestic Tax Authority [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Operating Loss Carryforwards | 16,000,000 | |
Operating Loss Carryforwards, Valuation Allowance | 7,100,000 | |
Operating Loss Carry forwards Expiration Period | beginning in 2022 | |
State and Local Jurisdiction [Member] | ||
Tax Credit Carryforward [Line Items] | ||
Operating Loss Carryforwards | 17,100,000 | |
Operating Loss Carryforwards, Valuation Allowance | $1,500,000 | |
Operating Loss Carry forwards Expiration Period | 2022 through 2034 |
LONGTERM_DEBT_Details
LONG-TERM DEBT (Details) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Debt Instrument [Line Items] | ||
Total | $0 | $560,874 |
Less amount due within one year | 0 | 471,574 |
Long-Term Debt | 0 | 89,300 |
Note Payable Issued One [Member] | ||
Debt Instrument [Line Items] | ||
Total | 0 | 100,000 |
Note Payable Issued Two [Member] | ||
Debt Instrument [Line Items] | ||
Total | 0 | 200,000 |
Note Payable Issued Three [Member] | ||
Debt Instrument [Line Items] | ||
Total | 0 | 16,800 |
Note Payable Issued Four [Member] | ||
Debt Instrument [Line Items] | ||
Total | 0 | 32,000 |
Note Payable Issued Five [Member] | ||
Debt Instrument [Line Items] | ||
Total | 0 | 89,300 |
Note Payable Issued Six [Member] | ||
Debt Instrument [Line Items] | ||
Total | $0 | $122,774 |
LONGTERM_DEBT_Details_Textual
LONG-TERM DEBT (Details Textual) (USD $) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||
31-May-13 | Jan. 31, 2013 | Jul. 31, 2007 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | |
Debt Instrument [Line Items] | |||||||||
Debt Instrument, Unamortized Discount | $353,583 | $353,583 | $0 | ||||||
Convertible Notes Converted Into Common Stock | 14,882 | 33,334 | |||||||
Debt Instrument, Maturity Date | 30-Apr-08 | ||||||||
Interest Paid | 21,627 | 14,503 | 43,233 | 56,433 | 55,198 | 31,008 | |||
Repayments Of Notes Payable Due | 450,958 | ||||||||
Repayments Of Notes Payable Due In Year One | 120,000 | ||||||||
Repayments Of Notes Payable Due In Year Two | 120,000 | ||||||||
Secured Debt Common Stock Shares | 8,889 | ||||||||
Escrow Account Release Of Common Stock Shares Description | The escrow account releases 1/3 or 4,445 shares per year to the Company if there is no default. | ||||||||
Note Payable Issued One [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Note Payable Issued Date | 26-Oct-09 | ||||||||
Debt Instrument, Unamortized Discount | 0 | 0 | |||||||
Debt Instrument, Interest Rate During Period | 8.00% | ||||||||
Convertible Notes, Conversion Price | $26.25 | ||||||||
Note Payable Issued Two [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Note Payable Issued Date | 12-Jun-10 | ||||||||
Debt Instrument, Interest Rate During Period | 12.00% | ||||||||
Convertible Notes, Conversion Price | $13.50 | ||||||||
Note Payable Issued Three [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Note Payable Issued Date | 23-Dec-10 | ||||||||
Debt Instrument, Interest Rate During Period | 10.00% | ||||||||
Convertible Notes, Conversion Price | $6.30 | ||||||||
Debt Instrument, Maturity Date | 23-Dec-12 | ||||||||
Note Payable Issued Four [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Note Payable Issued Date | 21-Sep-10 | ||||||||
Debt Instrument, Interest Rate During Period | 12.00% | ||||||||
Convertible Notes, Conversion Price | $13.50 | ||||||||
Debt Instrument, Maturity Date | 30-Mar-12 | ||||||||
Note Payable Issued Five [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Note Payable Issued Date | 1-Jan-11 | ||||||||
Debt Instrument, Interest Rate During Period | 6.00% | ||||||||
Convertible Notes, Conversion Price | $11.25 | ||||||||
Debt Instrument, Maturity Date | 1-Jan-15 | ||||||||
Note Payable Issued Six [Member] | |||||||||
Debt Instrument [Line Items] | |||||||||
Note Payable Issued Date | 6-Nov-12 | ||||||||
Debt Instrument, Unamortized Discount | $21,138 | ||||||||
Debt Instrument, Interest Rate During Period | 20.00% | ||||||||
Convertible Notes Converted Into Common Stock | 13,889 | ||||||||
Convertible Notes, Conversion Price | $7.50 | ||||||||
Debt Instrument, Maturity Date | 6-Apr-13 |
RENT_OBLIGATION_Details
RENT OBLIGATION (Details) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
Operating Leased Assets [Line Items] | ||
2014 | $36,000 | |
2015 | 37,000 | 37,000 |
2016 | 38,000 | 38,000 |
2017 | 39,000 | 39,000 |
2018 | 3,600 | |
2019 | $0 | $3,000 |
RENT_OBLIGATION_Details_Textua
RENT OBLIGATION (Details Textual) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | |
Property Subject to or Available for Operating Lease [Line Items] | ||||||
Lessee Leasing Arrangements, Operating Leases, Term of Contract | 5 years | 5 years | ||||
Lease Expiration Date | 31-Jan-18 | 31-Jan-18 | ||||
Operating Leases, Rent Expense | $15,719 | $11,162 | $48,775 | $46,321 | $61,150 | $45,961 |
LIABILITY_FOR_EQUITYLINKED_FIN2
LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Details) (USD $) | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2009 | Dec. 31, 2008 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock price | $26.25 | $26.25 | ||
Exercise price | $57.68 | $34.50 | ||
Expected life | 6 months | 2 years 6 months | ||
Expected volatility | 59.00% | 54.00% | 63.00% | |
Assumed dividend rate | 0.00% | 0.00% | 0.00% | |
Risk-free interest rate - Minimum | 0.13% | 0.13% | 2.00% | |
Risk-free interest rate - Maximum | 2.97% | 2.97% | 4.50% | |
Minimum [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock price | $4.50 | |||
Exercise price | $0.75 | |||
Expected life | 2 years | 2 years 6 months | ||
Maximum [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock price | $37.50 | |||
Exercise price | $24.38 | |||
Expected life | 6 years 6 months | 7 years 6 months |
LIABILITY_FOR_EQUITYLINKED_FIN3
LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Details 1) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
Sep. 30, 2010 | Jun. 30, 2010 | Mar. 31, 2010 | Dec. 31, 2009 | Sep. 30, 2009 | Jun. 30, 2009 | Sep. 30, 2010 | Dec. 31, 2009 | Dec. 31, 2008 | |
Class of Warrant or Right [Line Items] | |||||||||
Initial Value | $31,506 | $31,332 | $25,553 | $12,698 | $39,743 | $169,854 | $790,596 | $702,205 | $479,910 |
Annual Gain (Loss) | 617 | -738 | 20,847 | -369,642 | -390,368 | ||||
Total | 790,596 | ||||||||
Value At 2009 [Member] | |||||||||
Class of Warrant or Right [Line Items] | |||||||||
Initial Value | 12,081 | 40,481 | 149,007 | 1,071,847 | 870,278 | ||||
Total | 1,071,847 | ||||||||
Value At 2010 [Member] | |||||||||
Class of Warrant or Right [Line Items] | |||||||||
Initial Value | 10,615 | 592 | 539 | 28 | 62 | 1,604 | 1,506 | ||
Total | 14,946 | ||||||||
Gain Loss 2010 [Member] | |||||||||
Class of Warrant or Right [Line Items] | |||||||||
Annual Gain (Loss) | 20,891 | 30,740 | 25,014 | 12,053 | 40,419 | 147,403 | 868,772 | ||
Total | 1,145,292 | ||||||||
Value At 2011 [Member] | |||||||||
Class of Warrant or Right [Line Items] | |||||||||
Initial Value | 54,775 | 6,714 | 6,109 | 752 | 1,624 | 6,293 | 89,796 | ||
Total | 166,063 | ||||||||
Gain Loss 2011 [Member] | |||||||||
Class of Warrant or Right [Line Items] | |||||||||
Annual Gain (Loss) | -44,160 | -6,122 | -5,570 | -724 | -1,562 | -4,689 | -88,290 | ||
Total | -151,117 | ||||||||
Value At 2012 [Member] | |||||||||
Class of Warrant or Right [Line Items] | |||||||||
Initial Value | 53,437 | 631 | 2,408 | 337 | 714 | 0 | 111,652 | ||
Total | 169,179 | ||||||||
Gain Loss 2012 [Member] | |||||||||
Class of Warrant or Right [Line Items] | |||||||||
Annual Gain (Loss) | 1,338 | 6,083 | 3,701 | 415 | 910 | 6,293 | -21,856 | ||
Total | -3,116 | ||||||||
Value At 2013 [Member] | |||||||||
Class of Warrant or Right [Line Items] | |||||||||
Initial Value | 0 | 0 | 0 | 0 | 0 | 0 | 11,599 | ||
Total | 11,599 | ||||||||
Gain Loss 2013 [Member] | |||||||||
Class of Warrant or Right [Line Items] | |||||||||
Annual Gain (Loss) | 53,437 | 631 | 2,408 | 337 | 714 | 0 | 100,053 | ||
Total | 157,580 | ||||||||
Value At 2014 [Member] | |||||||||
Class of Warrant or Right [Line Items] | |||||||||
Annual Gain (Loss) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Gain Loss 2014 [Member] | |||||||||
Class of Warrant or Right [Line Items] | |||||||||
Initial Value | $0 | $0 | $0 | $0 | $0 | $0 | $11,599 |
LIABILITY_FOR_EQUITYLINKED_FIN4
LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Details Textual) (USD $) | 9 Months Ended | 12 Months Ended | |||||
Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2009 | Dec. 31, 2010 | Dec. 31, 2008 | Dec. 31, 2012 | Jan. 02, 2009 | |
Derivative Instruments and Hedging Activities Disclosures [Line Items] | |||||||
Warrants Not Settleable In Cash, Fair Value Disclosure | $479,910 | ||||||
Weighted Average Remaining Life | 6 months | 2 years 6 months | |||||
Additional Paid in Capital | 486,564 | ||||||
Retained Earnings (Accumulated Deficit) | 6,654 | ||||||
Total Current Liabilities | $4,842,380 | $3,469,065 | $3,414,301 | $479,910 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 59.00% | 54.00% | 63.00% | ||||
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price | $57.68 | $34.50 | |||||
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price | $26.25 | $26.25 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 1.37% | ||||||
Minimum [Member] | |||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | |||||||
Weighted Average Remaining Life | 2 years | 2 years 6 months | |||||
Reduction In Stock Price | $16.50 | ||||||
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price | $0.75 | ||||||
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price | $4.50 | ||||||
Maximum [Member] | |||||||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | |||||||
Weighted Average Remaining Life | 6 years 6 months | 7 years 6 months | |||||
Reduction In Stock Price | $37.50 | ||||||
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price | $24.38 | ||||||
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price | $37.50 |
RELATED_PARTY_TRANSACTIONS_Det
RELATED PARTY TRANSACTIONS (Details Textual) (USD $) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 6 Months Ended | 0 Months Ended | 1 Months Ended | |||||||||||||||||||||||
31-May-13 | Apr. 30, 2013 | Nov. 30, 2012 | Aug. 31, 2012 | Jun. 30, 2012 | Apr. 30, 2012 | Mar. 31, 2012 | Jul. 31, 2007 | Sep. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2002 | Sep. 30, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 30, 2013 | Sep. 11, 2013 | Dec. 31, 2013 | 31-May-12 | Jan. 31, 2014 | Feb. 28, 2014 | Aug. 31, 2014 | Aug. 04, 2014 | Jul. 31, 2014 | Jun. 30, 2014 | Feb. 04, 2014 | Jan. 31, 2013 | Mar. 28, 2012 | Dec. 31, 2008 | Aug. 15, 2012 | Mar. 14, 2012 | |
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $3,000,000 | |||||||||||||||||||||||||||||
Related Party Transaction, Due from (to) Related Party | 2,000 | |||||||||||||||||||||||||||||
Converible Note Percentage | 20.00% | 20.00% | 20.00% | |||||||||||||||||||||||||||
Converible Note Principal Amount | 156,243 | 600,000 | 240,000 | |||||||||||||||||||||||||||
Debt Instrument, Convertible, Effective Interest Rate | 24.00% | 24.00% | ||||||||||||||||||||||||||||
Cash Advance Net Of Interest | 60,000 | |||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $7.50 | $1.05 | $9 | $4.88 | ||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Units | 600,000 | |||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 20,623 | |||||||||||||||||||||||||||||
Stock Transferred During Period | 100,000 | |||||||||||||||||||||||||||||
Shares Issued Related Party Transactions One | 3,704 | |||||||||||||||||||||||||||||
Price Per Share Related Party Transactions | $6.75 | |||||||||||||||||||||||||||||
Compensation Issued In Lieu Of Cash | 25,000 | |||||||||||||||||||||||||||||
Warrants Shares Related Party Transactions | 400 | |||||||||||||||||||||||||||||
Warrants Price Per Share Related Party Transactions | $11.25 | |||||||||||||||||||||||||||||
Shares Issued Related Party Transactions Three | 20,833 | |||||||||||||||||||||||||||||
Proceeds from Related Party Debt | 155,000 | |||||||||||||||||||||||||||||
Convertible Note Due Date | 31-Aug-13 | |||||||||||||||||||||||||||||
Related Party Transaction, Description of Transaction | listing the Company’s shares on NASDAQ pursuant to an underwritten offering of the Company’s securities resulting in gross proceeds of between $5 million and $30 million, then the Company would have to be required to deliver to Dr. Herschkowitz the following compensation: (A) $75,000 upon consummating the shell merger, (B) $150,000 upon consummating the qualifying financing round and (C) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $1,000,000. The Company was also required to reimburse Dr. Herschkowitz at his actual out-of-pocket cost for reasonable expenses incurred in connection with the shell transactions, with a maximum limit of $10,000 for such expenses. | (i) financing raising not less than $1 million, compensation of $75,000; (ii) a going private transaction, compensation of $200,000 or greater and (iii) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $3,000,000. In May 2013 Dr. Herschkowitz received $75,000 after the Company surpassed raising $1 million. | ||||||||||||||||||||||||||||
Stock Issued During Period Shares New Issues | 4,763 | 13,889 | ||||||||||||||||||||||||||||
Compensation Payment Pursuant To Merger | listing the Companys shares on NASDAQ pursuant to an underwritten offering of the Companys securities resulting in gross proceeds of between $5 million and $30 million, then the Company would have to be required to deliver to Dr. Herschkowitz the following compensation: (A) $75,000 upon consummating the shell merger, (B) $150,000 upon consummating the qualifying financing round and (C) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $1,000,000. The Company was also required to reimburse Dr. Herschkowitz at his actual out-of-pocket cost for reasonable expenses incurred in connection with the shell transactions, with a maximum limit of $10,000 for such expenses. | (i) financing raising not less than $1 million, compensation of $75,000; (ii) a going private transaction, compensation of $200,000 or greater and (iii) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $3,000,000. In May 2013 Dr. Herschkowitz received $75,000 after the Company surpassed raising $1 million | ||||||||||||||||||||||||||||
Common shares received per share on resignation | $24.38 | |||||||||||||||||||||||||||||
Compensation received from serving as board members | 267 | |||||||||||||||||||||||||||||
Issuance of shares to satisy previous contractual agreements | 400 | |||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | 30-Apr-08 | |||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 24.00% | 24.00% | ||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | 5,000 | |||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 37,440 | 1,482 | 61,539 | 61,539 | 28,986 | 4,831 | 21,538 | |||||||||||||||||||||||
Subsequent Event [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | 2,055,000 | |||||||||||||||||||||||||||||
Minimum [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Proceeds From Offering Of Securities | 2,000,000 | |||||||||||||||||||||||||||||
Maximum [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Proceeds From Offering Of Securities | 4,000,000 | |||||||||||||||||||||||||||||
First Advance [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Advance Under Note | 300,000 | |||||||||||||||||||||||||||||
Second Advance [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Advance Under Note | 84,657 | |||||||||||||||||||||||||||||
Related Party [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Related Party Transaction, Due from (to) Related Party | 46,000 | |||||||||||||||||||||||||||||
Samuel Herschkowitz [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Shares Issued Related Party Transactions Two | 353,334 | |||||||||||||||||||||||||||||
Debt Instrument Convertible Conversion Price Minimum | $1.05 | |||||||||||||||||||||||||||||
Debt Instrument Convertible Conversion Price Maximum | $4.88 | |||||||||||||||||||||||||||||
Stock Issued During Period Shares New Issues | 100,000 | |||||||||||||||||||||||||||||
Percentage Of Accrued Interest | 20.00% | |||||||||||||||||||||||||||||
Debt Instrument, Periodic Payment | 314,484 | |||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted | 299,509 | |||||||||||||||||||||||||||||
Samuel Herschkowitz [Member] | Non-Convertible Grid Note [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Effective Interest Rate | 10.00% | 10.00% | ||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 10.00% | 10.00% | ||||||||||||||||||||||||||||
Percentage Of Gross Proceeds Received In Advance | 10.00% | |||||||||||||||||||||||||||||
Samuel Herschkowitz [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Percentage Of Interest Rate On Event Of Default | 20.00% | |||||||||||||||||||||||||||||
Samuel Herschkowitz [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Percentage Of Interest Rate On Event Of Default | 24.00% | |||||||||||||||||||||||||||||
Sok Partners [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Notes Payable, Total | 357,282 | |||||||||||||||||||||||||||||
Advance Under Note | 300,000 | 300,000 | ||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Units | 61,539 | 61,539 | ||||||||||||||||||||||||||||
Stock Issued During Period Shares New Issues | 176,667 | |||||||||||||||||||||||||||||
Debt Instrument, Periodic Payment | 680,444 | |||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted | 648,050 | |||||||||||||||||||||||||||||
Sok Partners [Member] | Non-Convertible Grid Note [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Proceeds from Notes Payable | 300,000 | |||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | 28-Feb-14 | |||||||||||||||||||||||||||||
Amount Received In Three Tranches | 250,000 | |||||||||||||||||||||||||||||
Sok Partners [Member] | Non-Convertible Grid Note [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Notes Payable, Total | 305,589.04 | |||||||||||||||||||||||||||||
Additional Proceeds From Notes Payable | 20,000 | |||||||||||||||||||||||||||||
Percentage Of Increase In Interest In Case Of Default | 20.00% | |||||||||||||||||||||||||||||
Sok Partners [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Equity Bonus Valued At Common Stock Rate | $1.05 | |||||||||||||||||||||||||||||
Sok Partners [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Equity Bonus Valued At Common Stock Rate | $4.88 | |||||||||||||||||||||||||||||
Sok Partners [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Additional Issue Of Common Stock Shares | 213,334 | |||||||||||||||||||||||||||||
Dr Herschkowitz and Sok Partners Llc [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Stock Issued During Period Shares New Issues | 176,667 | |||||||||||||||||||||||||||||
Gadbaw [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Common Shares received on resignation | 667 | |||||||||||||||||||||||||||||
Morawetz [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Common Shares received on resignation | 667 | |||||||||||||||||||||||||||||
Board of Directors Chairman [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Payments Made To Officers One | 25,000 | |||||||||||||||||||||||||||||
Director [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Payments Made To Officers Two | 30,000 | |||||||||||||||||||||||||||||
Chief Executive Officer [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 52 | |||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Preferred Stock [Member] | ||||||||||||||||||||||||||||||
Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||
Stock Issued During Period Shares New Issues | 19,231 | |||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $25,000 |
RETIREMENT_SAVINGS_PLANS_Detai
RETIREMENT SAVINGS PLANS (Details Textual) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | |
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ||||||
Defined Contribution Plan, Employer Matching Contribution, Percent of Match | 100.00% | 100.00% | 100.00% | |||
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent | 4.00% | 4.00% | ||||
Defined Contribution Plan, Employer Discretionary Contribution Amount | $14,102 | $9,231 | $29,596 | $27,328 | $32,790 | $1,654 |
COMMITMENTS_AND_CONTINGENCIES_
COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $) | 9 Months Ended |
Sep. 30, 2014 | |
Loss Contingencies [Line Items] | |
Litigation Settlement, Amount | $500,000 |
Estimated Litigation Liability, Current | $200,000 |
Loss Contingency, Settlement Agreement, Terms | Payment of the outstanding balance under the Settlement Agreement will be accelerated if the Company raises $2 million or more of gross dollars in a single funding round or raises aggregate funding of $4 million of gross dollars on or before April 10, 2015 |
SUPPLEMENTAL_CASH_FLOW_DATA_De
SUPPLEMENTAL CASH FLOW DATA (Details Textual) (USD $) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | |
Cash Flow Supplemental Disclosures [Line Items] | ||||||
Interest Paid, Total | $21,627 | $14,503 | $43,233 | $56,433 | $55,198 | $31,008 |
Uncategorized_Items
Uncategorized Items | ||||
[us-gaap_SharesOutstanding] | 0 | |||
[us-gaap_StockholdersEquity] | 0 | 0 | 0 |